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RÉSUMÉ 
Chez l'homme, le cancer de la prostate (CaP) est le cancer le plus 
fréquemment diagnostiqué en Amérique du Nord. Lorsque localisé à la prostate, 
la chirurgie et la radiothérapie sont souvent efficaces bien qu'une proportion 
significative des patients subissent une rechute de la maladie (aussi connue 
comme récurrence biochimique ou RCB). Le traitement principal pour le CaP 
avancé ou récurent est la thérapie par privation d'androgènes (TPA), qui vise à 
diminuer l'activité transcriptionelle du récepteur aux androgènes (AR). Bien que 
la TP A puisse prolonger la vie des patients, un CaP dit androgéno-indépendant 
(AI) se développe éventuellement, pour lequel les traitements courants sont 
essentiellement de nature palliative. Plusieurs études indiquent qu'il existe 
plusieurs mécanismes AR-dépendants et AR-indépendants permettant aux cellules 
du CaP à résister à la TP A qui pourraient aussi influencer la réponse des cellules 
du CaP AI envers d'autres modalités de traitement. 
Les objectifs de ce projet de doctorat étaient d'innover dans le traitement 
du CaP et d'approfondir nos connaissances vis-à-vis les facteurs impliqués dans 
la progression clinique du CaP et la réponse thérapeutique. Comme tremplin pour 
atteindre ces objectifs, nous avons utilisé l'inositol hexakisphosphate (IP6), un 
agent phytochimique oralement non-toxique. Dans le chapitre 2, nous avons 
découvert que bien que l'IP6 présentait un activité anticancérese contre plusieu 
lignées du CaP, son effet était maximal contre les cellules du CaP AI n'exprimant 
pas le AR. Dans le contexte de la lignée cellulaire du CaPAI PC3 (AR-négative), 
l'efficacité de l'IP6 pouvait être modulée par l'expression stable du AR, 
indépendamment de la présence d'androgènes. En explorant ce phénomène, nous 
avons découvert que l'expression du AR empêchait l'apparition des 
manifestations de l'apoptose induites par l'IP6. De plus, l'expression du AR 
diminuait l'effet de l'IP6 sur l'expression d'un sous-groupe de gènes, impliquant 
potentiellement l'action de NF-KB et de protéines pro-apoptotiques de la famille 
BCL-2 tels NOXA et PUMA. 
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Suites à ces découvertes initiales, dans les capitres 3 et 4, nous avons 
utilisé des micro-étalages de tissus en combinaison avec l'immunohistochime, des 
méthodes d'analyse innovatrices, en plus d'algorithmes de modélisation 
multivariés émergeants (arbres de survie à base de partition récursive), pour 
évaluer l'omnipotence de NOXA, PUMA et du AR dans les tissus prostatiques. 
Pour la première fois, ces études ont identifié NOXA et PUMA en tant que cibles 
potentielles pour le traitement du CaP et ont établi NOXA comme étant un 
indicateur pronostique de RCB lorsque qu'évalué en combinaison avec certaines 
caractéristiques c1inico-pathologiques. Ces études ont également souligné 
l'implication potentielle du AR localisé au noyau dans les étapes initiales de la 
. progression du CaP. De plus, les résultats obtenus supportent l'étude future des 
fonctions cytoplasmiques et androgéno-indépendantes du AR, en vue de la 
prévalence du AR cytoplasmique dans le CaP AI et en vue de son utilité 
pronostique potentielle dans certàins contextes. 
Dans le chapitre 5, nous avons poursuivi l'exploration des mécanismes de 
l'IP6 dans le contexte des cellules du CaPAI PC3. Nous avons établi que, du 
moins dans cette lignée cellulaire, il est peu probable que l'action de l'IP6 
implique NF-KB. Par contre, nous avons présenté des évidences supportant le rôle 
des protéines de la famille BCL-2 dans le mécanisme d'action de l'IP6. D'autant 
plus important, les informations générées au sujet des mécanismes de l'IP6 nous 
ont permis de rationaliser une stratégie pour augmenter l'efficacité de l'IP6 à 
l'aide d'inhibiteurs du protéasome, une option thérapeutique émergente pour le 
traitement du CaP AI. En effet, nous avons découvert qu'un traitement combiné à 
l'IP6 et aux inhibiteurs du protéasome augmente significativement la cytotoxicité 
observée, qui impliquerait la dépolarisation mitochondriale et potentiellement les 
membres pro-apoptotiques de la famille BCL-2. 
Dans leur ensemble, les résultats présentés dans cette thèse de doctorat ont 
contribué au domaine du traitement du cancer de la prostate par l'entremise de 
découvertes de nouveaux marqueurs pronostiques et d'options thérapeutiques. 
Pris avec les recherches futures, nous croyons que les innovations avancés durant 
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de projet de doctorat pourraient éventuellement aider à mieux gérer le CaP et le 
CaPAI 
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SUMMARY 
Prostate cancer (PCa) is the most frequently diagnosed cancer in North 
American men. When localized to the prostate, surgery and radiotherapy are often 
used successfully although a significant proportion of patients experience disease 
relapse (also termed biochemical recurrence or BCR). The mainstay for treatment 
of advanced or recurrent PCa is androgen-deprivation therapy (ADT), which aims 
to reduce the transcriptional activity of the androgen receptor (AR). Although 
ADT can prolong the life of PCa patients, androgen-independent (AI) PCa 
eventually arises, for which treatment is essentially palliative. Several studies 
indicate that there are both AR-dependent and AR-independent mechanisms 
involved in the resistance to ADT, which may also influence the efficacy of other 
treatment modalities. As such, there is a pressing need to improve our ability to 
match patients with the appropriate treatment and to increase the number and 
potency of clinically available therapeutic options for PCa and AIPCa patients. 
The objectives of this doctoral thesis were to innovate in the treatment of 
PCa and to further our understanding of the factors involved in both clinical 
outcome and therapeutic response. Throughout the doctoral thesis, we have used 
inositol hexakisphosphate (IP6), an orally non-toxic phytochemical, as a stepping 
stone towards achieving these objectives. In chapter 2, we discovered that 
although IP6 presented anti-cancer activity against several PCa cell lines, its 
effect was greatest in AR-negative AIPCa cells. In the context of AR-negative 
PC3 AIPCa cells, the efficacy of IP6 could be modulated by stable expression of 
the AR, independently of the presence of androgens. In exploring this 
phenomenon, we discovered that the expression of the AR prevented the 
manifestations of apoptosis induced by IP6 as weIl as the up-regulation of a 
subset of genes, which indicated the potential implication of NF-KB and pro-
apoptotic members of the BCL-2 family such as PUMA and ~OXA. 
Following these initial discoveries, in chapters 3 and 4 we employed tissue 
microarray technology combined with immunohistochemistry, innovative analysis 
methods, as well as emerging multivariate modeling algorithms (recursive 
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partitioning-based survival trees) to assess the omnipotence of NOXA, PUMA 
and the AR in prostate tissues. For the first time, these studies identified NOXA 
and PUMA as potential targets for PCa treatment and established NOXA as a 
promising prognostic indicator of BCR when inc1uded within multivariate 
survival tree models inc1uding key c1inico-pathological features. These studies 
also highlighted the potential involvement of nuc1ear AR in the initial stages of 
PCa. In addition, given the observed prevalence of cytoplasmic AR in AIPCa 
patients and the finding that cytoplasmic AR may ho Id prognostic information in 
certain contexts; these studies provided further rationale for studying cytoplasmic 
androgen-independent functions of the AR. 
In chapter 5, we continued to explore the mechanisms of IP6 in the context 
of PC3 AIPCA cells. We established that, at least in these cells, the action ofIP6 
does not likely involve NF-KB. However, we provided further evidence 
supporting a role of BCL-2 family members in mediating the effects of IP6. Most 
importantly, the information collected allowed us to rationalize a strategy to 
enhance the activity of IP6 using proteasome inhibitors, an emerging therapeutic 
option for AIPCa. Indeed, we discovered that combined treatment of AIPCa cells 
with proteasome inhibitors and IP6 leads to a significantly enhanced cytotoxicity 
involving mitochondrial depolarization and likely implicating pro-apoptotic BCL-
2 family members. 
Overall, the results presented in this doctoral thesis have contributed to the 
field of prostate cancer therapy through the discovery of both novel prognostic 
markers and therapeutic options. Altogether with future research, we believe that 
the innovations brought forth during the course of this doctoral project could 
eventually lead to the better management of PCa and AIPCa. 
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CHAPTERI 
1. Introduction 
Over the last century, cancer has emerged as one of the most problematic 
diseases of the western world. With the advent of globalization and the increasing 
life expectancy worldwide [1], cancer is likely to become one of the most 
significant challenges to human medicine for centuries to come. In this chapter, 
we will begin by briefly reviewing the maintenance of cellular homeostasis and 
explore how this homeostasis is fundamentally altered in cancer cells. We will 
subsequently focus on the development of prostate cancer and its CUITent 
treatment. Emerging therapeutic concepts in prostate cancer will then be 
introduced and the potential of inositol hexakisphosphate will be showcased 
within this context. 
1.1 Cellular Homeostasis 
Cellular homeostasis can be defined as the equilibrium between 
production and destruction of cellular components. Although the cell processes a 
wide range of molecules, we will focus on the homeostasis deoxyribonucleic 
acids (DNA), of ribonucleic acids (RNA), and of proteins, as they are intimately 
linked and as they are of central importance for the development of cancer. 
1.1.1 DNA Homeostasis 
Chromosomal DNA is considered to be the primary holder of the genetic 
information within the cell and acts as a template for the production of RNA and 
proteins. The specific sequence of DNA within chromosomes constitutes the 
template for RNA synthesis and subsequent protein synthesis. This intimate 
relationship is of utmost importance for the cell, as changes in the DNA sequence 
may have a severe impact on cellular functions and consequently on the overall 
cellular homeostasis. 
1.1.1.1 DNA Replication and DNA Degradation 
In the normal ce Il , production of DNA through DNA replication is a 
tightly regulated process, allowed to occur only during the synthesis or S phase of 
the cell cycle (see section 1.2.1) [2]. This process is mediated by the action of 
various proteins including DNA primases, DNA ligases, DNA helicases, 
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topoisomerase, and finally DNA polymerases that play a most direct role by 
synthesizing a complementary DNA strand from a single strand template [3]. 
Counter to DNA polymerase activity, DNAses act to break down the DNA 
polymer into smaller sub-components. Exonucleases effectively digest DNA from 
one end to the other (either 5' to 3' or 3' to 5 ') while endonucleases cut within a 
DNA strand. The action of endo and exo-nucleases is important for diverse 
processes su ch as DNA repair (eg. Ape-l [4], see below) and apoptosis (eg. CAD 
[5], see section 1.2.3.3.2). 
1.1.1.2 Genome Integrity and the Impact of DNA Mutation 
It is ofutmost importance for the cell to maintain the integrity of the DNA 
sequence as any unwarranted change can potentially lead to the disruption of 
cellular homeostasis. In addition, this disruption may be transmitted to daughter 
cells following cell division. As such, various proteins (that are synthesized based 
on the DNA sequence, see section 1.1.3.1) are normally responsible for 
maintaining chromosomal integrity. These include enzymes involved in the repair 
ofDNA single-strand breaks [ego Ape-1, [4], PARP [6]], or double-strand breaks 
[e.g ATM, [7], DNA-PK and Ku proteins [8]], DNA mismatches [e.g, MSH, 
PCNA [7]], or that maintain the stability of DNA ends or te10meres (e.g 
Telomerase [9]). Other proteins su ch as p53 act as genome guardians and 
coordinate cellular response to DNA damage [10]. The proper regulation of these 
proteins is therefore also critical for maintaining a stable genome (see section 
1.2.4.2.2). 
1.1.2. RNA Homeostasis 
RNA is to DNA as paper is to a paper press and therefore any change that 
is made to the DNA template is automatically transferred unto the corresponding 
RNA message. The process of making RNA from DNA is referred to as 
transcription and occurs mainly in the nucleus and within the Gap 1 (G 1), S, and 
Gap 2 (G2) phases of the cell cycle [11] (see section 1.2.1.). As RNA is 
subsequently translated into proteins that play major structural and functional 
roles within the cell (see section 1.1.3.1), the tight regulation of transcription is 
extremely important for maintaining cellular homeostasis. As such, many cell-
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signaling pathways are devoted to the transcriptional control of genes (see 
sections 1.2.2.1, 1.2.3.2.5, 1.2.4.1, and 1.3.5.5). 
1.1.2.1. RNA Transcription and its Regulation 
Transcription is regulated both by DNA and prote in. Specific sequences in 
DNA (e.g gene promoters and enhancers) act as binding sites for transcription 
factors that initiate or activate the process of RNA synthesis through the action of 
RNA polymerases [e.g RNA Polymerase I [12], II [13], III [14]]. As such, DNA 
mutations that modify either the specificity of the DNA sequences recruiting 
transcription factors or that modify the specificity of transcription factors 
themselves can have a major impact on RNA homeostasis. 
The condensation state of chroma tin is one of the most fundamental 
regulators of gene expression. In its most basic form, chromatin is composed of 
negatively charged DNA wrapped around positively charged histone proteins 
(altogether called a nucleosome). Condensed chromatin (heterochromatin) is 
much less accessible to transcription factors, RNA polymerases, and their 
associated co-factors. Consequently, gene transcription generally occurs within 
100 se chromatin domains (euchromatin) [15, 16]. 
Whereas the DNA sequence regulates which transcription factors 
(including RNA polymerases) bind where, histone proteins are the structural 
regulators of the chromatin condensation state. Histone proteins can be post-
translationally modified by covalent addition of various moieties including acetyl, 
methyl, phosphoryl, and ev en ubiquitin groups. Post-translational modification of 
histones can lead to the alteration of chromatin structure. These modifications 
occur on specific histone residues and altogether constitute a histone code that 
acts in parallel to the genetic code provided by the DNA sequence [16]. 
Although researchers are finding the histone code to be increasingly 
complex [16, 17], it is generally considered that the acetylated state of histones is 
associated to transcription permissive euchromatin whereas de-acetylated histones 
are rather associated to repressive heterochromatin. Importantly, histone acetyl 
tranferases (HATs) mediate the addition of acetyl groups whereas histone de-
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acetylases (HDACs) mediate the removal of these moieties. In effect, activator 
transcription factors often act to recruit HA Ts while repressor transcription factors 
recruit HDACs [18]. 
1.1.2.2. RNA Processing and Degradation 
Once RNA is produced, it is subsequently processed and spliced into its 
mature form (rnRNA), void of intron sequences and equipped with a 5' 
methy1guanosine cap and a 3' poly-adenosine (PolyA) tail. While the 5' 
methylguanosine cap plays a role in the initiation of protein translation (see 
section 1.1.3.1) both the 5' methyl cap and the PolyA tail play a ro1e in protecting 
the RNA from degradation by RNAses, which oppose the action of RNA 
polymerases and promote RNA de-polymerization [11]. Recently, it has been 
found that the cell possesses a highly specific system of RNAses that permits the 
degradation of mRNA in sequence-specific manner. The RNA-induced si1encing 
complex (RISC) in concert with the RNA endonuclease dicer induces the 
degradation of specific mRNAs. N otably, exploitation of this endogenous cellular 
machinery has spawned the emergence small interfering RNA (siRNAs) and short 
hairpin RNA (shRNAs) technology that allows for the specific down-regulation of 
genes and their associated proteins using short complementary RNA sequences 
[19,20] (see chapter II). 
1.1.3. Protein Homeostasis. 
The main purpose of mRNAs is to act as an intermediate template for the 
production of protein through a process termed translation. This process is 
mediated by the ribosome, a large ribonucleoprotein complex composed of two 
sm aller subunits (40S and 60S). Much like RNA production, prote in translation 
occurs mainly in the G1, S, and G2 phases of the cell cycle [11]; however, unlike 
RNA transcription, this process occurs mainly in the cytoplasm and endoplasmic 
reticulum, although more restricted translation also occurs in other organelles 
such as the mitochondria [21] (see section 1.2.3.1) and the nucleolus [14, 22]. 
Notably, the nucleolus is the primary site for ribosomal RNA transcription and 
ribosome maturation [22]. 
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One of the first control points for prote in production is mRNA export from 
the nucleus, which proceeds through the TAPINFXl pathway and involves a large 
number of proteins including nuclear export receptors (eg. TAPINFXI), nuclear 
export adaptors (Aly/REF), A TPases/RNA helicases (eg. DBP5) and nucleoporins 
(eg. GIel and Nup family proteins) [23]. The second major control point for 
prote in production from mRNA involves translation initiation and recruitment of 
the 40S ribosome. This involves numerous elongation initiation factors (eIF) such 
as eIF4E that binds the 5' methylguanosine cap, eIF4E binding proteins (e.g 4E-
BPI), and eIF4G that also causes circularization of mRNA indirectly by its 
interaction with poly(A) binding protein (PABPI). Although regulation at the 
translation initiation step is better described, prote in translation can also be 
regulated at the elongation and termination steps through the action of elongation 
factors (eEFs) such as eEF2 [24]. As prote in production can have rather 
immediate functional consequences for cellular homeostasis, prote in translation is 
also tightly regulated through the concerted action of many signaling pathways, 
one ofwhich is the mTOR pathway ([25], see section 1.2.2.2), 
1.1.3.2. Protein Degradation and the Ubiquitin/Proteasome System 
Although lysosomal proteases account for 10-20% of cellular protein 
degradation [26], the 26S proteasome is the principle mediator of prote in 
degradation responsible for the ATP-dependent processing of 80-90% of cellular 
proteins [27]. The 26S proteasome is a large 2000 kDa multiprotein complex 
composed of a barrel-shaped 20S subunit and two "lid" 19S subunits. The 20S 
subunit contains several proteolytic sites within its two central p-rings and 
possesses trypsin-like, chymotrypsin-like and caspase-like protease activity. 
Notably, the chymotryptic-site is thought to be rate limiting in proteasome-
mediated degradation [27]. The 19S subunits are mainly regulatory in nature and 
direct proteasomal degradation by binding poly-ubiquitinylated proteins that, as 
such, have been targeted for degradation. Thus, the targeting of proteins for 
proteasome-mediated degradation by the process of poly-ubiquitination is a key 
regulatory step of protein homeostasis and can profoundly impact cellular 
homeostasis. 
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The ubiquitination of cellular proteins is mediated by a series of three 
types of enzymes, namely El ubiquitin-activating enzymes, E2 ubiquitin-
conjugating proteins, and E3 ubiquitin ligases [28, 29]. While mono-
ubiquitination can play a role in altering protein localization [30] and is 
increasingly thought to play a role in chromatin organization [31], poly-
ubiquitinylation (4 ubiquitin subunits or more) targets proteins for proteasomal 
degradation [28]. While only one El enzyme (Ubal) is required to conjugate 
ubiquitin to a small number of cellular E2 enzymes (UBCs) that have limited 
specificity, there are several E3 ubiquitin ligases (eg. Skp1l2, APC/C, mdm2, 
SCF~ TRCP) that confer most of the substrate specificity as weIl as temporal and 
spatial control to the ubiquitinlproteasome system [28, 29, 32]. The E3 ubiquitin 
ligases contain either Hect or RING-H2 domains and are notably involved in a 
variety of cellular processes including genomic surveillance (e.g mdm2 [33] see 
section 1.2.2.2 and 1.2.4.2), cell signaling (e.g SCF~TRCP[34], see section 
1.2.4.1.3), cell cycle (eg. SCF (skp1l2) [35, 36], APC/C [37], see section 1.2.2.3) 
and cell death (e.g. Mule/ARF-BP1[38] see section 1.2.3.2.6). 
1.2.Disruption of Cellular Homeostasis: Cell cycle, Apoptosis, and Cancer 
By definition, the homeostatic state is a stagnant balance between import, 
export, production, and degradation of each component of the cell. In reality, this 
balance is in continuaI reassessment. As the cell reacts to various stresses and 
stimuli, the homeostatic balance is perturbed and the state of the cell is altered. As 
we will soon discuss, the outcome of these perturbations depends on both the 
stimulus and the state of the cell. 
1.2.1.The Cell Cycle 
The cell cycle can be viewed as a programmed and controlled alteration of 
cellular homeostasis that leads to cytokinesis and cellular proliferation. The cell 
cycle is divisible in four stages, Gl, S, G2, and M (mitosis) [11]. These stages are 
associated to distinct cellular activities (see sections 1.1.1-1.1.3) and are 
periodically regulated at "checkpoints" that play a crucial role in overseeing the 
repli cation of the genome and its proper distribution within the resulting daughter 
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cells. The cell cycle checkpoints also play a crucial role in the control of cellular 
proliferation within the organism, as they can be regulated by growth factors and 
various extracellular signaIs [39](Refer to Chapter 1 Figure. l for an overview). 
1.2.1.1 Cyclin-Dependent Kinases 
The cell cycle is controlled by a complex network ofproteins ofwhich the 
mam constituents are cyclins and cyclin-dependent kinases (CDK). Although 
there are at least ni ne known CDKs, five of them play an active role throughout 
the cell cycle. Specifically, CDK 4, 6, and 2 are active during the G l phase, 
CDK2 is active in S phase while CDKI is active in both G2 and M phases. CDK7 
is active at aIl cell cycle phases. Although the kinase activity of CDK6, 4, 2 and 1 
changes throughout the cell cycle, their protein levels generally remain stable. 
CDK activity is regulated by cyclins, whose levels rise and fall periodically 
throughout the cell cycle [40-42]. 
1.2.1.2. Cyclins 
Much like CDKs there are over sixte en identified cyclins although many 
of them are not related to the cell cycle. cyclins DI, D2 and D3 are expressed 
maximally during the G 1 phase and associate to CDK4 and CDK6. cyclin E is 
expressed during the G liS phase transition and associates with CDK2. The 
activity of CDK2 following the G liS transition is maintained by its association 
with cyclin A, which is expressed throughout the S phase, progressively 
decreasing until the G2/M phase transition where it interacts instead with CDKl. 
During the initial stages of M phase, cyclin B levels are at their highest, leading to 
sustained activation of CDKI until the cycle repeats itself [41]. Notably, in 
contrast with cyclins E, A and B, D-type cyclin expression is regulated by growth 
factor signaling [42]. Importantly, CDKlcyclin complexes have varying 
specificities and can phosphorylate a wide range of proteins that promote changes 
in cellular organization, cell cycle progression, and eventually cell division. 
1.2.1.3 Cell Cycle Checkpoints and Cell Cycle Inhibitors 
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Acting as natural "brakes" for the cell cycle and playing important roles at 
the cell cycle checkpoints, CDK inhibitors block the activity of CDKlcyclin 
complexes. The better-known CDK inhibitors faU into two major families. The 
INK4 family comprises p15 (INK4b), p16 (INK4a), p18 (INK4c) and p19 
(INK4d) and present ankyrin repeat domains. INK4 family CDK inhibitors are 
generaUy thought to compete with D-type cyclins to block the cell cycle in G 1. 
The Cip/Kip fami1y comprises p21(Wafl/Cipl), p27(Cip2), p57(Kip2) and a1so 
share a comm6n inhibitory domain. Although Cip/Kip family CDK inhibitors act 
on cyclin D/CDK complexes in vitro, they preferentially act on CDK2 complexes 
in vivo [41,43]. 
Although INK4 and Cip/Kip family proteins are more or less direct CDK 
inhibitors, a third category of cell cycle inhibitors, the pocket proteins, mediate 
their effect through E2F transcription factors. E2F family transcription factors are 
key regulators of the G liS cell cycle transition but are also involved in cell 
differentiation and apoptosis [44, 45] (see section l.2.3.2.5). This family of 
proteins consists of at least seven members, of which E2F l, 2 and 3 are 
considered transcriptional activators that act upon release from their interaction 
with pRb: the prototypical pocket prote in family member. While the function of 
the other E2F family members is more obscure, E2F4 and E2F5 are thought to act 
as transcriptional repressors when bound to pocket proteins (including pRb, pl 07 
and p130) that also recruit HDACs. Among others, Rb proteins can be 
phosphorylated by CDK(4/6)/cyclin D or CDK2/cyclin E complexes during cell 
cycle progression. Phosphorylation of pRb family members results in their 
dissociation from E2F binding partners. The coordinated activity of E2F members 
results in the modulation of E2F-regulated gene expression and cell cycle 
progression [44, 46-48]. 
1.2.2. Regulation of the Cell Cycle. 
Net cyclin and CDK inhibitor expression at the protein level depends on 
mRNA availability, prote in production, and prote in degradation. As such this 
offers severallayers of regulation for cell cycle control. 
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1.2.2.1 Transcriptional Control of Cell Cycle Components 
The first level of control occurs at the level of mRNA transcription. For 
example, cyclin Dl mRNA expression is regulated by various transcription 
factors including NF-KB [49] and ~-catenin [50]. Upstream signaling pathways in 
tum regulate the activity of these transcription factors, such as that of 
PI3K/ AktlIKK (NF-KB) and WntlGSK3 (~-catenin) (see sections 1.2.4.1.1 to 
1.2.4.1.4). Moving forward in the cell cycle, cyclin E can be up regulated by E2F 1 
following hyper-phosphorylation of pRb [51]. In contrast, to haIt cell cycle 
progression, the expression of the pI5 (INK4b) CDK inhibitor can be up 
regulated at the mRNA level following cell stimulation by TGF-~ [52]. Similarly, 
the p53 transcription factor can induce p21 (Wafl/Cip1) mRNA up-regulation in 
response to DNA damage [53]. 
1.2.2.2. mTOR and the Translational Control of Cell Cycle Components 
One of the better-described pathways that regulate cell cycle and other 
proteins at the translation level is the mTOR (mammalian target of rapamycin) 
pathway. As its name implies, mTOR was first identified as a target ofrapamycin, 
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a drug that inhibits cell proliferation [54]. In normal cells, the mTOR pathway is 
typically initiated by an increased availability in amino acids or by upstream 
activation of PI3K and Akt. mTOR activation has been shown to lead to the 
inhibition of 4E-BPl that normally represses translation by binding eIF4E. Hence, 
activation of mTOR promotes translation of various proteins including cyclin Dl 
whereas inhibition of mTOR leads to decreased protein production and cell cycle 
arrest [25]. 
1.2.2.3. Proteasorne-Mediated Degradation of Cell Cycle Cornponents 
Another important cell cycle regulation mechanism is proteasome-
mediated degradation of cyclins and other proteins involved in cell cycle control. 
As mentioned previously, this involves several E3 ubiquitin ligases. SCF (skp/ cul 
/ F-box protein) E3 ligase complexes play an important role to this effect, 
mediating the degradation of CDK inhibitors such as p2l Cipl, p27Kipl and p57Kip2 
[32, 55] as well as of cyclin Dl [56] and cyclin E [57]. Notably, the composition 
of the SCF complex defines its target specificity. For example SCFI (skpl/cull/F-
box protein) complexes alter specificity through the changing of the F-box 
protein. Skp2, Fbw7 and ~-TrCP are the best known F-box proteins and while 
skp2 and fbw7 play direct role in the cell cycle, SCF complexes containing ~­
TrCP play a more indirect role by controlling cell signaling through the NF-KB 
and ~-catenin pathway [32, 34, 50] (see sections 1.2.4.1.3 and 1.2.4.1.4). In a 
similar fashion to SCF complexes, the APC (Anaphase Promoting Complex) 
ubiquitin ligase mediates the degradation of cyclin A and B [58]. Other important 
E3 ubiquitin ligases include MDM2, which controls the expression of the genome 
surveillance factor p53 [59]. 
1.2.3. Apoptosis. 
If the cell cycle can be viewed as a controlled perturbation of cellular 
homeostasis leading to cell division, then apoptosis may be described as a 
controlled response to the disruption of cellular homeostasis leading to cell death. 
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Likely almmg at containing cellular toxins that may be damageable towards 
surrounding cells, the apoptotic cell undergoes distinct morphological and 
biochemical changes. These typically inc1ude cell shrinkage, cell membrane 
blebbing and presentation of phosphatidyl-serine at the cell surface, loss of 
nuc1ear envelope integrity, chromatin condensation, and DNA fragmentation [60, 
61]. The apoptotic program can be initiated by both intracellular (intrinsic) and 
extracellular (extrinsic) signaling pathway [62]. Apoptosis is a highly regulated 
process and its progression involves a cascade of molecular events, implicating a 
myriad of proteins inc1uding pro- and anti-apoptotic proteins (see sections 
1.2 .. 3.2.1 to 1.2.3.2.3), inhibitors of apoptosis (lAPs, see section 1.2.3.3.3), 
proteases (see section 1.2.2.3.1) and DNAses (see section 1.2.3.3.2) [63,64] (see 
Chapter I Figure. 2 for an overall schematization). In the context of tissues and 
organs, the process of apoptosis is extreme1y important as it counterbalances the 
effects of cell division, thereby maintaining tissue homeostasis or active1y 
sculpting organ shape [65,66]. 
1.2.3.1 The Mitochondria 
Before we begin to review the molecular details of apoptosis and the 
processes of cell death, it is important to describe one of its central regulatory 
organelles: the mitochondrion. The mitochondrion possesses its own DNA, 
leading sorne to suggest that it may have evolved separately from the cell and was 
later incorporated in a symbiotic relationship [67]. Importantly, mitochondria not 
only provide eukaryotic cells with energy by acting as the main sites of ATP 
(adenosine tri-phosphate) production, but also act as key regulators of apoptosis 
and cell death in general [64,67]. 
1.2.3.1.1. Mitochondrial Energy Production 
The mitochondrion is composed of an outer membrane and a larger ruffled 
inner membrane encirc1ing the mitochondrial matrix. While the outer membrane 
acts as agate between the cytosol and the mitochondria, the inner membrane 
plays a major role in the production of ATP, holding all the components of the 
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e1ectron transfer chain. The electron transfer chain mega-complex is responsible 
for the establishment of a proton gradient between the inter-membrane space and 
the mitochondrial matrix. It is composed of several sub-complexes inc1uding the 
nicotinamide adenine dinuc1eotide (NAD) dehydrogenase complex, iron-suIf ur 
proteins, Co-enzyme Q (ubiquinone), cytochrome B complex (BIC 1), cytchrome 
C and also cytochrome oxydase (cytochrome NA3 complex) [68]. Notably, 
whereas most of these complexes reside within the inner-mitochondrial 
membrane, cytochrome C sits in the inter-membrane space. The process of ATP 
production by ATP synthase, which sits on the matrix side of the mitochondrial 
inner membrane, is driven by the proton motility force that results from the pH 
gradient between the outer/inner membrane space and the mitochondrial matrix. 
[64, 67, 68]. As the inter-membrane space is more acidic than the mitochondrial 
matrix, this yields an electrochemical gradient referred to as ~\{'m[64]. 
1.2.3.1.2. Mitochondrial and Cellular Inter-Dependence 
Within the mitochondrial matrix lays the mitochondrial genome, which is 
circular and much smaller than the nuc1ear genome (roughly 16 000 bp) and 
encodes for two ribosomal RNAs (rRNAs), 22 transfer RNAs (tRNAs) and 13 
polypeptides. The mitochondrial matrix also harbors its own translation-
competent ribosomes, although these are of significantly different composition 
than cytosolic ribosomes [21, 69] (see section 1.1.3.1 ). However, the 
mitochondrion is not auto-sufficient in that it requires the import of proteins 
encoded by nuc1ear genes, which are likely imported both post and co-
translationally (e.g as they traverse the outer-membrane) [70]. Mitochondrial 
import of RNA has also been described, particularly for transfer RNAs [71], 
although the mechanisms involved are much more obscure than those involved in 
protein import, that are known to proceed through the action of the Translocase of 
the Outer Membrane (TOM) pore complex [72]. 
1.2.3.1.3. VDAC/ANT Complexes and the Inter-Membrane Space 
Another key mitochondrial membrane pore complex involved III the 
transport of diverse molecules is VDACI ANT. This complex is formed of VDAC 
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(Voltage-dependent anion channel) which lies within the outer membrane, ANT 
(adenine nucleotide translocator) located in the inner membrane, and cyclophilin 
D that associates to the matrix portion of ANT. In addition, benzodiazepine 
receptor and hexokinase, an enzyme involved in glucose phosphorylation, are 
associated to VDAC on the cytosolic side of the channel. [73-80]. Although this 
remains debated, sorne studies suggest that this highly regulated inner and outer 
membrane spanning channel plays a role in apoptosis because it allows for the 
dispersion of known pro-apoptotic factors that are present in the inter-membrane 
space. As will be discussed subsequently, these include cytochrome C that binds 
Apaf-l and activates the apoptosome [81, 82], Apoptosis inducing factor (AIF) 
that plays several roles including chromatin condensation and DNA fragmentation 
[83], Diablo/Smac and Omi/HtrA2, both antagonizers of lAPs [84-86], EndoG 
that activates caspase-activated DNAse (CAD) [87, 88], as weIl as caspases 2 and 
9 [89-92] (see section). 
1.2.3.2. The Regulation of Mitochondrial Outer Membrane Permeability. 
Given the presence of pro-apoptotic factors within the inter-membrane 
space and given the importance of the maintenance of the proton gradient and 
~ \}' fi for ATP production by ATP synthase in the inner membrane, outer 
mitochondrial membrane permeability is an extremely weIl regulated process. In 
fact, a whole family of proteins is dedicated to its control. The BCL-2-family of 
proteins is characterized by the presence ofBCL homology domains (BHI, BH2, 
BH3 or BH4) and presently contains over 30 known members. These are 
generally categorized according to whether they promote or prevent apoptosis and 
how many (and which) BH domains the proteins contain [93]. 
1.2.3.2.1 Anti-Apoptotic BCL-2 Family Members 
Anti-apoptotic proteins of the BCL-2 family ultimately prevent the 
permeation of the mitochondrial outer membrane and generaIly contain at least 
two different BH domains. These currently include the prototypical BCL-2 [94], 
BCL-XL [95], BCL-XES [96], BCL-W [97], MCL-l [98], AlIBFL-1 [99], 
BRAG-I [100], BOO/DIVA [101], BCL-B [102] and BCL-2L-1O [103]. 
15 
1.2.3.2.2. Multi-Domain Pro-Apoptotic BCL-2 Family Members 
In contrast to anti-apoptotic BCL-2 proteins, pro-apoptotic proteins of the 
BCL-2 family lead to the leakage of apoptosis effectors residing within the inter-
membrane space into the cytoplasm (as described in section 1.2.3.1). These fall 
into two sub-categories based on whether they contain multiple different BH 
domains (multi-domain) or only one or sometimes two BH3 domains (termed 
BH3-only). Known multi-domain BCL-2-family members inc1ude BAX [104], 
BAK [105], BCL-XS [95], BOKlMTD [106], BCL-RAMBO [107] and BCL-GL 
[108]. Importantly, sorne of these proteins such as BAX, BAK and BID (see 
below) can form pore structures and permeate synthetic liposomes in vitro and 
may permit direct mitochondrial outer membrane permeation [109]. 
1.2.3.2.3. BH3-0nly Pro-Apoptotic Proteins 
Currently, known BH3-on1y pro teins incIude BAD [110], BID [111], 
BIK/NBK [112], BIM/BOD [113], HARAKIRI/DP5 [114], BNIP1 [115], BNIP3 
[116], PUMNBCB3 [117], NOXA [118], BCL-GS [108], MCL1-S [119], BMF 
[120], MAP-1 [121], ITM2B(S) [122] and SPlKE [123]. It is generally thought 
that the major ro1e of these proteins is to antagonize anti-apoptotic members of 
the BCL-2 family, although sorne such as BID and PUMA, may more directly 
promote pore formation mediated by multi-domain pro-apoptotic proteins such as 
BAX and BAK [124]. 
1.2.3.2.4. Control of outer membrane permeability by BCL-2-family proteins 
This long list of pro and anti-apoptotic factors of the BCL-2-family gives 
us a general sense of the importance and complexity of mitochondrial membrane 
permeability control. Overall, it is thought that the balance of active pro- and anti-
apoptotic proteins within the cell dictates the release of apoptogenic factors from 
the inter-membrane space of the mitochondria. Hence, we can invoke the notion 
of homeostasis to explain the action of BCL-2 family members on the 
mitochondria. For example, if the cell shifts its production towards accumulation 
of pro-apoptotic proteins, cells can survive in conditions where they would 
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normally die. In contrast, if cells accumulate pro-apoptotic proteins, they are 
rendered sensitive to various insults. 
However, this model is somewhat of an over-simplification as it is clear 
that different BCL-2 family members play different roI es in the ceIl, even though 
there appears to be considerable functional redundancy within BCL proteins 
[125]. Since most of these proteins were discovered in the past ten years (sorne 
1ike SPlKE were discovered 1ess than five years ago) the detai1s of their 
interactions are only beginning to be understood. It is clear from most studies that 
the multi-domain pro-apoptotic proteins, particularly BAX and BAK, play a 
central role. While BAK resides mainly in the mitochondrial outer membrane and 
homo-oligomerizes in response to a death stimulus [126], BAX is found mainly in 
the cytoplasm as a mono mer. BAX can subsequently translocate to the outer 
mitochondrial membrane following a variety of pro-death stimuli where it may 
homo-oligomerize similarly to BAK, leading either directly or indirectly (e,g 
through VDAC/ANT) to mitochondrial permeation (see section 1.2.3.1.3) [127-
129]. 
How BCL-2-family anti-apoptotic proteins prevent mitochondrial 
permeation and how BH3-only proteins promote it is currently a subject of intense 
debate. For example, one model suggests that anti-apoptotic proteins directly 
stabilize the mitochondrial membranes whereas BH3-only proteins actively 
destabilize it upon outer membrane attachment [130-134]. Other models propose 
that BCL-2-family proteins help to control what is termed the mitochondrial 
permeability pore, by regulating VDAC/ANT, thought to be one of its core 
components [135, 136]. In light of the interaction between the BHl-2-3 domains 
of anti-apoptotic proteins su ch as BCL-2 with the BH3 domain of multi-domain 
pro-apoptotic proteins, sorne have suggested that anti-apoptotic proteins directly 
antagonize multi-domain pro-apoptotic proteins. In this context, it is supposed 
that BH3-only proteins can release and further activate BAX/BAK such as has 
been suggested to be the case for BID [137, 138]. Notably, BID and PUMA have 
been shown to interact with the first alpha-helix of BAX, an interaction which 
was necessary to mediate BAX-induced mitochondrial depolarizarion [139]. 
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On the other hand, evidence suggests that anti-apoptotic proteins such as 
BCL-2, BCL-XL and MCL-l wou1d associate to and prevent the action ofBH3-
on1y proteins such as BID and PUMA that directly activate BAX/BAK. Recent 
studies suggest that BH3-only proteins interact with specifie anti-apoptotic 
proteins [124, 140, 141]. In one study using full length and mutant BH3-only 
proteins in vitro and in vivo, it was shown that the varying affinities of BH3-only 
proteins towards the anti-apoptotic family members 1eads to hierarchica1 
interactions. For examp1e, whereas NOXA disrupts the interaction of PUMA, BID 
and BIM with MCL-l, the binding of BAD disrupts the interaction of activator 
BH3-on1y proteins with BCL-2/BCL-XL [124]. 
1.2.3.2.5. Transcriptional Control of BCL-2 Family Members 
At this point, we can begin to appreciate that the regu1ation of BCL-2-
fami1y member expression and their activation is a key component of the 
apoptotic process. A number of transcription factors are known to modu1ate the 
expression of BCL-2-family members, often in a cell type specifie manner. For 
examp1e, NF-KB binding sites are found in the BCL-2 promo ter and over-
expression or activation of NF-KB can increase BCL-2 expression in various 
contexts inc1uding 1eukemia and breast cancer cells [142, 143]. NF -KB is a1so 
thought to regulate the expression of BCL-XL, although STAT and Ets-family 
transcription factors may a1so play a ro1e [144]. In mye10id cells, the JAKISTA T-
3 pathway is thought to control MCL-l expression in response to IL-6 [145]. 
With respect to pro-apoptotic proteins, NOXA and PUMA were initially 
discovered as targets of the p53 transcription factor [117, 118]. It was 1ater 
observed that the p53 homo log p73 cou1d regulate the expression of PUMA [146] 
and that transcription factors of the E2F family (particularly E2F 1) could induce 
NOXA and PUMA expression [147]. In addition, the expression of NOXA and 
BIM can be up regulated by forkhead family factors such as FKHRL 1 [147, 148]. 
Finally, it was recently found that CHOP-CIEBP-a mediates the up-regulation of 
BIM in response to endop1asmic reticulum (EnR) stress [149]. 
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Alternative splicing can also yield some form of control in the production 
of pro and anti-apoptotic proteins. Skipping of MCL-l exon II yields MCL-1S, 
which acts as a pro-apoptotic apoptotic protein in contrast with the full-Iength 
form [119]. Similarly BIM has several isoforms, one of the smaller ones being 
BIM-AD, which lacks the domain that normally allows the sequestering of BIM 
at the cytoskeleton, resulting in a highly potent pro-apoptotic form [150]. 
Similarly, BID possesses at least three splice variants, one of which (BID(S)) 
abrogates the pro-apoptotic effects of activated BID [151]. PUMA also has four 
potential splice variants although only PUMA-a and PUMA-p have the BR3 
domain and their activity is thought to be similar [117]. BAX also possesses 
splicing variants that may serve different functions, although these remain uncIear 
[152]. 
1.2.3.2.6. Post-Translational Control of BCL-2 Family Members 
In addition to transcriptional control and alternative splicing, post-
translational modifications play an important role in modifYing the activity of 
BCL-2-family members. Among others, these modifications incIude proteolytic 
cleavage, phosphorylation, and ubiqutinylation. A prime example of proteolytic 
cleavage is the processing ofBID into its truncated short form tBID (or pI5). This 
process exposes the BR3 domain ofBID, which is thought to aHow its interaction 
with BAX [139]. This process is often catalyzed by caspase 8, which can be 
notably activated following membrane receptor signaling (e.g. Fas receptor) [138, 
153]. Rowever, as tBID lacks a hydrophobic region, it requires further addition of 
a mirystoyl group to integrate the mitochondrial outer membrane [154]. 
Many BH3-only proteins can be phosphorylated in response to cellular 
stress or to cytokines. One of the cIassic examples is BAD, that is maintained in a 
phosphorylated state by the persistent activity of kinases such as Akt [155]. In its 
phosphorylated state, BAD binds to 14-3-3 proteins that sequester it and prevent 
its action [156]. BAD must be de-phosphorylated by phosphatases such as 
calcineurin [157] in order to be activated. BIKlNBK can also be phosphorylated 
by kinases such as casein kinase II (CKII), although in contrast with BAD, 
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phosphorylation of BIKlNBK leads to its activation [158]. Similarly, BIM and 
BMF can be phosphorylated by JNK on dynein light chain binding motifs, which 
releases them from the cytoskeleton in response to microtubule-targeting agents 
such as Taxol (BIM) or resulting from anoikis (BMF) [159]. On the other hand, 
ERK-mediated phosphorylation of BIM promotes its ubiquitination and 
proteasome-mediated degradation and this event is prevented upon EnR stress by 
the action of the PP2A phosphatase [149]. Although this has not been particularly 
well studied to date, other BCL-2-family members can be targeted for degradation 
by the ubiquitinlproteasome system. One well-known example is MCL-l, which 
contains a PEST domain that targets it for degradation by the proteasome 
following poly-ubiquitination by the Muie/ARF-BPI E3 ubiqutin ligase [38]. This 
event can be blocked by phosphorylation of the PEST sequence by ERK signaling 
[160]. 
1.2.3.3. Effectors of Apoptosis 
Once the integrity of mitochondrial outer membrane has been fully 
compromised, various effectors of apoptosis are released from the inter membrane 
space. These proteins are responsible for producing the hallmark morphological 
changes associated with apoptotic cell death. With respect to this, caspases play a 
crucial role. 
1.2.3.3.1 Caspases 
Caspases are selective cysteine-proteases that cleave their substrate 
following an aspartate residue [161]. There are at least Il caspases expressed in 
humans, initially produced as inactive zymogens (pro-caspases) (207-210). Active 
caspases are hetero-dimers that result from the proteolytic processing of the pro-
caspase form which yields a short C-terminal fragment, a long middle fragment 
and an N-terminal pro-domain that does not participate in hetero-dimerization. 
However, when fully activated, caspases are in fact composed of two hetero-
dimers. Notably, active caspases can activate their own inactive zymogens as well 
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as that of other caspases, yielding what is known as the caspase cascade [162-
166]. 
There are three essential categories of caspases: intitiator caspases, 
effector caspases, and caspases involved in inflammatory cytokine maturation. Of 
these, inititator and effector caspsases are of particular importance for apoptosis. 
Initiator caspases include caspase-2, -8,-9 and -10 while effector caspases consist 
of caspases -3, -6 and -7 [167, 168]. As one might gather from the nomenclature 
used to classify them, initiator caspases initiate the caspase cascade. As 
mentioned previously, caspases -2 and -9 are present in the inter-membrane space 
of the mitochondrion (see section 1.2.3.1.3). Their release from the mitochondria 
in response to cellular alterations that tip the balance towards the activation of 
pro-apoptotic BCL-2-family members initiates what is termed the intrinsic 
apoptotic pathway [62, 89, 92]. The role of the initiator caspases is to activate the 
effector caspases, which mediate the proteolysis of many substrates that lead to 
the hallmarks of apoptosis. One of the principle modes of activation of the 
effector caspases via the intrinsic pathway is through what is ca lIed the 
apoptosome, a complex containing Apaf-l and pro-caspase 9 that forms in the 
presence ofcytochrome c in an ATP-dependent fashion [169-172]. Caspase-2 has 
also been reported to form similar complexes with RAIDD and PIDD, which has 
been named the PIDDosome. The formation of the apoptosome (and/or the 
PIDDosome) leads to auto-activation of caspase-9 (or caspase-2), which in tum 
activates caspases -3, -6 and -7 [173-176]. In contrast, caspases -8 and -10 are 
associated to the extrinsic or death receptor pathway. This pathway is essentially 
associated to the TNF death receptor family that includes Fas, TNF-Rl, DR3, 
Trail-RIIDR-4, DR5IKiller/Trail-R2 and DR6 [177]. Upon the cell surface 
receptor binding of death-inducing ligands such as FasL, Trait and various others, 
the death receptors oligomerize and recruit adaptor proteins such as F ADD or 
TRADD via interactions through the death domain (DD). The adaptors 
subsequently recruît înitiator caspases -8 and/or -10 forming what is called the 
Death Induced Signaling Complex (DISC). Once in close proximity, caspases -8 
and caspase-lO undergo auto-activation and may initiate the caspase cascade. In 
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addition, as caspase-8 can c1eave BID into its active from tBID, the intrinsic 
pathway can feed back to the mitochondrial pathway, accelerating to apoptotic 
process [178-181]. 
1.2.3.3.2 Caspase Targets 
Once the effector caspases are activated, they are free to c1eave key 
substrates leading to DNA fragmentation and the formation of contained apoptotic 
bodies. One of these is ICAD, a natura! inhibitor of CAD (caspase activated 
DNAse). Cleavage of ICAD leads to activation of CAD and subsequent DNA 
fragmentation [182, 183]. Effector caspases aiso lead to the cleavage of proteins 
such as PARP [184] and DNA-PK [185] that are involved in the maintenance of 
genome integrity. In addition, the constitutively active truncated form ofROCK-l 
resuiting from caspase-mediated proteolysis leads to membrane blebbing through 
its role in actin cytoskeleton contraction [186]. 
1.2.3.3.3. Inhibitors of Apoptosis 
The activity of the caspases can be inhibited by a c1ass of proteins called 
lAPs (inhibitors of apoptosis). These proteins, including clAPI, clAP2, xIAP, 
ML-IAP, Survivin and Apollon, inactivate caspases through interactions via their 
BIR domains (bacuiovirai IAP repeat) [187-192]. Interestingly, sorne of the se 
proteins, such as clAPI, xIAP and Apollon contain Ubiquitin ligase RING 
domains and can mediate their own targeting for proteasomal degradation in 
response to an apoptotic stimulus [193, 194]. As mentioned previously, the 
activity of lAPs can be inhibited subsequently to leakage of the mitochondrial 
inter-membrane space through the action Diablo/Smac and Omi/HtrA2 (see 
section). 
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23 
1.2.3.4. Non-Apoptotic Cell Death 
It is important to mention that although bone fide apoptosis reqUIres 
caspase activation in order to occur, cell death does not necessarily require the full 
completion of the apoptotic program. As was mentioned previously, the formation 
of the apoptosome is an ATP-dependent process and as such, it is thought that 
metabolic shutdown leading to rapid energy depletion can prevent the execution 
of the normal apoptosis program, leading instead to necrosis or sorne intermediate 
form of death in between (e.g necrapoptosis [195]). In addition, preventing 
caspase activation using chemical pan-caspase inhibitors such as ZVAD-fmk 
[196] does not always prote ct from cell death but may instead prevent the 
appearance of apoptotic hallmarks su ch as membrane blebbing and cell shrinkage. 
These modes of death can be termed caspase-independent, as they do not require 
the activity of caspases in order to occur, ev en though caspase activity and sorne 
of its associated phenotypical manifestations may be observed throughout the 
process [197]. Another form of cell death that can occur in absence of caspases is 
mitotic catastrophe, which occurs during mitosis and is characterized by poly-
nucleation [198]. To a certain extent, irreversible growth arrest (senescence) can 
also be viewed as a form of caspase-independent cell death even though the 
metabolic activity ofthese senescent cells can persist for sorne time [199]. 
1.2.4. Deregulation of the Cell Cycle and Apoptosis in Cancer 
Having reviewed the various pro cesses of cellular homeostasis, we are 
now ready to explore how these are fundamentally altered in the context of the 
cancer cell. Before we proceed to address this in the specific case of prostate 
cancer (see the following section), we will briefly review important concepts and 
key molecular pathways implicated in cancer development. 
1.2.4.1 Important Conditions for the Development of Cancer 
It is thought by sorne of the pioneers in cancer research that specific 
characteristics need to be acquired by cancer cells in order to attain full-fledged 
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malignancy, although these conditions may be attained using several strategies 
[200]. It has been suggested that cancer cells must become self sufficient in 
growth signaling and acquire limitless replicative potential, become refractory to 
growth inhibition signaIs and able to evade apoptosis, acquire the ability to 
sustain angiogenesis and develop the ability to invade surrounding tissues and 
metastasize. As a last condition, it is thought that genomic instability can be a 
catalyst for the rapid acquisition of these abilities. N otably, at least three of these 
characteristics implicate the inadequate regulation of the cell cycle and of 
apoptosis. 
1.2.4.1 Self-Sufficiency in Growth Signaling. 
As mentioned previously (sections 1.2.1-1.2.2), the progression through 
the cell cycle is strongly influenced by growth factor signaling, particularly at the 
G 1 phase through the up-regulation of D-type cyclin expression. As such, in order 
to continually divide, cancer ceIls must acquire the ability to reproduce growth 
factor signaling in the absence thereof. Although this can be achieved in many 
ways, a few key pathways are frequently de-regulated in cancer cells. 
1.2.4.1.1. Receptor Tyrosine Kinases and the Ras Pathway 
Receptor tyrosine kinases play a major role in growth factor signaling. 
This class of receptors accommodates a wide range of growth factor ligands 
including transforming growth factor a (TGF-a), platelet-derived growth factors 
(PDGF), insulin growth factors (IGF) and epidermal growth factors (EGF) [201-
203]. Receptor tyrosine kinase (RTK) signaling proceeds through two major 
pathways whose activation depends on the ligand and receptor involved. The tirst 
pathway involves Ras and its downstream signaling effectors, which include Raf, 
MEK and MAPKs and leads to the phosphorylation of various proteins, including 
the Myc transcription factor that is involved in ceIl cycle progression, among 
others, through the regulation of cyclins [204-206]. It is thought that roughly 25% 
of aIl human cancers express a mutated form of Ras that is active independently 
of receptor tyrosine kinase signaling [206]. In addition, many cancers exhibit 
elevated levels of RTKs such as EGFR or Her-2 [207, 208], as weIl as increased 
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autocrine production of RTK ligands such as TGF-a [209]. Altemate1y, 
augmented expression of downstream effectors of Ras signaling, particularly of 
Myc, is observed in cancer (particularly in Burkitt's lymphoma) [210] and over-
expression of Myc drives tumor deve10pment in several mouse models [211] (for 
an overview, see Fig. 1.3). 
1.2.4.1.2. The PI3K1 Akt Pathway 
Another pathway important for self-sufficiency in growth factor signaling 
involves PI3K and its downstream effector Akt. PI3K activation leads to the 
phosphorylation of membrane-bound phosphatidyl-inostol (4,5) bi-phosphate 
(PIP2) into phosphatidyl-inosoitol (3,4,5) tri-phosphate (PIP3). The conversion of 
PIP3 back to PIP2 is catalyzed by the PTEN phosphatase, which acts as an 
important negative regulator of this pathway and is often mutated in cancer (see 
section). Membrane-bound PIP3 activates phosphatidylinositol-dependent kinases 
(e.g. PDK1), which leads to the phosphorylation and activation of Akt [212]. 
Counterbalancing the action of PDKs, the PP2A phosphatase can de-
phosphorylate and inactivate Akt [213]. Notably, Akt is a central signaling hub as 
it sits at the junction of several signaling pathways [214]. Akt activation also leads 
to the phosphorylation and activation of mTOR, which stimulates prote in 
translation and consequently affects several other pathways [215, 216] (see 
section). As mentioned previously, active Akt also maintains the BCL-2-family 
member BAD in a phosphorylated and inactive 14-3-3 protein-bound state, which 
promotes cell-survival [217]. Finally, Akt can also activate the NF-KB pathway 
[218,219] (for an overview, see Fig. 1.3). 
1.2.4.1.3. The NF-KB Pathway 
NF-KB is a dimeric protein composed of combinations of NF-KB 
monomer subunits p50, p65 (Re1A), p52, RelB and c-Rel. NF-KB activity is 
directly regulated by the action of IKB proteins (e.g. IKB-a, p, E, p100) and IKB 
kinases (lKK-a, p, y, E) [49, 220, 221]. IKBs retain NF-KB in the cell cytoplasm 
and diminish its transactivation potential whereas IKB kinases phopsphorylate 
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both IKBs as weIl as NF-KB itself. Phosphorylation of IKBs leads to their 
proteasome-mediated degradation and leads to the release and nuc1ear 
translocation of NF-KB trancription factors. In addition, phosphorylation of NF-
KB subunits (eg. p65) can lead to increased transactivation potential [222]. In 
what has been termed the c1assic or canonical NF-KB pathway, activation of IKB 
kinase ~ (IKK-~) by stimuli such as TNF-a, leads to the phosphorylation of IKB-
a. Phosphorylated IKB-a is quickly targeted for proteasome-mediated degradation 
through the action of SCF~TrCP [34]. Degradation of! KB-a is thought to lead to the 
specific release of p50 and p65 homo-and hetero-dimers. In the non-c1assical or 
non-canonical pathway, IKK-a leads to the phosphorylation and proteasome-
mediated proteolytic processing of plOO into the NF-KB p52 subunit. Dimers 
formed from RelB and p52 as weIl as p52 homo-dimers are generally associated 
to this pathway [34, 49, 223] (for an overview, see Chapter 1 Figure 3). The non-
c1assical pathway is typically activated by stimuli su ch as lymphotoxin Band 
lipopolysaccharide (LPS) [224] but also following long-term androgen 
stimulation as discovered recently in LNCaP prostate cancer cells [225]. By 
binding KB sequences within gene regulatory elements, NF-KB controls the 
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expression of hundreds of genes, many of which are involved in cell proliferation 
and cell survival [223]. 
1.2.4.1.4. Alternate Pathways: from Wnt to Nuclear Reeeptors 
In addition to the frequently observed constitutive activation of the Ras 
and PI3K signaling axes, cancer cells can exhibit aberrant signaling in the Wnt 
pathway, involving its receptor (e.g Frizzled) and effectors Disheveled, GSK-3~, 
APC and ~-catenin [226]. Increased signaling through G-protein coupled receptor 
and its effectors adenylate cyclase, PKA and the CREB transcription factor are 
also observed in cancer cells [227]. Furthermore, cancer cells can over-express 
and secrete interleukin-family cytokines su ch as IL-3 and IL-6 [228,229], whose 
autocrine effects are mediated by interleukin receptors (e.g gp130) that signal 
through JAK and ST AT trancription factors [230, 231]. Finally, nuclear receptor 
family transcription factors, which act as direct sensors and transducers of 
signaling by various ligands including steroid hormones, are often abnormally 
active in cancer. This event is frequently observed in breast cancer for the 
Estrogen Receptor (ER) [232] and in prostate cancer (PC a) for the androgen 
receptor (discussed in further detail in section 1.3.5). 
1.2.4.2. Insensitivity to Growth Inhibitory Signais 
1.2.4.2.1 Poeket Pro teins and Cell Cycle Inhibitors 
In addition to mimicking persistent signaling from growth factor signaling 
components, the cancer cell must become refractory to signaIs that promote 
quiescence through cell cycle exit and/or differentiation. Importantly, many of 
these signaIs converge to the pocket prote in family members pRb, pl07 and p130 
[47, 233]. Particularly loss of pRb functionality is frequently observed in cancer 
and several oncogenic viral proteins such as ElA and E7 also inactivate Rb [233, 
234]. Among others, loss of pocket proteins, particularly pRb, leads to the 
constitutive activity of E2F transcription factors, which promotes cell cycle 
progression in a manner that cannot be halted by anti-growth signaIs, such as that 
provided by TGF-p signaling for example [235]. Notably, although sorne of the 
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anti-proliferative effects of TGF-~ are mediated by the phosphorylation pRB, 
TGF-~ can also reduce the expression of myc and up-regulate CDK inhibitors 
such as p 15 (INK4b), p2l Cipl and p27Kipl through the action of SMAD 
transcription factors [235, 236]. As such, de-regulation of these proteins (e.g up-
regulation of myc or loss of CDK inhibitors) can lead the cell to become 
unresponsiveness to growth-inhibitory signaIs. 
1.2.4.2.2. p53 and the Response to DNA Damage 
Growth inhibitory signaIs can also originate from internaI cell signaIs such 
as those coming from DNA damage. In response to DNA damage, signaling 
kinases such as ATM and ATR activate a multitude of targets including p53, Bid 
and IKB-a [237, 238]. In this pathway, p53 is particularly important because it 
leads to the up-regulation of genes involved in cell cycle arrest such as p2l Cipl as 
weIl as genes involved in apoptosis such as NOXA, PUMA and BAX [53, 117, 
118, 239]. As such, p53 acts as a gatekeeper for the integrity of the genome that 
can be compromised in response to various genotoxins but also through un-
controlled progression through the ceIl cycle via the aberrant activation of 
oncogenes such as Ras for example [240]. Likely due to this central position in 
the cell, p53 is mutated in over 50% of cancers [241]. Notably, a negative 
regulator of p53, the MDM2 ubiquitin ligase, is also overexpressed in roughly 
10% of human cancers [242]. In paraIlel, the INK4B locus-encoded p16INK48 
(CDK inhibitor) and p19ARF, a negative regulator ofMDM2, are frequently lost in 
cancerous cells [243]. In any case, without p53, cancer cells are thought to be free 
to progress through the cell cycle and accumulate mutations that may lead them to 
even more rapid acquisition of additional characteristics important for optimal 
malignancy [200]. However, as nearly half of human cancers are not mutated for 
p53, it is clear that p53-mediated functions such as apoptosis, cell-cycle control, 
and DNA repair can be bypassed by other means as well. 
1.2.4.3. Resistance to Apoptosis 
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Another fundamental characteristic of cancer cells is their ability to bypass 
both extrinsic and intrinsic death signaIs. Similarly to the many ways that can be 
employed by cancer cells to attain growth factor cell-autonomy, resistance to 
apoptosis can be achieved by a variety of alterations in the pathways that lead to 
apoptosis. In fact, sorne of the signaling pathways that lead to growth factor self-
sufficiency and resistance to growth inhibitory signaIs also lead to resistance to 
apoptosis. For example, within the PI3K pathway, over-activation of Akt leads to 
the inhibition of the pro-apoptotic prote in BAD. Still within this pathway, the 
activation of NF -KB can lead to the up-regulation of anti-apoptotic proteins such 
as BCL-2, BCL-XL and AIIBf1 [142-144, 244] as well as of lAPs such as xlAP 
[245], c-IAPI and c-IAP2 [246]. Notably, the prototypical BCL-2 family member 
(BCL-2) was first discovered in the context of B-celllymphoma (hence its name) 
where it is up-regulated due to a chromosomal translocation that subjects it to 
transcriptional control by the immunoglobulin locus [247]. 
The down-regulation or loss of pro-apoptotic proteins may also promote 
cancer progression. However, because the functions of sorne pro-apoptotic 
proteins appear to be highly redundant, their contribution to tumor progression 
may be fairly context specific and it is likely that the inactivation of many pro-
apoptotic proteins is required to achieve a maximal impact [248]. For example, 
Bax-null transgenic mi ce very infrequently develop spontaneous tumors [249]. 
Nonetheless, sorne pro-apoptotic proteins have been found to increase 
tumorigenesis in mouse models, particularly in combination with oncogenes that 
stimulate cell proliferation. For example, loss of one or both alleles of Bim in 
transgenic mice expressing a myc transgene accelerates the onset of acute B-cell 
leukemia [250]. Analogous results are obtained in a similar model but where mi ce 
are instead deficient in BAX [251]. In addition, mice completely deficient for 
BID develop chronic monomyelocytic leukemia after approximately 2 years of 
life [252]. Although this is not always be the case as we will see in chapters II and 
V, loss of p53 curtails the up-regulation of its pro-apoptotic targets NOXA, 
PUMA and BAX in response to DNA damage and cytotoxic drugs [239, 253]. 
This phenomenon has been hypothesized to contribute to tumorigenesis in p53 
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defficient tumors. However, supporting the hypothesis that the cancer cell may 
require the inactivation of many pro-apoptotic genes to promote tumorigenesis, 
mice deficient for NOXA only modestly co-operate with transforming oncogenes 
ElA and Ras, which is aided by the additional 10ss of Bax [254]. On the other 
hand, mouse embryonic fibroblasts expressing ElA and Ras in which PUMA has 
been down regulated via shRNA exhibit markedly enhanced tumor formation 
when implanted in immuno-compromised mi ce [255]. These observations also 
appear to correlate with the relative contribution of PUMA and NOXA to p53-
mediated apoptosis in several contexts [248]. 
1.2.4.4 Other Important Characteristics. 
In addition to the cancer cell characteristics involving the cell cycle and 
apoptosis described in section 1.2.4.1 through 1.2.4.3, it is worthwhile to briefly 
mention key pathways that can confer limitless replicative potential, sustained 
angiogenesis and increased invasiveness. 
1.2.4.4.1. Unlimited Replication 
In contrast with normal ce Ils that can only replicate a fixed number of 
times ( 60-70 divisions), cancer cells have unlimited replication potential and are 
as such considered immortal. One of the processes that have been implicated in 
this phenomenon is the de-regulated increase of telomere length. Telomeres are 
formed from highly repetitive sequences present at the ends of each chromosome 
and prevent the loss of genetic information at the chromosome ends following 
replication. The length of telomeres is normally maintained by enzymes such as 
Telomerase or through a homologous recombination based pathway termed AL T 
or alternative lengthening of telomeres. Hence, de-regulated expression of 
Telomerase or of the enzymes involved in AL T can lead to increased telomere 
length [9, 256-260]. In addition, as the maintenance of telomere length is highly 
influenced by chromatin compaction, altered activity of proteins such HATS, 
HDACs and histone methylases (e.g SUV39Hl and SUV39H2) can also impact 
the length oftelomeres [9]. 
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1.2.4.4.2. Sustained Angiogenesis 
In maintaining access to blood and oxygen, the VEGF growth factor is 
thought to be of major importance as it is one of the main signaling molecules 
involved in the recruitment of peripheral blood vessels. By producing cytokines 
such as VEGF either directly or indirectly, growing tumors can re-route blood 
vessels in order to remain well-oxygenated [261]. Altematively, cancer cells that 
lay in the center of tumors where hypoxic conditions are encountered may 
constitutively up-regulate RIF -1 a, a transcription factor that promotes the 
production of TGF-a, PDGF and VEGF in acute low-oxygen conditions [262]. 
Under normal conditions, RIF-la is degraded by the prote as orne through the 
action of the p VRL ubiquitin ligase, which is notably frequently mutated or lost in 
sorne forms of cancer (eg. renal cancer, hemangioblastoma) [263, 264]. In 
addition, RIF-la is stabilized and up regulated by aberrant activation of the 
mTOR pathway [265, 266]. 
1.2.4.4.3. Enhanced Invasiveness 
The ability of the cancer cell to invade the surrounding tissue and infiltrate 
distant sites can be achieved by various means. Notably, matrix metaloproteinases 
(MMPs) such as MMP-9 are thought to play a role in this process [267, 268]. In 
addition, cell adhesion molecules including integrins and E-cadherin can play a 
role in the process of cancer cell detachment form the primary tumor site and 
attachment to distant sites. Notably, these proteins are also involved in cell 
signaling, such as E-cadherin within the ~-catenin pathway, which can be 
important for cell survival in conditions of anoikis (cell detachment) that may 
otherwise lead to apoptosis [200, 269]. 
1.3. Prostate Cancer Development and Pathology 
Now that we understand the over-arching principles implicated in cancer 
development, we can begin to look at how cancer develops in the specific context 
of the prostate. Before we can fully appreciate this disease however, it is 
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important to briefly review sorne of the basic anatomical characteristics of the 
prostate in addition to the known factors that regulate its development. 
1.3.1 Anatomy of the prostate 
The prostate is a primarily exocrine gland situated at the base neck of the 
bladder and in front of the rectum. In adults, the normal prostate weighs roughly 
15-20 grams although prostate size often increases with age [270]. The prostate is 
composed of two lobes that surround the proximal part of the urethra extending 
from the bladder neck [271]. Within the prostate, there are three histologically 
distinct regions, discernable on the basis of the glandular architecture. The 
peripheral zone represents roughly 70% of the prostate, while the central and 
transitional zones represent approximately 25% and 5% of the prostate volume 
respectively [272]. The function of the prostate is to secrete a nutrient-rich fluid 
that also contains enzymes involved in sperm liquefaction such as prostate 
specific antigen (PSA) [270, 273, 274]. The alveolar architecture of the prostate 
gland allows for the collection of the prostatic fluid into the urethra, where it 
rejoins secretions from the seminal vesic1es, which are situated above the prostate 
between the bladder and the rectum [270, 271]. 
1.3.1.1 Cellular composition of the secretory glands 
The secretory glands that constitute the glandular network are composed 
of three cell types. The luminal epithelial cells normally compose a single layer of 
differentiated cells at the lumen interface and are the main contributors to the 
secreted prostatic fluid [275]. Surrounding the layer of differentiated luminal cells 
is a much thinner layer of basal cells, which are essentially the renewable 
progenitors of both luminal cells and neuroendocrine cells [276]. Neuroendocrine 
cells produce neuropeptides involved among others in the control of cellular 
proliferation [277]. These cell types can be differentiated by the expression of 
specific proteins. Notably, whereas only luminal cells express the AR and 
cytokeratins 8/18, cytokeratin 5 and cytokeratin 34pE 12 are primarily expressed 
in basal cells [276]. Finally, the prostate secretory glands are surrounded by fibro-
muscular tissue referred to as the stroma, which is thought to play a role in the 
34 
regulation of epithelial ceIl growth through the secretion of growth promoting 
factors such as FGF as weIl as growth inhibitory factors such as TGF-~[278-280]. 
1.3.2. Factors Important for Prostate Development 
The development of the prostate is strongly influenced by androgen 
growth factors. The testes are the main producers of androgens, although the 
adrenal glands also produce a sm aIl amount. The testicular production of 
androgens is regulated by the LHRH (lutheinizing hormone-releasing hormone) 
sex hormone that is secreted by the pituitary gland [281-284]. The androgen 
thought to be the most active throughout prostate development is 
dihydrotestosterone (DHT). Notably, one important enzyme involved in the 
production ofDHT is 5-a-reductase, which catalyses the conversion of the double 
bond present in position 4,5 oftestosterone into a single bond through the addition 
of two hydrogens [282]. DHT and androgens in general mediate their effects 
through the androgen receptor (AR), a nuclear receptor family transcription factor 
(described in greater detail in section 1.3.5). 
Although the role of androgens in prostate development is clear, little is 
known about other factors that influence prostate development. In fact, many of 
the genes currently thought to regulate prostate development are regulated by 
androgens. For example, androgens regulate the expression of the NKX3.1 
homeobox transcription factor, thought to play an important role in prostate 
development [285, 286]. The FGF-lO cytokine, which plays a role in establishing 
glandular branching is also regulated by androgens [287]. In addition, a very 
recent study has further established a role for androgens in up-regulating the 
expression of the FGF -10 receptor FGFRiiib, of Sonic hedgehog and its receptor 
Ptc, of Hoxb 13, and of BMP7, aIl factors that are thought to contribute to prostate 
development and morphogenesis [288]. 
1.3.3. Prostate Cancer: Origins, Prevalence, and Risk Factors 
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Prostate cancer typically develops from the peripheral zone of the prostate, 
accounting for 60-70% of prostate cancers (PCa) [289]. PCa tumors arise almost 
exclusively from the epithelial cells that compose the prostate glandular network. 
Furthermore, PCa develops most frequently from luminal and basal cells whereas 
tumors ofneuroedocrine origin are more rare [290]. 
According to recent statistics, 22 300 new cases of prostate cancer are 
expected for 2007 in Canada, making it the most frequently diagnosed cancer. 
However, in terms of mortality PCa ranks as the third most frequent killer in men 
following lung and colorectal cancer, with an expected 4300 deaths in Canada for 
2007 [291] . 
Although several studies have set out to understand the etiology of PCa, 
only a few risk factors have been established so far. Age is thought to be one of 
the most important factors. Notably, as suggested by a recent report from the 
Canadian Cancer Society, the 10-year risk for PCa development was found to be 
nearly 70 times higher in 70-79 year old men as compared to men age 40-49 
[292]. 
It is thought that only 5-10% of PCa cases are linked to hereditary causes. 
Notably, PCa risk increases when a close family member such as a brother or 
father has developed the disease [293]. On the other hand, the specific causes of 
hereditary PCa are far from c1ear even though a few potential polymorphisms and 
susceptibility genes have been identified. These include genes such as 
endoribonucleases RNAseL [294] and ELAC2 [295], which may respectively 
interfere with antiviral response [296] and anti-proliferative TGF-~ signaling 
[297], NBS1, CHEK2 [298, 299], and p27Kip1 that are involved in cell cycle 
control, as well as BRCAI and BRCA2 that are involved in DNA repair [300, 
301]. In addition certain polymorphisms of the AR (see section 1.3.5) and of5-a-
reductase have been found to be associated to PCa risk [302]. 
Although isolating the specific dietary components involved is often 
particularly challenging due to a multitude of potentially confounding factors, it is 
becoming increasingly clear that nutritional habits are linked to the progression of 
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PCa or lack thereof. Nutrients currently thought to have a protective effect against 
PCa inc1ude lycopenes (such as found in tomatoes) [303], ~-carotenoids [304], 
vitamin D [305], vitamin E [306], selenium (as found in garlic) [307], 
sulforaphane, indole-3 carbinol (in cruciferous vegetables such as broccoli) [308], 
polyphenols (green tea, red wine) [309, 310], and curcumin (Indo-Asian spice) 
[311]. Other foods such as soy are rich in factors thought to prote ct against PCa 
inc1uding isoflavones such as genistein, daidzein and equo1 [312] as well as other 
molecules such as inositol hekakisphosphate (as we will review in further detail in 
section 1.4.4). In contrast, high dietary calcium and zinc intake may potentially 
increase PCa risk [313]. 
Likely linked to both nutritional and genetic factors, race has emerged as 
another risk factor for PCa. Notably, African Americans are the most susceptible 
to PCa, followed by Caucasians, Hispanics, and Asians [314]. 
1.3.4. Genetic and Molecular Events Involved in Prostate Cancer Progression 
Whereas hereditary PCa constitutes a minority of PCa cases, sporadic 
genetic events are thought to account for over 90% of the observed cases. In the 
context of cellular homeostasis, it is therefore relevant to point out sorne of the 
commonly encountered chromos omal alterations in PCa and their impact on the 
process of prostate epithelial cell transformation. 
1.3.4.1. Chromosomal Losses and the Role of Tumor Supressors 
Partial or complete loss of chromosomes 5q, 6q, 8p, 9q, lOp, 10q, 13q, 
16q and 17p has been detected to various extents in PCa tumors [315-334]. 
Although the mediators of the effects on tumorigenenesis present within the 
chromosomal domains have not all been identified, it is reasonable to expect that 
they involve various tumor repressors. Of note, chromosome 9q contains the CDK 
inhibitors p15 (INK4B) and p16 (INK4A) [316] (see section 1.2.1.3.). As 
mentioned previously, the IN4KA locus also codes for p19 (ARF), a negative 
regulator of the MDM2 prote in that targets p53 for degradation (see section 
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1.2.4.2.2.). Chromosome 10q contains the PTEN phosphatase, a negative 
regulator of the PI3K pathway (see section 1.2.4.1.2) and is lost in up to 63% of 
metastatic PCa [317, 330]. In addition, transgenic mice that present homozygous 
loss of PTEN specifically in the prostate progressive1y deve10p metastatic PCa 
[335]. Chromosome 13q contains pRb involved in cell cycle progression (see 
sections 1.2.1.3 and 1.2.4.2.1), which is lost in approximately a third of localized 
PCa and in up to 75% ofmetastatic PCa [315, 317]. Chromosome 16q contains 
the cell adhesion molecule E-cadherin, which is also involved in regulating ~­
catenin signaling [317, 325, 332]. Finally, the gene encoding for the p53 protein 
involved in response to DNA damage, genome integrity, and apoptosis, is located 
on chromosome 17p that is lost in 18% of localized PCa and up to 50% of 
metastatic prostate tumors [317, 334]. 
1.3.4.2. Chromosomal Gains and the Role of Oncogenes 
In parallel, chromos omal gains and gene amplifications are also observed 
in PCa tumors. Notably, gains in chromosomes lq, 2q, 7p, 8q, IIp and 17q have 
been reported [317, 318, 336-339]. The effects of chromosome 8p gain, a fairly 
frequent event (observed in up to 85% of metastatic PCa), are thought to be 
associated to the myc gene that it harbors [317,339,340] (see section 1.2.4.1.1). 
The contribution of myc to locally invasive PCa has been also observed in 
transgenic mice that over-express myc in a prostate-specific fashion [341]. 
Although less frequent (8%), the effects of chromosome 7p gain are attributed to 
EGFR [337] (see section 1.2.4.1.1). Similarly, the EGFR homo log HER-
2/NeulErbB2 is present on chromosome 17q whose gain was reported in 30% of 
metastatic tumors [317, 339]. Finally, the gain of chromosome 11 p, observed in 
nearly half of metastatic PCa, is thought to promote tumorigenesis in part via 
increased expression the Ras oncogene [317]. 
1.3.4.3. Other Important Genetic Events 
Beyond major chromosomal alterations, sorne specific genetic 
transformations are thought to be involved early on in PCa deve1opment. Notably, 
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the role of the NKX3.1 gene was established through the observation that 
NKX3.1 knockout mi ce develop epithelial hyperplasia and dysplasia [342], 
Besides its role in the morphogenesis of the prostate and associated role in cell 
differentiation, it is interesting to note the NKX3.1 has recently been found to 
negatively regulate AR expression, stabilize p53, and inhibit Akt activation in 
PTEN knockout mice [343]. Another potentially important recent discovery was 
that of the TMRPSS2-ETS gene fusions that result from chromosomal 
rearrangement and that have been detected in almost 80% of PCa tumors. These 
fusions bring together the androgen-responsive gene promoter of the TMRPSS2 
gene in proximity with ETS transcription factors, which promote cell proliferation 
[344]. Last but not least, and indirectly impacting other potential oncogenes such 
as the TMRPSS2-ETS gene fusions, several mutations, gene amplifications and 
X-chromosome alterations link the AR to PCa progression. Notably, transgenic 
mice over-expressing the AR specifically in the prostate exhibit increased cell 
proliferation and signs of the initial stages of invasive PCa [345]. 
1.3.5. The Androgen Receptor 
One of the most significant advances in PCa treatment in the last century 
was linked to the discovery that castration (loss of androgen production) leads to 
the remission of metastatic prostate tumors [346] (see section 1.3.7.3). These 
experiments established androgens and their cellular target the AR as crucial 
regulators of prostate and PCa cell survival and proliferation. 
As mentioned previously, the AR is a member of the large family of 
nuc1ear receptor transcription factors. Its major structural components inc1ude an 
N-terminal transactivation domain (AF-I), a central DNA-binding do main 
(DBD), and a hinge region that links the DNA-binding domain to a second C-
terminal trans-activation do main (AF-2), within which is nested the androgen-
binding domain (ABD) [347]. 
1.3.5.1. The AF-1 Domain 
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The AF-I domain is particularly important for AR-mediated transcription. 
This is brought to light by the observation that de1eting the ABD do main of the 
AR yie1ds a receptor with constitutive transcriptional activity, equivalent to the 
full-Iength receptor [348]. The AF-I domain interacts with a variety of well 
known transcriptional co-activator proteins including ARA family co-activators 
(ARA24/RAN[349] , ARA70[350], ARAI60[351], ARA 267-a[352]), SRC-
1[353], CBP[354] and TFIIl{[355]. Sorne cell cycle proteins, including cyclin E 
[356] and pRb [357], also interact with the AF-I domain and lead to enhanced 
AR-mediated transcription. The AF-l domain interacts with several other proteins 
with various functions such as BRCAI [358], Raf [359], GAPDH [360], 
Caveolin-l [361] and mitochondrial COXVb [362]; however, the biological 
significance of these interactions is less clear. The AF-I domain contains both a 
poly-glutamine tract and a poly-glycine tract that are highly polymorphic due to 
polymerase slippage caused by the repetitive DNA sequence [363]. Notably, the 
poly-glutamine tract is thought to be important for co-activator recruitment [364]. 
Interestingly, the length ofboth poly-glutamine and poly-glycine tracts are linked 
to the risk of developing PCa [363]. 
1.3.5.2. The Hinge Region and the DNA-binding Domain 
Whereas the hinge region is thought to play a role in the translocation of 
the AR towards the nucleus [348, 365], the DNA-binding domain mediates the 
interaction between the AR (which usually acts as a dimer) and androgen 
response e1ements (ARE) [364]. The DBD recognizes the AREs through two 
Zinc-finger domains that intercalate the DNA major groove [366]. Much like AF-
l, the DBD/hinge interacts with various proteins including other transcription 
factors such as c-Jun [367], PDEF[368], ATF2[369], GR, OCTl/2 and p65(ReIA) 
[370]. Contrary to the other transcription factors, the NF-KB subunit p65 (Re1A) 
has an inhibitory effect on AR-mediated transcription. Analogously, other 
proteins such as calreticulin (a calcium-dependent chaperone) [371] and cyclin Dl 
[372] interact with the DBD/hinge and repress AR transcriptional activity. 
1.3.5.3. The AF-2 and Androgen-Binding Domains 
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The AF-2 and the nested ABD mediate the binding of androgens and elicit 
androgen-dependent transcription. Overall, this combined domain interacts with 
several proteins including co-activators such as ARA54 [373], ARA55/Hic-5 
[374] and the HAT named P/CAF [375]. The AF-2/ABD domain also interacts 
with other transcription factors such as ~-catenin [376], which acts as a 
transcriptional co-activator, SMAD-3 [377] that acts as an AR co-regulator, and 
p53 that represses AR-mediated transcription [378]. Notably, the AF-2/ABD of 
the AR interacts with cytoplasmic regulatory chaperones and co-chaperones su ch 
as Hsp90 [379-381] and cdc37[382]. 
1.3.5.4. AR Phosphorylation 
The AR is also known to interact with or be phosphorylated by several 
potein kinases. For example, Akt interacts with the AF-2/ABD domain [383] and 
phosphorylates the AR within AF-l and AF-2, which is thought to prime the AR 
for poly-ubiqutination and proteasome degradation through the interaction of 
MDM2 with the AF-l domain [384]. Other phosphorylation events mediated for 
example by PKA [385] and Src [386] onto the AF-l domain or by JNK [387] 
towards the hinge region, can instead activate AR-mediated transcription. PKC 
signaling initiated by phorbol ester has also been reported to lead to 
phosphorylation on serine 650 of the hinge region. However, it remains unclear 
whether phosphorylation at this site influences AR transactivation [388, 389]. 
1.3.5.5. Effects of Androgen Binding 
Importantly, the binding of androgens to the AR leads to structural 
rearrangements that lead to functional changes in the AR. When the AR is not 
bound by androgens, it is normally associated to chaperones such as Hsp90 and 
cdc37. Androgen binding disrupts the interaction between the AR and these 
cytoplasmic chaperones, which leads to the eventual shuttling of the AR towards 
the nucleus [348, 364, 365, 390]. In addition, androgen binding causes the 
displacement of a-helix 12 within the AF-2/ABD, which frees interaction sites 
important for co-activator recruitment [391, 392]. Bound by androgens, the AR 
has been reported to directly and indirectly regulate the expression of hundreds of 
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genes involved in a myriad of processes including differentiation metabolism, cell 
proliferation, cell cycle, and cell survival [393-395]. 
1.3.5.6. Cytoplasmic Androgen Receptor Functions 
Interestingly, an increasing number of studies suggest that the AR may 
play additional roles in the cytoplasmic compartment, particularly at the level of 
the cytoplasmic membrane. One study done in osteoblasts and HeLa cells 
suggests that androgen-bound AR can trigger the MAPK signaling pathway prior 
to shuttling to the nucleus, by interacting with and activating Src via the AF-2 
domain. This was associated to the resistance to apoptosis triggered by the DNA 
damaging drug etoposide [396]. Conversely, very recent studies done in PC3 
prostate cancer cells suggest that, independently of androgens, the AR can inhibit 
EGFR signaling. This is thought to occur by preventing receptor intemalization 
into endosomes via the caveolin-lIclathrin pathway [397], an event required for 
optimal EGFR signaling [398]. 
1.3.6. Commonly used Prostate Cancer Celllines. 
NKX3.1 and prostate-specific PTEN knockout mIce as well as mIce 
expressing the AR, myc (see sections 1.3.4.2 and 1.3.4.3) or transforming SV40 
pro teins [399] (see discussion section 6.3) specifically in the prostate are 
emerging as useful tools for the study of PCa development and treatment [400]. 
Although these recently developed mouse models have certainly contributed to 
our understanding of the factors important for PCa development, much of what is 
currently known stems from observations made from celIlines that were derived 
from either primary PCa tumors or metastases. This section will briefly review 
sorne important characteristics of the better known and most frequently used cell 
lines. 
1.3.6.1. The DU145 Cell Line 
DU145 cells were the first PCa cells to be isolated in culture. They were 
obtained from the brain metastasis of a 69-year old caucasian man that also had 
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lymphocytic leukemia [401]. The DU145 cell line contains on average 64 
chromosomes and exhibits many chromos omal alterations. A mutant form of p53 
as well as a non-functional mutant form of Rb is expressed in these cells [402, 
403]. Interestingly, the DU145 may have originated from epithe1ial ce Ils at a stage 
situated somewhere in between basal and luminal cell stage, as they do not 
express neuro-endocrine markers or the AR but simultaneously express 
cytokeratins 8, 18 and cytokeratin 5 [403-405]. The DU145 cell line forms 
aggressive tumors in immuno-compromised mi ce [406]. 
1.3.6.2. The PC3 Cell Line 
Another cell line that is very frequently used is the PC3 cell line, which 
originates from the lumbar metastasis of a 62 year old Caucasian male [407]. The 
PC3 cell line is also fully aneuploid with an average of 58 chromosomes. 
Similarly to DU145 cens, PC3 do not express the AR although the do express 
cytokeratins 8, 18 and 5, suggesting they may originate from basal-luminal 
intermediates [402, 403]. Also analogously to DU 145 cells, PC3 cells form 
metastatic tumors in mouse xenograft models. Notably, the p53 gene is mutated in 
PC3 cells, which results in a premature stop codon. As such p53 is not expressed 
in this cellline [403]. 
1.3.6.3. The 22Rvl Cell Line 
The 22Rvl cell line was derived through seriaI sub-cutaneous 
xenografting of the parental androgen-sensitive cell line CWR22R in castrated 
mice, which was initially obtained from the primary prostate carcinoma of a 
patient in which the cancer had already metastasized to the bone [408]. Karyotype 
analyses of the 22RVI genome have revealed that this cellline has an unstable 
genome and in particular, was found to have gained extra copies of chromosomes 
7, 8, and 12 [402,403]. Notably, as mentioned in section 1.3.4.2, chromosomes 7 
and 8 are thought to promote tumorigenesis because they contain EGFR and Myc 
oncogenes respectively. In addition, the p53 gene of 22RVI cells presents 
heterozygous mutations in exons 8 and 9 [403]. 22RVl cells express cytokeratins 
8 and 18 as well as the AR, although the AR presents two mutations, one in the 
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AF-l do main and the other in the AF-2/ABD. 22Rvl cell growth is stimulated by 
androgens although they continue to grow in absence of androgens [409], In 
addition, the growth of 22Rvl cells is stimulated by EGF but and is not inhibited 
by TGF-~ [403, 406]. 22Rvl cells form large tumors in mice but do not 
metastasize wh en injected intra-prostatically [410]. 
1.3.6.4. The LNCaP Cell Line 
The LNCaP cell line was isolated from a metastatic lymph node biopsy 
obtained from a 50-year old caucasian male [411]. LNCaP cells are aneuploid, 
reportedly containing an average of 76 to 91 chromosomes. In LNCaP cells, 
Chromosome lOg has suffered deletions in the PTEN locus and as such, LNCaP 
cells do not express PTEN. However, they express cytokeratins 8 and 18, a wild-
type p53 and the AR [402, 403]. Notably, the AR is mutated at position 877 in the 
ABD which alters its specificity. Conseguently, the LNCaP AR is responsive to a 
wider range of ligands, inc1uding flutamide, an anti-androgen used for androgen 
depletion therapy (see section 1.3.7.3) [412]. LNCaP cell growth is at least 
initially dependent on androgens; however, several LNCaP sublines have been 
derived from prolonged culture in androgen-depleted media [413]. When 
implanted in mice, LNCaP cells readily form tumors [406] but stay confined to 
the prostate when injected orthotopically [414]. 
1.3.6.5. RWPE-l Cells 
Unfortunate1y, there are very few human celllines that have been derived 
from normal prostate epithelium and those that have been isolated are not well 
characterized. Of note the non-tumorigenic R WPE-l cell-line was generated 10 
years ago using human papillomavirus 18 [415] as an immortalizing agent. The 
RWPE-l model is increasingly used as a mode1 for carcinogenesis and cellular 
transformation, like1y because un-modified RWPE-l cells do not form tumors in 
mice [416, 417]. 
1.3.7. Detection, Pathology, and Current Treatment of Prostate Cancer. 
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1.3.7.1. Detection of Prostate Cancer 
During the early stages of PCa when the tumor is re1atively small and 
localized, the disease is large1y asymptomatic. Although the digital rectal exam 
(DRE), which has been wide1y used for PCa detection during decades, can 
sometimes be sufficient to detect such tumors, its success rate is fairly poor at the 
early stages of PCa. The detection rate of early stage PCa was greatly increased 
subsequently to the discovery of PSA [418], an AR-regulated prote in [419]. As 
mentioned previously, PSA is mostly a component of the prostatic fluid although 
small amounts are normally secreted in the blood stream. Increasing prostate size, 
increased AR activity, and importantly PCa tumor progression can alllead to an 
increase in PSA secretion in the blood. Detection of PSA in the bloodstream as a 
detection method was adopted towards the end of the 1980s and has proved to be 
one the most significant improvements in PCa detection to date [420]. 
1.3.7.2. Diagnosis and Histopathology 
Unfortunately, bone fide PCa is not the only factor that can lead to an 
increase in PSA. For example, benign prostatic hyperplasia (BPH) can also lead to 
an increase in PSA [421]. As such, additional pathological information obtained 
from biopsies or trans-urethral resections of the prostate (TURP), a surgi cal 
procedure often used to re-establish urinary flow in patients with enlarged 
prostates due to BPH or PCa [422,423], is often necessary to confirm the cancer 
diagnosis. At the tissue leve1, pathologists notably look at epithelial gland 
morphology patterns as well as the expression of cytokeratins to confirm or refute 
the presence of PCa. Glandular morphology is "quantified" according to the 
Gleason scale. This semi-subjective system is a 5-step scale based on the 
arrangement of the glands and the degree of differentiation of the epithelial tissue 
[424]. Pathologists then determine the Gleason score (2-10), which is the sum of 
the two major Gleason patterns (1-5). Importantly, a high Gleason grade/score is 
indicative of aggressive cancer [425, 426]. Cytokeratin expression is particularly 
useful for discerning between normal glands and what are considered to be pre-
cancerous lesions, namely prostatic intra-epithelial neoplasia (PIN). Glands 
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considered as presenting PIN somewhat resemble normal glands but have several 
layers of luminal epithelial cells and have partially lost the basal celllayer, which 
can be detected by immunohistochemical staining for cytokeratin 5 [427] or 
cytokeratin 34pEl2 [428]. 
1.3.7.3. Prostate Cancer Staging and Treatment 
If the presence of PCa has been confirmed, its treatment will depend on 
the quantity of PSA in the blood and velocity of PSA progression, the Gleason 
score (when available), and the clinical stage [429]. The clinical stage (TNM) is 
determined from the available clinical information obtained by non-invasive 
means, such as the DRE and radiological imaging, pertaining to the extent of 
tumoral invasion and metastasis [429]. Notably, PCa metastases usually arise in 
the pelvic lymph nodes, the bones, and the brain. When it is suspected that the 
cancer is localized and confined to the prostate (TNM of Tl and T2), surgical 
intervention (radical prostatectomy, RP) or radiotherapy (or both) is often used 
successfully. Although it is more invasive and involves the risk of sexual 
dysfunction and incontinence, RP is arguably preferable as it is more clinically 
informative. Following surgery, pathologists re-assess the state of the disease and 
de termine the pathological stage of the RP specimens. The pathological stage is 
also based on the TNM scale but is more accurate than the clinical stage because 
of the added information provided by the surgery and the RP specimen. Notably, 
the presence of cancer at the surgical margins is also assessed because it is often 
indicative of whether or not the disease is likely to re-occur following surgery 
[426]. The re-occurrence of PCa is detected through PSA monitoring. When PSA 
levels are found to reach a certain threshold (usually set between 0.2 to 0.4 ng Iml 
[430], the disease is considered to have relapsed. This event is termed 
Biochemical recurrence and occurs in roughly 35% of patients having undergone 
RP. Of note, patients that relapse within two to three years are at higher risk of 
dying from recurrent PCa [431]. 
The use of RP is rarely employed when the clinical TNM stage is of T3 or 
T 4 (extending beyond the prostate) as this procedure does not remove the cancer 
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that extends beyond the prostate. Since the pioneering studies of Huggins and 
Hodges in the early 1970s [346], the mainstay for these advanced cases, as well as 
for recurrent PCa, has been androgen deprivation therapy (ADT) (Sooriakumaran, 
2006 #466; Jani, 2006 #470; Sharifi, 2005 #471}. Whereas ADT in combination 
with radiotherapy is most frequently used for locally advanced cancers [432], 
ADT is the currently the principal treatment option [433]. ADT is achieved by 
two princip le means. The first is by decreasing blood testosterone levels either by 
surgical castration (orchiectomy) or through the use of LHRH analogs which 
cause long term reduction of LH production and inhibition of testosterone 
secretion by testicular Leydig cells (chemical castration) [283]. The second is 
through the direct inhibition of the AR using inhibitory androgen analogs such as 
flutamide and Bicalutamide (Casodex) that compete with DHT for the ABD ofthe 
AR [434]. Notably, LHRH analogs and AR inhibitors are often used 
simultaneously to increase treatment eficacy[435]. 
1.3.8. Androgen-Independent Prostate Cancer 
Although ADT often initially causes massive apoptosis of both normal and 
cancerous AR-expressing prostate cells, PCa cells almost invariably resist the 
treatment, leading to what is called androgen-independent PCa (AIPCa) [436, 
437]. Presently, there are few available options for patients once AIPCa develops, 
all of which are palliative in nature. Compounding the problem, studies have 
suggested that AIPCa cells are also more resistant to other forms oftherapy [438, 
439]. There are an increasing number of studies that altogether demonstrate the 
existence of multiple "molecular paths" that can be undertaken by PCa cells in 
order to acquire the AIPCa phenotype [440]. At the core, these pathways can be 
essentially divided into two categories: those that involve the AR and those that 
do not. 
1.3.8.1. Androgen Receptor-Dependent Pathways 
AR-dependent pathways to AIPCa can be further subdivided into two 
categories. The first category groups all genetic mutations that can directly affect 
the expression, structure and function of the AR. This includes mutations within 
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the ABD su ch as that observed in the LNCaP AR that can be activated by the anti-
androgen flutamide [412]. Other mutations may affect the transactivation 
domains, such as the amplification of the poly-glutamine tract or the point 
mutations present in the AR of 22Rv1 cells [409]. The hinge region of the AR is 
also frequently mutated and though this may yield an AR with delayed nuclear 
translocation kinetics, sorne of the mutations also result in heightened 
transactivation potential [364]. Also falling under this category, AR gene 
amplification is observed in close to 30% of AIPCa cases [441]. The second 
category of AR-dependent pathways includes those indirectly affecting AR 
activity. For example, the up-regulation ofseveral ARA family members has been 
reported in AIPCa [442]. In fact, over-expression or constitutive activation of 
several of the AR-interacting co-activators listed in section 1.3.5 has been 
suggested to promote AIPCa. In addition, hyper-activation of the MAPK pathway 
has been found to increase AR activity through its phosphorylation [387]. 
1.3.8.2. Androgen Receptor-Independent Pathways 
Fully AR-independent mechanisms of resistance to ADT can operate ev en 
in the complete absence of the AR. Prime examples of cells that employ these 
pathways are the PC3 and DU145 celllines. However, the prevalence of these 
pathways in AIPCa patients is somewhat unclear, as most AIPCa specimens 
express the AR [363, 441, 443, 444]. Nonetheless, deregulations in two 
potentially close1y linked pathways appear to permit AIPCa cell survival, even in 
the absence of the AR. The first directly leads to the inhibition of apoptosis. 
Several studies have shown that AIPCa cells can resist ADT through the up-
regulation of anti-apoptotic proteins. In particular, the up-regulation of BCL-2-
family members BCL-2 [438], BCL-XL [445] and MCL-l [446] have been found 
to contribute to AIPCa cell survival. In close association to this, hyper-activation 
of the PI3K signaling axis is also thought to be of significant importance for 
AIPCa cell survival, ev en in AR negative cells [447, 448]. As mentioned 
previously, hyper-activation of the PI3K1Akt pathway can lead to the inactivation 
ofpro-apoptotic proteins such as BAD, the activation of the mTOR pathway, and 
activation of NF-xB. As mentioned previously, NF-xB is thought to regulate the 
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expreSSIOn of several anti-apoptotic BCL-2-family members and lAPs (see 
sections 1.2.3.2.5 and 1.2.3.3.3). 
1.3.8.3. Current Treatment of Androgen-Independent Prostate Cancer 
Currently, the treatment of AIPCa does not go beyond palliation, with the 
principle outcome of the treatment being reduction of pain and symptoms 
associated to the development of metastases, particularly those developing in the 
bones. Today, chemotherapy using the taxane family chemotherapeutic agent 
docetaxel, which targets microtubules is the standard of care for AIPCa [449]. 
However, other agents used also include inhibitors of adrenal testosterone 
production such as ketoconazole as well as injectable strontium or samarium 
radioisotopes. Bisphosphonates are also increasingly used to control pain due to 
bone metastases and to reduce complications due to bone fractures, which are 
typically associated to LHRH analog-induced ADT [450-452]. As LHRH analog 
therapy also impacts estrogen production, this results in bone demineralization 
and osteoporosis [453]. However, recent studies suggest that higher doses of 
bisphosphonates such as Zoledronic acid can also directly prevent PCa cell 
proliferation and survival [454]. 
1.4. Emerging Therapeutic Strategies in the Management of Prostate Cancer 
In a clinical context, it is of critical importance to maximize the impact of 
the treatment while minimizing the side effects that can affect patient quality of 
life. As the aging population is increasingly at risk of developing cancer, the 
successful application of this concept is likely to have major repercussions on 
both cancer mortality rates and the overall cost ofhealthcare. 
1.4.1. Chemoprevention 
An emerging concept in PCa management is that of chemoprevention 
[455]. This involves the chronic administration of a non-toxic, minimally 
insidious compound that prevents or delays cancer progression. Recently 
completed Phase III clinical trials looking at the potential utility of finasteride, an 
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inhibitor 5-a-reductase (that converts testosterone to DHT, see section 1.3.2), 
found that this agent could reduce the occurrence of PCa by 25% [456]. However, 
finasteride use for chemoprevention is not universally accepted, as sorne have 
suggested that it may also increase the incidence of high-grade cancer [457]. 
However, demonstrating the growing interest for chemoprevention strategies, the 
large-scale U.S-based SELECT clinical trial assessing the potential of the 
naturally occurring phytochemicals lycopene, vitamin E and selenium, was 
initiated in 2001 in response to promising retrospective studies [458, 459]. 
Although the results are not yet available, a similar NCIC-funded study initiated 
in 2003 looking at a combination of vitamin E, selenium and multi-component 
soy extract is also currently being conducted [460]. 
1.4.2. Molecular markers 
In parallel with chemoprevention, a considerable effort has been devoted 
to isolate molecular markers that can help to predict PCa progression and to 
predict the response to currently available therapies. Sorne of these markers were 
briefly alluded to previously (sections 1.3.3 to 1.3.4.). However despite the many 
candidates, molecular markers have yet to reach the bedside and join the ranks of 
currently available clinical and pathological markers (such as those described in 
section 1.3.7) to help guide clinicians in their choice of treatment. 
1.4.2.1 Methods for the evaluation of molecular markers 
Molecular markers are typically evaluated retrospectively for their ability 
to pre di ct an outcome that has in fact already occurred. To this effect selected 
archivaI prostate specimens from PCa patients are probed for the presence of 
molecular markers either by in situ hybridization or using immuno-histochemical 
techniques. Markers are generally quantified semi-subjectively and their 
prevalence is subsequently confronted to patient outcome. This is very often done 
following the dichotomization of marker expression according to a threshold 
value. Although this threshold is sometimes determined empirically, it is 
frequently obtained optimally through statistical methods such as receiver 
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operating characteristic (ROC) curves, p-value optimization, or recurSlve 
partitioning. Threshold determination by ROC, a statistical method initially 
developed for assessing diagnostic test efficacy, is based on the sensitivity and 
specificity of the dichotomization in relation to outcome prediction [461]. The 
optimal p-value method simply consists of finding the cut-point that yields the 
lowest p-value with respect to the resulting prognostic groups [462]. FinaIly, 
recursive partitioning consists of choosing as the threshold a marker expression 
value that separates the patient cohort into the two most homogenous subgroups 
that, between themselves, exhibit the greatest difference with respect to another 
given characteristic such as the onset of BCR for example [463] (see section 
1.3.7.3). 
Notably, the recent invention of the tissue mlcro-array has greatly 
facilitated the process of molecular marker identification by allowing for the 
probing of hundreds of small tissue cores in a single experiment. This 
technological advance has led to the evaluation of an increasing number of 
candidate markers. This large amount of information has also led the application 
and elaboration of statistical models, such as multivariate Cox analyses, 
nomograms and survival trees (that can be obtained by recursive partitioning, see 
chapters III and IV). Importantly, while aIl of the se statistical models can be 
useful, each has particularities that render them more or less appealing in certain 
contexts. Notably, the Cox models are the most frequently used and though these 
allow the use ofboth dichotomized (e.g high vs. low) and continuous values, they 
are difficult to interpret in a practical sense and do not perform weIl when there 
are complex interactions between multiple markers. Nomograms are more 
practical for clinical assessment of patient risk but they do not provide much 
information pertaining to the relationships between molecular markers. FinaIly, 
survival trees present a particularly appealing and easily interpretable graphical 
format, allowing for the visualization of multi-marker interactions. However, in 
contrast with the two other methods, the dichotomization of marker values IS 
inherent to the survival tree algorithm [464-468]. 
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1.4.2.2. Prognostic Biomarkers for Predicting Prostate Cancer Relapse 
The ideal molecular marker, in the context of the initial PCa diagnosis, is 
one that accurately predicts whether a patient should undergo surgery, 
radiotherapy, or none of the above. However, in the post-surgical context, 
markers that could predict whether or not PCa patients will suffer from recurrent 
disease following RP would also be very useful. As ADT can have major 
repercussions on patient quality of life and is currently the primary option for 
recurrent cancer, patients would likely bene fit from more targeted intervention at 
this crucial stage. This point is also highlighted by recent findings in transgenic 
mice expressing the Myc oncogene, where it has been found that mice castrated 
shortly following the apparition of PCa tumor exhibited complete tumor remission 
whereas residual PCa cells were detected in those castrated later on [341]. 
1.4.2.2.1. Cell Cycle Markers 
Although different studies often disagree on prognostic marker abilities, 
and although the biological significance of the findings may be counter-intuitive 
in sorne cases, sever al molecular markers have been reported to predict patient 
prognosis in terms of either biochemical recurrence or patient survival following 
RP. Interestingly, most of these markers are linked to the cell cycle. For example, 
in one study, loss or decreased pRb has been found to predict poor patient 
survival [469] although others have failed to observe this [470]. Similarly 
decreased p27Kipl expression was found to be associated to poor prognosis [471-
474], although in contrast, increased p16(INK4B) [475-477], and increased 
p21 Cipl [478-480] were linked to poor patient outcome. In addition, increased 
cyclin D and cyclin A [481] were both found predictive of unfavorable prognosis. 
Genomic amplification of the MYC gene was also concluded to be a poor 
prognostic indicator in at least two studies [318, 482]. Finally, increased p53 
nuclear accumulation has been linked to the ons et of biochemical recurrence in 
several studies [483-492]. 
1.4.2.2.2. Apoptosis Markers 
52 
Many other markers relate to apoptosis. Notably, a high expression of 
BCL-2 is linked to adverse clinical outcome following RP [489-493]. Perhaps in 
relation, evidence suggests that nuclear NF-leB p65 is also associated to 
biochemical recurrence and poor clinical prognosis, including increased risk of 
pelvic lymph no de metastases [494, 495]. In contrast however, at least three 
studies have found that an increasing number of apoptotic cells (apoptotic index) 
is adversely prognostic [496-498]. Nonetheless, besides a number of very 
conflicting studies pertaining to the relationship between BAX and PCa 
prognosis, few studies have aimed to assess the contribution of pro-apoptotic 
proteins to PCA prognosis [499-503] (see chapter III). 
1.4.2.2.3. The Androgen Receptor 
It is particularly interesting to note that even given the ample suggestions 
pointing to the AR as an important player throughout the development of both 
PCa and AIPCa, the utility of the AR as a prognostic factor in the specifie case of 
recurrent disease is blurred by contradictory findings [504-508]. 
1.4.3. Emerging Therapies in Prostate Cancer Treatment 
As mentioned previously, therapeutic regimens using docetaxel are the 
eurrent standard of care for AIPCa patients (see section). However, it is important 
to note that docetaxel alone or in combination with other available therapies has 
relatively mode st effects on the overall survival of AIPCa patients, generally 
increasing the median survival by two to three months [509]. As such, there is an 
increasing effort to expand the arsenal of available therapeutic options. 
1.4.3.1. Single-Target Strategies 
Several ongoing pre-clinical studies and clinical trials have been initiated 
using a number of different strategies to address the problem of AIPCa. Many of 
these aim to inhibit specific targets. For example the BCL-2 antisense G3139 
(Oblimersen) has recently completed phase II clinical trials in eombination with 
docetaxel for treatment of AIPCa [510]. Relating to the AR, sorne pre-clinical 
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strategies have aimed to use peptide mimeticks to block the interaction between 
the AR and its co-activators [511]. Others using radioisotopes linked to antibodies 
(J591) targeting the AR-regulated prostate-specifie membrane antigen (PSMA) 
are being evaluated in combination with chemotherapy [512]. In addition, much 
attention has been put towards the development of therapeutics targeting the 
receptor tyrosine kinase pathway. While most target the EGFR, (gefitinib, 
cetuximab, trastuzumab, lapatinib and erlotinib) [440, 513], others target platelet-
derived growth factor receptor (PDGFR) such as imantinib and leflunomide [514, 
515] or the VEGF receptor (VEGFR) such as Avastin (bevacizumab) [516]. Other 
promising single-target strategies involve inhibitors of the mTOR pathway such 
as CCI -779 and RADOO 1 [517, 518]. Although only at the pre-clinical stage, CCI-
779 has shown promising results in a mouse xenograft model in combination with 
docetaxel [518]. 
1.4.3.2. Multi-Target Strategies 
While many strategies have taken advantage of specifie targets and aim to 
inhibit specifie signaling pathways, others strategies aim to affect diverse targets 
simultaneously through a single agent. In contrast with the truly single target 
approach, it is thought that this strategy should decrease the potential for recurrent 
disease because it limits the "available" pathways that may lead to AIPCa cell 
survival. To this effect, chaperones have been emerging as interesting targets, For 
example, the Hsp90 inhibitor 17-Allylamino-17-Demethoxygeldanamycin (17-
AAG) has recently undergone phase II clinical trials with promising results [519, 
520]. Notably, Hsp90 is chaperone to and regulates several key client proteins 
including the AR (see section 1.3.5.5), Her-2/Neu, Raf, CDK4, Akt, p53, HIF-I n, 
survivin and telomerase [519, 520]. Similarly, anti-sense therapy against clusterin, 
a cytoprotective chaperone whose clients are involved in apoptosis and DNA-
repair, is currently undergoing phase II clinical trials in combination with 
chemotherapy [521]. 
1.4.3.2.1. Proteasome Inhibitors 
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Another strategy that is likely to affect multiple targets is the inhibition of 
proteasome degradation. These inhibitors usually consist of small synthetic 
peptides that compete for the chymotryptic binding site of the proteasome. Many 
proteasome inhibitors are routinely used for in vitro research (e.g MG-132 and 
ALLN); however, Bortezomib is the main clinical representative of this class of 
drugs, having been recently approved by both the FDA and the EMEA for 
recurrent multiple myeloma [522]. Bortezomib has also shown promising results 
in early phase clinical trials for AIPCa [523, 524], although one recently 
completed phase II trial suggests it may add little benefit to standard 
chemotherapy using docetaxel [525]. Notably, proteasome inhibitors may 
sensitize to various therapeutic insults; however, the mediators of these effects 
remain controversial. Although the activity of proteasome inhibitors was initially 
attributed to the inhibition of NF-KB through decreased degradation of IKB 
proteins, increasing evidence suggests that proteasome inhibitors may affect the 
expression of various proteins, including cell cycle inhibitors, p53, and pro-
apoptotic proteins [522] (dicussed in chapter V). 
1.4.4. Inositol Hexakisphosphate 
As mentioned previously, one of the potentially active anti-cancer 
components present in soy is inositol hexakisphosphate (IP6). IP6 was the first 
inositol phosphate to be discovered [526] and was initially tested for its anti-
cancer properties over 15 years ago, following epidemiological evidence 
suggesting that diets rich in IP6 were inversely linked with colon cancer incidence 
[527]. Since then, IP6 has been reported to exhibit both chemopreventive and 
chemotherapeutic activity against several malignancies. In vitro, IP6 has been 
shown to inhibit the proliferation and/or induce the death of erythroleukemia 
[528, 529], colon [530, 531], lung [532], liver [533], mammary [534], cervix 
[535], skin, soft tissue and prostate cancer cells [531, 536, 537] (see chapters II 
and V). Administered mostly in the drinking water or as a dietary supplement, the 
in vivo anti-cancer activity of IP6, has also been reported in various mouse models 
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of colon [538-547], liver [548, 549], lung [550, 551], breast [543, 547, 552-554], 
skin [555] , soft tissue [556, 557] and prostate cancer [558]. Importantly, in vivo 
studies suggest that IP6 can be effective as a dietary supplement and that it does 
not elicit noticeable secondary effects [527]. 
1.4.4.1. The Synthesis of Inositol Hexakisphosphate 
IP6 consists of a 6-carbon ring myo-inositol backbone that is mono-
phosporylated at every carbon via hydroxyl groups. Although IP6 is particularly 
abundant in soy, legumes, and fiber-rich foods, where it is thought to act as a 
phosphate store, IP6 is present at concentrations of 10-60 IlM in almost all 
mammalian cells [559]. IP6 is produced by the successive phosphorylation of 
lower inositol phosphates by several inositol kinases. In humans, the enzyme that 
catalyses the final step in the formation of IP6 has been recently identified as 
1,3,4,5,6-pentakisphosphate 2-kinase (Ins5P2K) [560]. 
1.4.4.2. Inositol Hexakisphosphate and Cell Signaling 
Endogenous IP6 and inositol po1y-phosphates are thought to play 
important roles within the cell. For example, signaling via phospholipase C (PLC) 
leads to the hydrolysis of cell membrane-bound PIP2 (phosphatidyl-inositol-2-
phosphate) into diacylglycerol (DAG) and inositol-1,4,5 tri-phosphate (IP3) 
[212]. As mentioned previously, PIP2 is a substrate of PI3K whose 
phosphorylation results in the activation of PDKs and downstream Akt (see 
section 1.2.4.1.2). While DAG plays a role in the activation of PKC, IP3 is 
involved in the opening of endoplasmic reticulum calcium stores via IP3 receptors 
(IP3R) [561, 562]. As mentioned above, the successive phosphorylation of IP3 
leads to the production of IP6. Several studies point to a role of IP6 III 
endocytosis/exocytosis and signaling functions at the plasma membrane. In 
pancreatic ~-cells, IP6 was shown to prevent insulin exocytosis by inhibiting the 
activity of PKC [563]. Again in pancreatic cells, IP6 was found to inhibit the 
activity of prote in phosphatases such PP1, PP2A and PP3, and lead to L-type 
calcium channel opening [564]. In neural cells, IP6 was found to bind to 
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synaptotagmins and regulate the secretion of neurosecretory vesicles [565, 566]. 
In addition, components of the caveolin-l/clathrin-mediated endocytosis pathway 
such as AP-2 [567] and AP-3/API80 [568, 569] have also been reported to bind 
IP6. In this context, IP6 was found to prevent the assembly of clathrin cages 
required for endocytosis. Still at the level of the plasma membrane, the inhibitory 
effect of Arrestin on G-protein coupled-receptor activity was reported to require 
the presence of IP6 [570]. Finally, addition of IP6 at physiological doses (25~M) 
was recently found to stimulate a 3-fold increase in CKII activity in vitro [571]. 
Interestingly however, except for some indications that IP6 concentrations may 
change during the cell cycle, cellular concentrations of IP6 are thought to remain 
stable even following cell stimulation [572]. 
1.4.4.3. Inositol Hexakisphosphate in DNA repair and mRNA export 
Other potentially important functions of endogenous IP6 are linked to the 
nuclear compartment. IP6 was found to stimulate non-homologous end-joining 
DNA-repair by binding the Ku70/80 subunits of DNA-PK [573, 574]. Yeast 
genetic studies established a potential role for IP6 in mRNA export [575, 576]. 
This was recently confirmed in a study that showed that IP6 stimulates the 
activity of the Dbp5 RNA-dependent ATPase in collaboration with the Gle-l 
prote in [577]. As mentioned previously (section 1.1.3) this pathway is particularly 
important for the export of Poly A-containing mRNA. 
1.4.4.5. The Many Potential Anti-Cancer Mechanisms of IP6. 
Although it appears that IP6 may function by several mechanisms 
simultaneously, the specifie molecular mediators of the anti-cancer activity of IP6 
have not been clearly identified. 
1.4.4.5.1. Metal Chelation and Anti-Oxidant Properties 
One mechanism that was proposed to mediate the chemopreventive 
abilities of IP6 activity was through its role as an anti-oxidant. The negatively 
charged phosphates in position 1,2 and 3 constitute a unique (axial-equatorial-
axial) conformation that confer antioxidant properties to IP6 by chelating F e3+ and 
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preventing Fe3+-catalyzed hydroxl radical formation [578-580]. IP6-mediated 
chelation of other metals su ch as Zinc, Calcium and Magnesium has also been 
proposed to play a role due to the potential role of these divalent cations in cell 
proliferation [547, 581, 582]. 
1.4.4.5.2. Effects on Cell Membrane and Signaling 
Using supra-physiological doses of IP6, others have found more direct 
evidence that IP6 may exhibit an anti-tumoral response by modulating cell 
signaling, particularly at the level of the cytoplasmic membrane. Notably, one 
study in DU145 cells showed that IP6 inhibits the association between AP-2 and 
EGFR. The loss of this interaction was paralleled with reduced TGF-a-induced 
EGFR signa1ing through the Shc/MAPK pathway. The phenomenon was 
suggested to be linked to a de crea se in AP-2-mediated EGFR endocytosis. This 
study also showed that IP6 inhibited TGF-a- induced PI3K and Akt activation 
and suggested that this event results in the inhibition of PI3K1 AktlRab5- mediated 
fluid-phase endocytosis, as evidenced by decreased DU145 uptake in HRP-linked 
albumin [537]. These events were associated to a reduction of DU145 cell 
proliferation. Inhibition of EGF and TPA-induced PI3K and MAPK activity was 
also reported in JB-6 murine epidermal cells. This led to the downstream 
inhibition of AP-1 transcriptional activity and prevented EGF and 
tetradecanoylphorbol 13-acetate -induced transformation of JB-6 cells [536]. IP6-
mediated inhibition of UVB-induced AP-1 activity via ERK1I2 and JNK was also 
observed in JB-6 cells in another study [583]. On the other hand, two studies did 
not find that IP6 reduced TNF-a-induced (HeLa ceIls) or UVB (JB-6 ceIls) 
induced PI3K activation [535]. However, both studies found that IP6 inhibited 
NF-KB activity induced by these agents, and in Hela ceIls, IP6 also inhibited Akt 
activation (phosphorylation). In relation to this, constitutive NF-KB activity in 
DU145 cells was reportedly inhibited by treatment with IP6 [584]. 
1.4.4.5.3. Effects Relating to the Cell Cycle and Apoptosis 
Another possible mechanism mediating the anti-cancer effects of IP6 is 
through the inhibition of the cell cycle and the induction of apoptosis. One study 
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demonstrated that treatment with IP6 could block DU 145 cells in the G 1 phase of 
the cell cycle. This was associated with increased expression of p2l Cip 1 and 
p27Kipl , decreased in vitro CDK6/4-mediated phosphorylation of Rb and reduced 
in vitro CDK2-mediated phosphorylation of histone Hl, as well as increased 
native DU145 pRb phosphorylation leading to a reduced interaction with E2F4. 
In this study treatment with IP6 also led to the cleavage of PARP and caspase-3 
and a mode st increase cell-surface presentation of phosphatidyl-serine [585]. 
Similar findings were observed in LNCaP cells, where decreased AKT activity, 
increased BAX and decreased BCL-2 expression were also detected [586]. As we 
will see in chapter V, the activity of IP6 in PC3 cells may be at least partially due 
to the modulation of the expression of several BCL-2 family members at the 
protein level. On the other hand, suggesting that IP6 may have cell-type specific 
effects on the cell cycle, treatment with IP6 leads to cell cycle arrest at the G2/M 
phase in sorne leukemia celllines [528] instead ofin Gl phase as observed in PCa 
cell lines. Of note, this study also found that IP6 had no effect on normal bone 
marrow speCImens. 
1.4.4.5.4. In Vivo Effects 
At least in vivo, the effect of IP6 may be linked to other effects su ch as 
vascularization, immune response and tumor invasion. In what constitutes the 
only in vivo study looking at the effect of IP6 on PCa progression, DU145 
xenograft tumors obtained from mi ce given 2% IP6 in drinking water exhibited 
decreased microvasculature and VEGF expression, as well as increased 
expression of IGF-binding protein-3 (IGFBP3), a secreted protein that binds and 
antagonizes IGF growth factors [558]. In another study, IP6 was found to 
antagonize bFGF binding [587]. IP6 was also found to enhance natural killer 
(NK) immune cell activity in vitro and prevented carcinogen-induced repression 
of NK cell activity in vivo [588]. Finally, IP6 was reported to inhibit MMP-9 
secretion in MDA-MB 231 breast cancer cells, suggesting it may hait tumor 
infiltration and metastasis [589]. 
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2. Doctoral thesis objectives 
The over-arching goal of this doctoral project was to innovate in the 
treatment of PCa and to further our understanding of the factors involved in both 
clinical outcome and therapeutic response. To this effect, we initially tumed our 
attention to IP6. The evidence presented in section 1.4.4. initially suggested that 
treating cells with IP6 could potentially affect several molecular pathways 
simultaneously. Analogously to the strategies employed by emerging anti-cancer 
agents such as 17-AAG and proteasome inhibitors, we hypothesized that a multi-
targeted therapeutic approach could be beneficial for the treatment of AIPCa, 
particularly given the multiple pathways that lead to the AIPCa phenotype. 
Because the effects of IP6 in the context of PCa had been thus far studied almost 
exclusively in DU145 ceIls, one of our first goals was to establish whether IP6 
could be effective in other PCa ceIllines. 
This was addressed in chapter II. The results of the study confirmed that 
IP6 was active in at least three other PCa cell lines, although its effect was 
evidently greater in AR-negative AIPCa cells. In light of this, we proceeded to 
de termine whether the AR could prote ct cells from the effects of IP6, using the 
PC3/PC3(AR) cell lines as models. We found that at least in PC3 ceIls, an 
androgen-independent AR-linked function could decrease the efficacy of IP6. 
Because of other studies suggesting that AIPCa is frequently also resistant to 
chemotherapy [438,439], we set out to understand how the AR could mediate this 
effect. Evidence from the literature known to us at that time suggested that IP6-
treated DU145 cells exhibited impaired PI3K1AktINF-KB signaling and 
underwent RblE2F-mediated G 1 cell cycle arrest and apoptosis (see section 
1.4.4.2.2 and 1.4.4.2.3). So-guided, we looked at the effect of the AR on IP6-
induced changes in the mRNA expression profile of a subset of relevant genes. 
We found that in parallei with reducing the manifestations of apoptosis, 
expression of the AR in PC3 cells prevented the IP6-induced up-regulation of 
puma and noxa, as weIl as of the NF-KB-responsive genes IKB-a and irf-2 at the 
mRNA level. 
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Following this initial study, it became apparent that the pro-apoptotic 
NOXA and PUMA could be potential downstream effectors of IP6 action (a 
possibility we further explored in chapter V). As such, it seemed relevant to 
de termine whether these proteins were expressed in PCa patients. Importantly, the 
expression of NOXA and PUMA had not yet been characterized in prostate 
tissues. As mentioned in section 1.4.2.2.2, very litde is known conceming the 
contribution of pro-apoptotic proteins to PCa clinical outcome. Consequently, we 
were also interested in determining whether NOXA and PUMA expression could 
be use fuI markers for PCa prognostic, as this could impact the use of currently 
available treatments and foreshadow the potential usefulness of IP6 for PCa 
treatment. These questions were addressed in chapter III. 
Beyond identifying NOXA and PUMA as potential mediators of the effect 
of IP6, the results obtained in chapter II suggested that an androgen-independent 
AR function could negatively impact IP6 efficacy. Therefore, we set out to assess 
the expression of the AR in prostate tissues and to de termine how AR expression 
related to the risk of recurrent disease. Although others have previously evaluated 
the prognostic ability of the AR regarding BCR following RP, there is to date no 
consensus on its prognostic utility (see section 1.4.2.2.3). Based on evidence from 
the literature (see section 1.3.5.6) and results from chapter II suggesting 
potentially important cytoplasmic roles of the AR, we also deemed it justified to 
study AR sub-cellular localization. Hence, we set out to study the expression and 
sub-cellular localization of the AR in prostate tissues and to evaluate its ability to 
predict recurrent PCa in chapter IV. 
Because the precise target( s) of IP6 remam somewhat unclear, we 
continued our exploration of the mechanism of IP6 in the context of PC3 cells. 
Flowing from the observations made in chapter II, we proposed that the up-
regulation of pro-apoptotic genes such as noxa, puma and bax could be involved 
in mediating the effects of IP6. We also suggested that, in contrast with other 
reports, the NF -KB pathway could be triggered by treatment with IP6. These 
possibilities were explored in chapter V. An underlying long-term goal of this 
endeavor was to further understand the influence of the AR on the effects of IP6. 
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As opposed to a more direct AR-focused strategy, we opted for this rather indirect 
route in light of the multiple binding partners of the AR (as presented in section 
1.3.5) and of the hundreds of AR-regulated genes. Guided by the over-arching 
goal of innovating in the treatment of PCa, we also reasoned that better 
understanding the mechanisms of IP6 could lead to the improvement of its 
therapeutic impact for use either alone or in combination with CUITent and 
emerging PCa treatment modalities. 
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Abstract 
BACKGROUND: Inositol hexakisphosphate (lP6) is a phytochemical exhibiting 
anti-cancer activity. Because few prostate cancer (PCa) celllines have been used 
to study IP6, we assessed its efficacy in a panel of PCa cell lines. METHODS 
AND RESULTS: Using WST-l assays we observed that, although androgens did 
not modulate its efficacy, IP6 was more active in androgen receptor (AR) 
negative cells than in AR-positive cells. Stable expression of the AR in PC3 cells 
(PC3(AR)) decreased the response to IP6, which was reversed by an AR-targeting 
siRNA. Furthermore, AR expression in PC3 cells resulted in significantly reduced 
caspase-3 activation (p<O.OOl) and DNA fragmentation (p<O.05) in response to 
IP6. Similarly, although treatment with IP6 caused the up-regulation of NF-KB-
responsive (lKB-a, IRF-2) and p531E2F-responsive genes (Puma, Noxa) in PC3 
cells, this increase was reduced in PC3AR cells (p<O.Ol). CONCLUSION: We 
conclude that resistance to IP6 can be linked to a ligand-independent AR function. 
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Introduction 
One of the major issues in prostate cancer (PCa) treatment is the appearance 
of androgen-independent (AI) PCa that progresses in the face of androgen 
deprivation therapy (ADT) and is generally resistant to conventional therapeutic 
modalities. This advanced stage of the disease, which deve10ps in roughly a 
quarter of PCa patients, is associated with a very poor clinical outcome resulting 
from its highly aggressive metastatic phenotype and its resistance to 
chemotherapy (1, 2). 
The target of hormone-therapy is the androgen receptor (AR), a nuclear 
receptor family transcription factor important in prostate cell survival (3). The AR 
is composed of two trans-activation domains and a DNA-binding domain that 
recognizes androgen response elements. While the C-terminal trans-activation 
domain of the AR requires androgen binding to activate gene transcription, the N-
terminal trans-activation domain does not (4). In addition to its known role as a 
transcription factor, evidence suggests that the AR may also ho Id other functions 
although these are not well understood. For example, it has been shown that Rb 
interacts with the AR in an androgen-independent fashion (5). In addition, the AR 
forms complexes with cyclin DI(6) and interacts directly with cyclin E (7). The 
AR has also been found to exhibit mutual transcriptional inhibition with the NF-
KB subunit Re1A (8) and has been reported to interact with and act as a substrate 
for Akt kinase (9). 
Aberrant AR activation or expression is frequently observed in AIPCa and 
is believed to at least partially mediate its resistance to ADT (10, II). In addition, 
although it is not clear how the se become prominent in response to androgen 
ablation, multiple pro-survival signaling pathways have been found to be hyper-
activated in AIPCa cells. For example, up-regulation of anti-apoptotic proteins 
such as BCL-2 (12) as well as deregulated activation ofmitogen activated protein 
kinases (MAPKIERK) (13), prote in kinase C (PKC) (14), jun kinase (JNK) (15), 
AP-I (16), J3-catenin (17), E2F (18), ErbB family growth factor receptors and NF-
KB (19-22) have been observed in various PCa models. This has led sorne to 
suggest that targeting multiple pathways simultaneously could be a good strategy 
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to effectively manage AIPCa (23). 
With respect to this idea, phytochemicals are a rich source of candidate 
multi-target compounds, having the added advantage of being generally weIl 
tolerated by patients (reviewed in (24)). One ofthese multi-target phytochemicals 
is phytic acid or Inositol hexakisphosphate (IP6). IP6 is found most abundantly in 
soy and legumes and has demonstrated anti-cancer activity in a wide range of 
cancers (25). Although definite mechanisms have yet to be established, IP6 
activity has been reported to involve several processes (26). In relation to PCa, 
IP6 was found to inhibit constitutive NF-KB activity (27) and induce apoptosis of 
DU145 cells by inhibition of fluid endocytosis and ErbBI receptor signaling 
through the MAPK signaling cascade (28). It was also reported that IP6 
modulates cdk-cyclin and pRblE2F complexes, up-regulates p21 and p27 cell 
cycle inhibitors, causing DU 145 cells to block in Gland undergo apoptosis (29). 
Because most studies pertaining to IP6 in PCa have focused on the AR-negative 
DU145 cell line, we set out to compare the in vitro efficacy of IP6 on both 
androgen-sensitive and androgen-insensitive PCa celllines. 
Materials and Methods 
Cell culture: 22Rvl, PC3, LNCaP and DU145 were obtained from ATCC 
(RockviIle, MD). The PC3(AR) that stably over-expresses fuIllength human AR 
(denoted as PC3(AR)2 in Heisler et al. 1997) was a kind gift from Dr. T.l. Brown 
(University of Toronto) and was also derived from PC3 cells provided by ATCC. 
Except for 22Rvl ceIls, which were maintained in DMEM, cells were maintained 
in RPMI 1640 complemented with 10% FCS (or charcoal-stripped FCS), 
gentamicin (50 !-tg/ml) and amphotericin B (250 ng/ml) (Gibco-BRL, MD, USA). 
The PC3(AR) cell line was maintained in charcoal-stripped media and 
complemented with 100 !-tg /ml Hygromycin B. Cell cultures were incubated at 
37°C in a humidified 5% CO2 atmosphere and sub-cultured at 1:3 (LNCaP), or 
1:5 (PC3, PC3AR, 22Rvl, DU145) by trypsinization with 0.25% trypsin for 5-10 
minutes at 37°C (Gibco-BRL, MD, USA). 
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WST-l metabolic assay: Cells were grown to confluence, trypsinized, and 
counted on a hemocytometer. For experiments assessing the effect of androgens 
on IP6 sensitivity, cells were maintained in either charcoal-stripped (steroid-free) 
10% FCS-supplemented RPMI 1640, normal 10% FCS-supplemented RPMI 
1640, or normal 10% FCS-supplemented RPMI 1640 + 10 nM R1881 (a synthe tic 
androgen analog) for 72 hours priOf to seeding. Cells were diluted in the indicated 
media at 20 000 cells/well (100 1-11). Cells were allowed to adhere ovemight priOf 
to treatment and were treated with indicated concentrations of myo-inositol 
hexakisphosphate dodecasodium salt (Sigma-Aldrich, USA) dissolved in water. 
Another well containing only media was included for WST -1 assay background 
correction. After 24 hours, 10 1-11 WST-1 reagent (Roche, USA) was added to the 
wells and plates were incubated at 37°C in a humidified 5% CO2 atmosphere. 
Incubation times were optimized for each cell 1ine as recommended by 
manufacturer. WST-1 signal was measured on a Bio-Rad Model 3550 microplate 
reader at 450 nm with reference at 655 nm wavelength. Following data 
acquisition, cell metabo1ic activity was calculated by first subtracting the readout 
of the WST-1 background (media + WST-1) from all values. Subsequently, 
relative metabolic activity was calculated as being the WST -1 readout of treated 
well / WST -1 readout of mock-treated well. Average and standard error of the 
mean were calculated from normalized replicate values as indicated in the figures 
and cellular metabolic activity was plotted as a function of IP6 concentration. 
Determination of cell doubling time: Cells were plated at a density of 100 000 
cells per 2 ml serum supplemented media in 6-well plates. 24, 48 and 72 hours 
following plating, cells were washed with PBS and incubated in 1 ml trypsin at 
37°C for 15 minutes. Cells were then counted on a hemocytometer. Cell doubling 
time was determined using the formula (doubling time= 2/slope) where slope was 
determined by plotting the fold change in cell number against time. Experiments 
were repeated twice in triplicate. 
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Transfection of siRNA: siRNA targeting the AR and the RISC-free siGLO 
fluorescent siRNA control were purchased from Dharmacon (Chicago, IL, USA). 
Briefly, ceUs were seeded at 400 000 ceUs per 100 mm petri an aUowed to grow 
for 72 hours prior to transfection which was done as recommended by the 
manufacturer using the Dharmafect 2 transfection reagent. Ce Us were incubated 
for 24 hours after which transfection media was replaced with normal 10% FCS-
supplemented RPMI 1640. The following day, ceUs were seeded as described for 
the WST -1 assay or at 400 000 ceUs 1 2 ml in 6-well plates for protein or RNA 
extraction 
Protein extraction: After treatments, media was aspirated, cells were scraped, 
washed twice with cold PBS and pellets were frozen at -80°e. Subsequently, 
whole cell extractions were performed by applying cold lysis buffer (10 mM Tris-
Hel, pH 7.4,150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM NaF, 0.5% NP-40, 
0.5 mM PMSF, 0.2 mM orthovanadate, 2 J.lg/ml of aprotinin, leupeptin and 
pepstatin) on ice for 30 min. Who le cel1 extracts were collected after 
centrifugation in a Heraeus Biofuge (13,000 rpm for 10 min at 4°C) and were 
immediately stored at -80°C. Protein concentration was measured by Bradford 
assays (Bio-Rad Laboratories Inc., Hercules, CA) according to the manufacturer's 
instructions. 
Western blot analysis: For Western blot analysis, 20 J.lg of whole ceU protein 
extract were resolved on a 10% polyacrylamide gel and then transferred onto 
nitrocellulose membranes. Blots were blocked using 5% non-fat dry milk in TBS-
Tween 0,05% buffer overnight at 4°C and probed using anti-AR antibody 
(NeoMarkers, Clone AR-441, MS-443-P) in blocking buffer (l :500) for 1 hour at 
room temperature. Membranes were then incubated with secondary antibody 
conjugated to horseradish peroxidase (Amersham Life Sciences Inc., Arlington 
Heights, IL) in blocking buffer for 1 hour at room temperature and developed 
with enhanced chemiluminescence (ECL) substrate (Amersham Life Sciences 
Inc., Arlington Heights, IL). 
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Caspase-3 fluorigenic assays: PC3 and PC3AR cens were plated at a density of 
200 000 cells/ml and treated with 2 mM IP6 or water for 24 or 48 hours. Cells and 
media were coUected by scraping and washed twice with PBS. cens were 
resuspended in 50 Jlllysis buffer (10 mM Tris HCI pH 7.5, 10 mM NaH2P04, 
lOmM Na2HP04, 13 mM NaCL, 10 mM N~P207, 1% Triton X-100) and 
incubated for 10 min on Îce. Supernatants were c1eared by centrifugation and 
dosed using the Bradford reagent (see protein extraction). 70 Jlg of protein was 
used per caspase assay. Each sample was supplemented with lysis buffer to reach 
a final volume of 56 Jll to which 44 JlI of caspase assay mix was added [32 Jll of 
caspase assay buffer (312.5 mM HEPES pH 7.6, Sucrose 31.25%, CHAPS 
0.3125%), 1 Jll DTT (lM) and 2 JlI Ac-DEVD-AFC caspase-3 substrate (1.82 
Jlg/JlI, Biomol International, PA, USA) and 9 JlI of lysis buffer]. Fluorescence 
was measured every minute for 30 minutes at 37°C in a black 96-well plate using 
a Fluostar Optima (BMG, Durham, NC, USA). Fluorescence was plotted as a 
function of time and the slope was calculated in Excel using the linear part of the 
curve. Data is expressed as a treated/untreated slope ratio. Experiments were 
repeated 2-3 times and caspase activity measurements were done in duplicate for 
each experiment. 
Filter elution assays (DNA fragmentation): Prior to the assay, cells were plated 
at 400 000 cells in normal 10% FCS-supplemented RPMI 1640 per 100 mm petri 
(10 ml volume) and labeled with 1 Jlei [14C]-thymidine for 72 hours. After 
labeling, cells were counted and plated at 400 000 cens per 2 ml in 6-well plates 
and allowed to adhere overnight. The following day, cells were treated with water 
or 2 mM IP6. Filter elution assays were performed at 24 and 48 hours as 
described previously (30). Briefly cells were scraped using a rubber scraper and 2 
ml of labeled cells were loaded on protein adsorbing 25 mm diameter Metricel 
membrane vinyllacrylic copolymer filters, (Pan Corporation, Ann Arbor, MI, 
USA) and washed with 3 ml PBS. After elution by gravity, lysis was performed 
with 5 ml of lysis solution (2% SDS, 0.04 M EDTA, pH 10.0). After the lysis 
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solution had dripped through, the filters were washed with 5mL 0.02 M EDTA 
(pH lO.O). Filters were then removed and treated with IN HCI for 1 hour at 60°C 
to depurinate the DNA. 3 ml NAOH was then added to release labeled DNA from 
the filters. Radioactivity was counted in each fraction (loading wash, lysis, EDTA 
wash, filter) by liquid scintillation spectrometry. DNA fragmentation was 
determined as the DNA fraction in the loading wash fraction + lysis fraction + 
EDTA wash fraction relative to total DNA (sum of the four fractions). The results 
were expressed as the percentage of DNA fragmented in treated cells compared to 
DNA fragmented in untreated cells (background) according to the formula (F-
FO/1-FO) X 100 where F and FO represent DNA fragmentation in treated and 
control cells, respectively. 
Quantitative Real time PCR: PC3 and PC3AR cells were plated at a density of 
200 000 cells/ml and treated with 1 mM IP6 or water. After 24 hours, media was 
removed and RNA was extracted with Trizol reagent according to manufacturers 
instructions (Invitrogen, ON, Canada). Concentration of RNA samples was 
determined using a Beckman DU-600 spectrophotometer. 2/-lg RNA was used to 
synthesize a cDNA using the SuperScript first-strand synthesis system (random 
hexamer method) according to manufacturers instructions (Invitrogen, ON, 
Canada). The QuantiTect SYBR Green PCR kit was used as recommended 
(Quiagen, ON, Canada). Real time PCR reactions were performed on a Rotor-
gene RG-300 (Corbett ReseliTch, Australia). Optimal threshold and reaction 
efficiency were determined using the Rotor-gene software. Melt curves for each 
primer exhibited a single peak, indicating specific amplification, which was also 
confirmed by agarose gel. Ct values were determined using the Rotor-gene 
software at the optimal threshold previously determined for each primer. Relative 
mRNAIactinB ratios were calculated using the method described by Pfaffl et al. 
(2001) (31). Fold induction was calculated relative to the mock treated control for 
each gene. Experiment was done twice and real time measurements were done in 
duplicate for each gene in each experiment. Primer sequences used were as 
follows (5' to 3', F= forward, B=backward). Bax 
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F=AACTGGTGCTCAAGGCCCTG B=GGGTGAGGAGGCTTGAGGAG. Noxa 
F=TTCGTGTTCAGCTCGCGTCC B=CTCGGTTGAGCGTTCTTGCG. Puma 
F=TGGACTCAGCATCGGAAGGT B=GCACCAGCACAACAGCCTTT. BCL-
2 F=CCGCTACCGCCGCGACTTC B=AAACAGAGGCCGCATGCTG. IKB-a 
F=CTGGCTTTCCTCAACTTCCA B=GTCTCGGAGCTCAGGATCAC. 
BCLXLF=GGTATTGGTGAGTCGGATCG 
B=TGCTGCATTGTTCCCA TAGA. cyc1in DI 
F=CGTGGCCTCTAAGATGAAGG B= CCACTTGAGCTTGTTCACCA. 
ActinB F=ACTCTTCCAGCCTTCCTTCC B=GTACTTGCGCTCAGGAGGAG. 
IRF -2 F=CCATGAA TTCCTTGCCTGAT B= AAGCCCCAGAGATGACTCAA. 
Cyc10philin B F= GCCCAAAGTCACCGTCAAGGTGT 
B=GCTCTTTCCTCCTGTGCCA TCTC. Primers for each target gene were 
designed with the he1p of the Primer 3 software (32) with the exception ofthose 
for puma noxa and bax that were obtained from Dr. Richard Bertrand and for 
BCL-2 which were described elsewhere (33). 
Statistics: Statistical significance of observed differences between PC3 and 
PC3AR cells or between siRNA-transfected cells was assessed using a two-tailed, 
two-sample, unequal variance T-test in Excel (Microsoft, USA). In addition, one-
way ANOVA analyses using SPSS v.lI (SPSS Inc. Chicago, USA) were 
performed in order to confirm the significance of differences in IP6 sensitivity 
following siRNA transfection obtained by T -Test, as well as to evaluate the 
significance of differences in cell doubling times. P values below 0.05 were 
considered as significant. 
ResuUs 
Prostate cancer cells that do not express the AR are more sensitive to the 
effects of IP6 on cellular metabolism 
To compare the effect of IP6 on PCa cell lines, we used the WST-l 
colorimetric assay, which is widely employed for the assessment of compound 
cytotoxicity (34-37). The activity of cellular and mitochondrial membrane 
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electron transport enzymes on WST -1 yields a soluble formazan dye that can be 
measured by spectrophotometry (37). Hence, WST-l readout correlates to the 
metabolic activity of the cell. We chose LNCaP, 22Rvl, PC3 and DU145 cell 
lines to assess the relative efficacy of IP6 so as to include both hormone-sensitive 
and hormone-insensitive PCa celllines. Cells were treated with IP6 from 0-3 mM 
concentrations and cell survival was calculated relative to mock treated control as 
described in Materials and Methods. Figure la) shows that IP6 is strikingly more 
effective at inhibiting metabolic activity in PC3 and DU145 wh en compared to 
LNCaP and 22RVl celllines. As shown in figure lb, no significant differences in 
ceIl doubling times were observed between the cell lines (p>0.05, ANOV A) 
Hence, the extent of metabolic toxicity did not correlate with cell growth rate. 
Similar results were obtained in relation to basal metabolic activity (data not 
shown). 
Androgens do not affect metabolic sensitivity to IP6 
One important parameter that differentiates the LNCaP, 22Rvl and PC3, 
DU145 cell lines is that the former express the AR whereas the latter do not 
(reviewed in (38, 39)). In light of this, we determined whether the androgen-
dependent activity of the AR could affect the sensitivity of cell lines to IP6. To 
address this question, we performed WST -1 assays in conditions of androgen 
deprivation and supplementation. Cells were pre-treated in steroid-free media or 
media supplemented with 10 nM R188l, a synthetic androgen analog, for 72 
hours prior to seeding. Figure 2a-d) show that androgen supplementation does not 
decrease IP6 sensitivity in AR positive LNCaP and 22Rvl cell lines. Similarly, 
androgen deprivation does not sensitize these cells to the effects of IP6 on 
metabolic activity. 
Expression of the AR protects PC3 cells from the effect of IP6 on cell 
metabolic activity 
Because the AR possesses an androgen-independent trans-activation 
domain (4) and has been reported to interact with certain proteins such as Rb in an 
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androgen-independent fashion (5), we addressed the possibility that the physical 
presence of the AR couid alter the efficacy of IP6. To this effect, we compared 
the activity of IP6 on wild-type PC3 cells and a PC3 cellline in which the human 
AR had been previously transfected (PC3(AR» and is stably expressed «40) and 
Fig. 4a). WST-I assays performed in normal serum-supplemented conditions 
showed that although PC3 and PC3(AR) cells divided at similar rates (figure 1 b), 
PC3(AR) cells were significantly more resistant to IP6 than PC3 cells at all 
concentrations (p<0.05) (Fig. 3a). Supporting our previous observations in 
LNCaP and 22Rvl cells, androgen supplementation or deprivation did not 
respectively protect or sensitize PC3(AR) cells to the effects of IP6 on cell 
metabolic activity (Fig 3b). To further address the role of androgens in this 
phenomenon, we used the non-steroidai AR inhibitor Casodex, which also had no 
effect on IP6 efficacy (data not shown). 
An AR-targeting siRNA sensitizes PC3(AR) cells to the effects of IP6 on cell 
metabolism 
In order to eliminate the possibility that our observations were due to 
clonaI effects in PC3(AR) cells, we used a siRJ'I.J"A to knock down expression of 
the AR protein. Figure 3c shows that the siRJ'l.J"A had effectively decreased AR 
protein expression when IP6 cytotoxicity was assessed. Figure 3d shows that 
PC3(AR) cells transfected with a siRJ'l.J"A targeting the AR significantIy increased 
IP6-induced metabolic inhibition compared to both mock transfected (p<0.003) 
and siGLO RISC-free siRJ'l.J"A control-transfected cells (p<O.OOOOl). On the other 
hand, siRJ'l.J"A transfection had no effect on PC3 sensitivity to IP6 (Fig. 3e). In 
contrast to what was observed in PC3(AR) cells, although AR-targeting siRJ'l.J"A 
effectively reduced AR expression in both LNCaP and 22Rvl cells (4a), transient 
knockdown of AR expression did not further sensitize LNCaP or 22Rvl cells to 
the effects of IP6 on cellular metabolism (4b-c). 
Expression of the AR protects PC3 ceUs from IP6-induced caspase-3 
activation 
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Although the WST -1 assay is a valid method for determining cellular 
metabolic activity, it does not necessarily denote cell death per se. lt has been 
previously suggested that IP6 induces caspase-3 activation and apoptosis in other 
cancer celllines (26, 29, 41). Rence, we compared caspase-3 activation following 
a 24 or 48-hour treatment with 2mM IP6. In order to quantify caspase-3 activity, 
we used the DEVD-AFC fluorigenic substrate that emits light upon c1eavage of 
the DEVD sequence by active caspase-3 or caspase-3-1ike cysteine proteases (42, 
43). Figure 3c shows that increased caspase-3-like activity was detectable in PC3 
cells as early as 24 hours following treatment with IP6 and was sustained over 48 
hours. Although caspase-3-like activity was also increased by IP6 treatment in 
PC3(AR) cells, this increase was of significantly lower magnitude both at 24 and 
48 hours (p<0.05). 
Expression of the AR protects PC3 cells from IP6-induced DNA 
fragmentation 
We also looked at DNA fragmentation, a marker oflate stage apoptosis, in 
response to treatment with IP6. While this is typically assessed subjectively by 
observing DNA laddering on agarose gel, DNA fragmentation can be 
quantitatively measured using DNA filter elution assays (30). Using this method 
we followed DNA fragmentation at 24 and 48 hours after treatment with 2mM 
IP6. We can see from the data presented in figure 3d that although a 14.7% 
increase in DNA fragmentation was already observable at 24 hours in PC3 cells, 
an increase of less than 7% was observed in PC3(AR) cells even at 48 hours 
whereas PC3 cells had reached a 32.8% increase in fragmented DNA at this time. 
The observed differences between PC3 and PC3(AR) cells pertaining to DNA 
fragmentation induced by treatment with IP6 were statistically significant at both 
24 (p<O.Ol) and 48 hours (p<0.05). 
IP6 treatment induces the expression of a subset of NF-KB-responsive genes 
as weil as of pro-apoptotic genes in PC3 but not PC3(AR) cells. 
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Following from the observation that the AR protects PC3 ceUs from IP6-
induced apoptosis, we determined whether this could translate in differences in 
the induction of gene expression folIowing a treatment with IP6. Using real time 
PCR, we measured the expression of the pro-apoptotic genes bax, puma and noxa, 
and of the anti-apoptotic genes BCL-2 and BCL-XL. Because of reports 
suggesting that IP6 inhibits constitutive NF-KB activation in DU145 cells (27) as 
weIl as TNF-induced NF-KB activation in HeLA cells (41), we also probed for the 
expression ofIKB-a, IRF-2 and cyc1in Dl, which have been shown to be NF-KB-
responsive (44-46). PC3 and PC3(AR) ceUs were treated with ImM IP6 and the 
fold change in gene expression (relative to actin B) was calculated and are 
represented in figures 4a-h. We observed moderate to strong induction of bax 
(4.6-fold), puma (6.3-fold), noxa (1.6-fold), IKB-a (l8.7-fold) and IRF-2 (3.6-
fold) in PC3 ceUs. In comparison, the fold change in puma (1.3-fold), noxa (0.6-
fold) , IKB-a (0.8-fold) and IRF-2 (0.9-fold) was significantly reduced in 
PC3(AR) cells (p<0.05 for each gene). Though on average bax induction was also 
decreased in PC3(AR) (1.1 compared to 4.6 in PC3 ceUs), this was not 
statistically significant (p=O.13). Minimal changes in the expression of BCL-XL, 
BCL-2 and cyc1in Dl were observed (between 0.75 and lA fold) although to 
similar extents in both celI lines. Similar results were obtained using cyc10philin 
B as a reference gene (data not shown) 
Discussion 
The evidence presented in figure la suggests that there is a link between 
AR expression and IP6 efficacy as celllines that express the AR are less sensitive 
to the metabolic effects of IP6 even though growth rates are similar between aIl 
cell lines under the conditions tested here (lb). In contrast, treatment with an 
androgen analog does not hinder on the ability of IP6 to inhibit PCa cell metabolic 
activity, nor does androgen deprivation protect from its effect (fig. 2a-d, 3b), 
suggesting that androgens are not involved in this phenomenon. Surprisingly, 
steroid-free conditions conferred a slight protection to 22Rvl ceUs (fig 2b). This 
may be due to the lack of other steroids in the culture media resulting from the 
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charcoal-stripping procedure (47). Regardless, addition of the R188l androgen 
analog c1early had little effect on IP6 activity in this cellline. 
Further supporting a link between AR expression and IP6 efficacy, we 
found that stable expression of the AR in the PC3 cell line interferes with the 
effects of IP6 on cell metabolism and cell death (fig. 3a, 3c-g). However, as 
opposed to its c1ear effect on PC3(AR) cell metabolic sensitivity to IP6, short 
term knockdown of the AR did not modula te the efficacy of IP6 in LNCaP or 
22Rvl cells. These results indicate that while AR may be an important component 
of response, other pathways may also act to modulate IP6 efficacy in LNCaP and 
22Rvl cells. Nonetheless, these results also demonstrate that the exogenous 
expression of the AR in the PC3 cellline is a suitable model for studying the AR-
associated function involved the resistance to IP6 observed here. In combination 
with the observation that androgen supplementation or deprivation does not 
prote ct or sensitize any of the androgen-responsive celllines to the effects of IP6 
(fig. 2a-b, 3a), these data suggest that a ligand-independent function of the AR 
hinders on the toxicity of IP6 at least when expressed in PC3 cells. 
The results reported here support the notion that the AR may contribute to 
chemotherapy resistance in AIPCa. Two studies have previously reported on the 
effect of ligand-mediated AR functions on apoptosis. It has recently been shown 
that androgens could up-regulate caspase-2 expression and protect PCa cells from 
TNF receptor family ligand-induced apoptosis (48). In contrast, a separate study 
found that an androgen-dependent AR activity was required to sensitize PCa cells 
to pac1itaxel and y-radiation (49). To our knowledge, this is the first report of an 
androgen-independent effect of the AR on apoptosis induced by a cytotoxic agent. 
As a first endpoint to assess the effectiveness of IP6 on PCa celllines, we 
looked at cellular metabolic activity using the WST -1 assay. Given that WST -1 is 
an indicator of metabolic activity and not cell death, and since IP6 had been 
previously shown to induce apoptosis in other PCa cell lines, we also quantified 
caspase-3-like activity (fig. 3c) and DNA fragmentation (fig. 3f) as altemate 
endpoints for comparison. Although it had been previously observed that IP6 
inhibits PC3 cell growth and induces their differentiation (50), the observed 
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increase in DNA fragmentation and caspase-3-like activity supports that IP6 also 
promotes apoptosis in PC3 cells as has been observed in other celllines (29, 41). 
Overall, the differences observed between PC3 and PC3(AR) cells in relation to 
apoptosis markers correlated with those detected using metabolic toxicity assays. 
On the other hand, the extent of metabolic toxicity conferred by 2mM IP6 
treatment at 24 hours in both PC3 and PC3AR cells appeared to be greater than 
the extent of caspase-3-1ike activity and DNA fragmentation at the same time and 
IP6 concentration (compare fig. 3a to fig. 3c and 3d). This may indicate that the 
metabolic effects of IP6 occur first. Altemately, this could also suggest that a 
portion of cells die early on by necrosis. 
Real time PCR analyses showed that a subset ofNF-KB-responsive genes 
is up-regulated upon treatment with IP6 in PC3 cells (fig 4f-h). This somewhat 
contradicts one study where constitutive NF-KB binding to KB sequences in 
DU145 cells was inhibited by a 24-hour treatment with IP6 (27) and another study 
in HeLa cells where TNF/insulin-induced NF-KB-Iuciferase reporter activation 
was also inhibited by pre-treatment with IP6 (41). Because IKB-a prote in is in 
nim an inhibitor of the c1assical NF -KB subunits (p50/ReIA), it may be that IKB-a 
up-regulation eventually translates into the net inhibition ofNF-KB activity (44). 
However, the up-regulation ofIKB-a and IRF-2, and to a lesser extent cyc1in Dl, 
suggests that NF -KB is at least activated within the first 24 hours following 
treatment with IP6. 
Although IKB-a is strongly induced in PC3 cells (18.7 fold, fig 4f), cyc1in 
Dl is only minimally up-regulated (1.4-fold, fig. 4h) and BCL-2 expression is 
slightly decreased (O.75-fold, fig. 4d) in response to IP6. Interestingly, cyc1in Dl 
and BCL-2 have been shown to be responsive to non-c1assical NF-KB p52 homo-
dimers in breast epithelial cells (45, 51). Conversely, IKB-a is regulated by 
c1assical p50/Re1A heterodimers (44). If this regulatory network were maintained 
in PC3 cells, it would be tempting to speculate that the c1assical as opposed to the 
non-c1assical NF-KB pathway is preferentially activated in response to IP6 in this 
system. 
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We also observed that the pro-apoptotic protein-encoding genes bax, noxa 
and puma, but not the anti-apoptotic protein-encoding genes BCL-2 and BCL-XL 
were up-regulated in PC3 cells following treatment with IP6. Though 
characterization of the prote in expression and sub-cellular localization of the gene 
products will be necessary to address whether bax, puma and noxa may be 
directly involved in IP6-induced apoptosis, it appears to be a likely possibility. 
Notably, both noxa and puma are p531E2FI responsive genes. Given that PC3 
cells are null for p53 (38), this supports the notion that IP6 may exert sorne of its 
effects through E2F family transcription factors; however, our observations 
suggest activation rather than suppression of net E2F transcriptional activity as 
proposed by others (29). This contradiction may be due to the fact that the DUl45 
cells used in the aforementioned study harbor a mutant pRb, which is an 
important modulator of E2F function. In addition, the authors observed that 
although E2F4/Rb complexes increased in reaction to IP6, overall E2F4 was in 
turn down-regulated. Because the status of the transcriptional activator E2FI and 
overall E2F -dependent transcriptional regulation was not assessed, it remains 
possible that this could result in a net increase of E2F-regulated gene expression, 
particularly since E2F4 is thought to be repressive in nature (52). 
The mechanism underlying the inhibition of IP6-induced PC3 cell death 
by an androgen-independent AR-associated function remains unc1ear. The finding 
that NF -KB and E2F responsive genes are up-regulated significantly less in 
PC3(AR) cells in response to IP6, compared with PC3 cells brings forth the 
possibility that the AR may interfere somewhere along one or both of these 
signaling pathways. Although NF -KB has been shown to promote apoptosis in 
certain contexts (53), it is generally considered to be anti-apoptotic (54). In the 
latter case, its initial activation may be a counter-response to pro-apoptotic signaIs 
such as those responsible for the up-regulation of Puma and Noxa in PC3 but not 
PC3(AR) cells. Hence, the E2F pathway may dominate the response to IP6, and 
may itselfbe influenced directly or indirectly by the AR. Interestingly, cyc1in Dl, 
cyc1in E, as well as Rb are known components of the E2F pathway and have all 
been shown to interact with the AR (5-7). In fact, the interaction between Rb and 
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the AR was found to be androgen-independent (5). Altemately, since the AR 
possesses a ligand-independent trans-activation domain, it is also possible that a 
ligand-independent transcriptional activity of the AR mediates the expression of a 
currently unidentified protein that modulates IP6 toxicity. Studies addressing 
these possibilities are currently underway. 
Conclusions: 
We conc1ude that there is a link between AR-expression and sensitivity of 
PCa cell lines to IP6. Furthennore, we show that this could involve a ligand-
independent AR function that can prote ct PC3 cells from the effects of IP6 on cell 
metabolism and subsequent apoptosis. We also conc1ude that IP6 indue es the 
expression of NF-KB-responsive genes as well as E2F-responsive genes in PC3 
cells that may be involved in IP6-induced apoptosis. In addition, we find that 
stable expression of the AR in PC3 cells significantly diminishes NF-KB and E2F-
responsive gene up-regulation. Overall, this suggests that, in addition to its role in 
ADT resistance, the AR could contribute to AIPCa resistance to chemotherapy as 
well. We believe that IP6 will be a useful tool to explore this newly discovered 
property of the AR with a long tenn goal of identifying pathways that can either 
sensitize AIPCa tumors to known chemotherapeutic agents or that can lead to the 
development of novel therapeutics. 
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Figure 1. IP6 decreases cellular metabolic activity in PCa cell Unes. A) 
Dashed lines represent hormone insensitive, AR negative, cell Hnes while solid 
Hnes represent hormone sensitive, AR-positive, celllines. Cells were treated with 
increasing doses of IP6 for 24 hours and metabolic activity was measured using 
the WST -1 assay as described in material and methods. Metabolic activity was 
calculated relative to the mock treated control of each cellline. Values represent 
an average of 4-7 replicate experiments. Error bars represent standard error of the 
mean. B) Cell doubling times in normal serum supplemented media. Data 
represents average of 2 experiments done in triplicate. Error bars represent 
standard error of the mean. ANOV A analysis revealed no significant differences 
in doubling times between any ofthe celllines (p>O.05). 
87 
a) LNCaP b) 22RVl 
1.5 1.5 
1 1 
0.5 - 0.5 
t;- o , 0 
:~ 0 1 2 3 0 1 2 3 
-
<:.1 -Q-- SF 
~ 
-6- " 
.:= ~ Rual 
= c) d) .c PC3 DU145 S 
a.I 
~ 1.5 
1 1 
0.5 
0 0 
0 1 2 3 0 1 2 3 
.. 
mMIP6 
Figure 2. Androgens do not modulate the efficacy of IP6 in prostate cancer 
cells 
88 
Figure 2. Androgens do not modulate the effect of IP6 on PCa cell line 
metabolic activity. Cells were pre-treated in the respective conditions for 72 
hours prior to the assay, which was carried out as described in material and 
methods. Dashed lines represent steroid free conditions (SF), solid lines are 
normal serum supplemented conditions (N), and thick lines are normal serum 
conditions supplemented with 10 nM RI881 synthetic androgen (RI881). 
A verages were calculated from 2-4 duplicate experiments. Error bars represent 
standard error of the mean. 
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Figure 3. Effect of stable expression of the AR in PC3 ceUs. a) AR expression 
in PC3 cens protects from the effects of IP6 on cen metabolism. WST -1 assays 
were performed in normal serum complemented media as described in material 
and methods. Data represents average of 3 experiments done in triplicate. 
Differences between PC3 and PC3(AR) cens were significant at an concentrations 
(p<0.05). b) Prote ct ive effect of the AR is not androgen-dependent. WST -1 assay 
was performed as described in Figure 2. Data represents average of 2-3 duplicate 
experiments. SF= steroid free culture medium, N= normal serum complemented 
culture medium, N+R= Normal serum-complemented culture medium with lOnM 
R188l. c) SiRNA was transfected as described in material in methods. 72 hours 
fonowing transfection, 2mM IP6 was added. WST -1 assays were performed 24 
hours later. Protein was extracted from the same cens as those used in WST-l 
assays 24 hours after IP6 treatment (mock-treated). Western blotting demonstrates 
that the siRNA targeting the AR effectively decreased AR expression in PC3(AR) 
cens compared to siGLO transfection control. d-e) An siRNA targeting the AR 
sensitizes PC3(AR) but not PC3 cens to the effects of IP6. Data represents 
metabolic activity as measured by WST -1 relative to mock-treated control of 
PC3(AR) (d) and PC3 (e) cens after 24 hour treatment with IP6. Mock= mock-
transfected cens; siAR=cens transfected with AR-targeting siRNA+ siGLO 
RISC-free transfection control siRNA; siGLO= RISC-free transfection control 
siRNA. Data represents average of 3 triplicate experiments. An Error bars are 
standard error of the mean. Indicated p values were calculated using student' s T-
test. Differences were also significant using ANOVA (p<O.OOl). f) IP6 induces 
caspase-3-like activation in PC3 cens but to a lesser extent in PC3(AR) cens. The 
caspase-3 assay was performed as described in materials and methods after a 24 
or 48-hour treatment with 2 mM IP6. Data represents fold change in caspase-3-
like activity as compared to mock-treated control. Fold changes were calculated 
from 4-8 replicates. *p<O.OOl, **p<O.OOl. g) IP6 increases DNA fragmentation to 
a lesser extent in PC3(AR) cens than in PC3 cens. Filter elution assays were 
performed as described in material and methods using 2 mM IP6 after 24 or 48 
hours. Data represents average % increase in DNA fragmentation as compared to 
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mock-treated control. % Increase in fragmented DNA was calculated using 
formulas described in material and methods from 3 independent duplicate 
experiments. *p<O.Ol, **p<O.05. 
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Figure 4. No effect of AR-targeting siRNA on LNCaP and 22Rvl cells on IP6 
efficacy. A) SiRNA was transfected as described in material in methods and cells 
were treated as described in figure 3. Western blotting demonstrates that the 
siRNA targeting the AR effective1y decreased AR expression in LNCaP and 
22Rvl cells compared to siGLO transfection control. b-c) AR-targeting siRNA 
does not sensitize LNCaP or 22Rvl cells to the effects of IP6. Data represents 
metabolic activity as measured by WST -1 relative to mock-treated control of 
LNCaP (b) and PC3 (c) cells after 24-hour treatment with IP6. Mock= mock-
transfected cells; siAR=cells transfected with AR-targeting siRNA+ siGLO 
RISC-free transfection control siRNA; siGLO= RISC-free transfection control 
siRNA. Data represents average of 2-3 triplicate experiments. All Error bars are 
standard error of the mean. No statistically significant differences were revealed 
by T -Test or ANOV A. 
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Figure 5. IP6 induces the expression of NF-KB-dependent and p53/E2F-
regulated genes in PC3 but not in PC3(AR) cells. CeUs were treated with ImM 
IP6 for 24 hours as described in materials and methods. FoUowing RNA 
extraction and cDNA synthesis, Real-time PCR was performed and gene 
expression (relative to actin B) was calculated using the method described by 
Pfaffl et al. a-c) pro-apoptotic protein-encoding genes puma (a), noxa (b) and bax 
(c). d-e) Anti-apoptotic protein-encoding genes bel-2 (d) and bel-XL (e). f-h) NF-
KB-responsive genes IKB-u (f), IRF-2 (g) and cyclin Dl (h). Data represents fold 
change in gene expression from mock-treated control to IP6-treated samples. 
A verages were calculated from 2 independent duplicate experiments. Error bars 
represent standard error of the mean. Differences between fold induction of gene 
expression by IP6 in PC3 and PC3(AR) ceUs were significant for puma 
(p<O.002), noxa (p<O.OOI), IRF-2 (p<O.OI) and IKB-u (p<O.OOOl). 
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Abstract 
Purpose: To assess the expreSSIOn of pro-apoptotic NOXA and PUMA in 
prostate tissues and delineate their association with prostate cancer (PCa) 
recurrence. 
Experimental Design: Nonnal, prostatic intraepithe1ial neoplasia (PIN), 
honnone-sensitive (HS) prostate cancer (PCa), and honnone-refractory (HR) PCa 
tissues were used to build tissue microarrays encompassing a total of 135 patients. 
Two observers assessed the intensity ofNOXA and PUMA immunohistochemical 
staining using a composite color scale. 180 Recursive Partitioning And 
Regression Tree (RPART) models were generated to predict biochemical 
recurrence (BCR) within HS cancer patients using NOXA, PUMA and clinical 
parameters. Models were then ranked according to the Integrated Brier Score 
(lBS). 
ResuUs: Increasing NOXA expressIOn was associated with PCa progressIOn 
reaching the highest levels in HR PCa. Increased NOXA expression was observed 
in 68% of HS cancer patients and was predictive of BCR (LR=8.64 p=0.003). In 
contrast, PUMA expression was highest in HS cancer and although 70% of HS 
cancer patients exhibited increased PUMA expression, PUMA alone could not 
predict the ons et of BCR. Interestingly, the top-ranking RP ART model generated 
(lBS=0.107; 95% CI=0.065-0.128) included surgical margin status, NOXA and 
PUMA expression although recurrent prognostic classification schemes obtained 
in the top ten models favored a survival tree model containing margin status, 
NOXA expression and pre-operative prostate specific antigen (PSA) (lBS=0.114; 
95% CI=0.069-0.142). 
Conclusion: We conclude that NOXA and PUMA expression may be linked to 
PCa progression and propose further validation of a survival tree model including 
surgical margin status, NOXA expression, and pre-operative PSA for predicting 
BCR. 
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Introduction 
Prostate cancer (PCa) remains a leading cause of cancer-re1ated death in 
North American men (1). Although localized forms of the disease can often be 
successfully treated by surgery or radiotherapy, a significant proportion of 
patients having undergone su ch interventions are at risk of disease relapse. For 
this reason, considerable efforts have been made in order to discover new 
molecular markers that can accurately predict the onset of disease relapse and lead 
to better-targeted and more effective treatment. 
Androgen deprivation therapy is often used to treat recurrent PCa and can 
increase patient survival; however, this form of therapy eventually gives rise to 
androgen-independent PCa (or AIPCa) (2, 3). Because the treatment of AIPCa 
remains palliative to date (4-6), much effort has been devoted to describing the 
molecular mechanisms associated with the transition of androgen-dependent PCa 
to an androgen-independent state. Many studies have established a role for 
androgen receptor (AR) signaling in this phenomenon (7,8). However, increasing 
evidence suggests that other signaling pathways may also be important for 
progression to an androgen-independent state (9-14). At the convergence ofmany 
of these pathways, it has been suggested that PCa cells can become resistant to 
treatment-induced apoptosis through the up-regulation of anti-apoptotic proteins 
such as BCL-2, BCL-XL and MCL-1 (15, 16). Several studies have detected up-
regulated BCL-2, BCL-X, and MCL-1 expression in high-grade PCa tumors and 
in AIPCa (17-21). 
In theory, enhanced resistance to apoptosis can also be achieved by the 
down-regulation of pro-apoptotic proteins (22). To date, few studies have looked 
at the expression of pro-apoptotic proteins in PCa. So far, most studies addressing 
this question have focused on BAX, a pro-apoptotic protein that elicits its effect at 
the level of the mitochondrial outer membrane where it promotes mitochondrial 
depolarization, a key event in the intrinsic apoptotic pathway. Although it is c1ear 
from several immunohistochemistry (IHC) studies that BAX is expressed in the 
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large majority of tumors, the association between BAX expressIOn and PCa 
progression remains uncertain (18, 23-26). 
NOXA and PUMA are two BH3-only pro-apoptotic proteins that act 
upstream of BAXlBAK in order to promote mitochondrial depolarization. NOXA 
is essentially thought to sensitize cells to the action of activator BH3-only pro-
apoptotic proteins by disrupting their interaction with anti-apoptotic proteins. 
Recent evidence suggests that NOXA specifically disrupts the interaction of 
MCL-l with activator BH3-only proteins BID, BIM and PUMA (27). In tum, 
activator BH3-only proteins such as PUMA and BID interact with the Ha 1 helix 
of BAX to induce conformational changes leading to permeation of the 
mitochondrial outer membrane (28). 
To date, few IHC studies have looked at PUMA or NOXA expression in 
cancer. In melanoma, weak PUMA expression was 1inked to poor patient surviva1 
(29) particularly in patients also showing elevated levels of phosphorylated AKT 
(30). In colorectal cancer, no relationship with clinical outcome was found 
although 29% of tumors overexpressed PUMA (as opposed to 4% showing 
decreased expression) (31). Similarly, NOXA expression was increased in 16% of 
colorectal tumors but was not associated with disease outcome (32). To date, 
neither NOXA nor PUMA has been studied in relation to PCa progression and 
clinical outcome. 
To assist III the process of prognostic marker discovery, increasingly 
powerful statistical methods are being developed and applied. Of these methods, 
survival trees are particularly attractive when looking at multiple markers within 
one or more signaling pathways. Survival tree algorithms are based on recursive 
partitioning of the covariate space (33, 34) and their graphical output facilitates 
the visualization of prognostic groups reflecting multi-marker interactions. In this 
study, we looked at the expression of NOXA and PUMA using tissue micro-
arrays containing normal prostate tissue, primary PCa and its adjacent non-
neoplasic tissue, as weIl as specimens of androgen-independent PCa, representing 
a total of 135 patients. We then used survival trees to evaluate the ability of 
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NOXA and PUMA, al one or in combination with c1inical markers, to predict the 
onset of biochemical recurrence in patients presenting primary PCa. 
Materials and Methods 
Patient cohort 
A total of 51 normal prostate specimens were obtained from cancer-free 
patients. An additional 64 paraffin-embedded human primary PCa specimens 
from patients who had undergone radical prostatectomy between 1993 and 2000 
were also used. Futhermore, trans-urethral resections of the prostate (TURP) 
specimens from 30 AIPCa patients were obtained. Regions of non-neoplasic and 
cancerous epithe1ial tissue were identified by two pathologists and subsequently 
spotted on tissue micro-arrays. In the sub-cohort of 64 primary PCa tumors, which 
was used for retrospective prognostic studies, no patient received preoperative 
hormone therapy and aH cases had a c1inical foHow-up of at least 5 years or until 
death (average foHow up of 72 months). No age difference was observed between 
the group of patients who relapsed and the group that did not. Postoperative PSA 
was available for aH patients. The time to biochemical recurrence (BCR) was 
defined as the time elapsed between the date of surgery and the date where PSA 
first increased from undetectable levels to above 0.3 ng/ml and rising, consistent 
with previous studies (35-37). Non-relapsed patients had a PSA remaining below 
0.3 ng/ml after radical prostatectomy. For PCa specimens, the final staging, 
grading and histo-pathological diagnosis was based on the pathology report in 
agreement with the review from an independent pathologist. Specimens were 
obtained from consenting patients and the institutional ethics review committee 
approved the study. 
Tissue array construction and verification 
Tissue arrays containing a total of 613 one millimeter-wide cores of 
prostate tissues were built and used for IHC studies. For the sub-cohort containing 
normal tissue cores obtained from 51 autopsied patients, two cores per patient 
were spotted on a tissue micro-array. For the prognostic sub-cohort of primary 
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tumors, two non-neoplastic and four cancerous cores per patient were sported on 
tissue arrays. For the hormone-refractory TURP sub-cohort, four cores per patient 
were included on a tissue microarray. Following tissue microarray construction, 4 
Ilm thick cross-sections were put on glass slides and stained with hematoxylin & 
eosin as well as for cytokeratin 34~E 12 and reviewed by two pathologists. AlI 
cores were subsequently re-categorized as containing no epithelial cells, non-
neoplasic epithelium, focal atrophy, PIN, or adenocarcinoma. Cores containing no 
epithelial cells or focal atrophy were not considered in the analysis. Following 
reclassification, the final specimen cohort consisted of 601 cores representing 43 
patients with normal prostate tissues, 62 patients presenting primary PCa tissues 
and 30 patients with hormone-refractory PCa for a total of 135 patients. Patient 
characteristics are summarized in Table 1. 
Protein extraction 
Confluent LNCaP, 22Rvl, PC3 and DU145 cells were scraped, washed twice 
with cold PBS and pellets were frozen at -80°C. Subsequently, who le cell 
extractions were performed by applying cold lysis buffer (10 mM Tris-Hcl, pH 
7.4,150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM NaF, 0.5% NP-40, 0.5 mM 
PMSF, 0.2 mM orthovanadate, 2 mg/ml of aprotinin, leupeptin and pepstatin) on 
ice for 30 min. Whole cell extracts were collected after centrifugation in a 
Heraeus Biofuge (13,000 rpm for 10 min at 4°C) and were immediately stored at-
80°C. Protein concentration was measured by Bradford assays (Bio-Rad 
Laboratories Inc., Hercules, CA) according to the manufacturer's instructions. 
Western blot analysis: 
For Western blot analysis, 50 Ilg of whole cell protein extract were 
resolved on a 12.5% polyacrylamide gel and then transferred onto PVDF 
membranes (Millipore, Billerica, MA, USA). Blots were blocked using 5% non-
fat dry milk in PBS-Tween 0,05% buffer overnight at 4°C and probed using either 
a monoclonal antibody raised aga in st recombinant GST-tagged full-length NOXA 
(OP180, Calbiochem, La Jolla, CA), polyclonal antibody raised against ami no 
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acids 2-16 of PUMA (PC686, Calbiochem, La Jolla CA) or actin B (ab6276-100, 
Abcam, Cambridge, UK) for 1 hour at room temperature in blocking buffer 
(1 :500). Membranes were then incubated with secondary antibody conjugated to 
horseradish peroxidase (Amersham Life Sciences Inc., Arlington Heights, IL) in 
blocking buffer for 1 hour at room temperature and developed with enhanced 
chemiluminescence (ECL) substrate (Amersham Life Sciences Inc., Arlington 
Heights, IL). 
Immunohistochemistry 
Samples were immunostained with either anti-NOXA antibody (OPI80) at 
50 ng/Ill or anti-PUMA antibody (PC686) at 4 ng/Ill diluted in PBS. Primary 
antibody detection was done using the LSAB 2 peroxidase system from Dako 
Diagnostics Inc (CA, USA). Staining was performed as described previously (35, 
38-40). Briefly, tissue samples were deparaffinized, rehydrated, and treated with 
0.3% H20 2 to eliminate endogenous peroxidase activity. An antigen retrieval step 
was performed using 10 mM citrate buffer (pH 6.0) applied for 17.5 minutes at 
95°C. All following steps were performed at room temperature. The sections were 
blocked with a protein-blocking serum-free reagent (Dako) and incubated with 
primary antibody for 60 minutes, followed by a 20 minute treatment with the 
secondary biotinylated antibody (Dako), washed 5 minutes in PBS, and then 
incubated for 20 minutes with streptavidin-peroxidase (Dako). F ollowing an 
addition al 5 minute PBS wash, reaction products were developed with 
diaminobenzidine (Dako) containing 0.3% H202 as a substrate for peroxidase. 
Nuclei were counterstained with Harris hematoxylin (Sigma-Aldrich, MO, USA). 
No non-specific secondary antibody staining was observed wh en PBS was used 
in ste ad of the primary antibody. 
Scoring procedure 
For NOXA and PUMA-stained tissues, digital pictures were taken of each 
core on an Olympus BX51 microscope using Q capture imaging software 
(Olympus, London, UK). Two independent observers quantified epithelial 
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staining intensity usmg a color scale (Fig.2h) constructed from the vanous 
staining intensities observable in the digital pictures using the eyedropper tool in 
Adobe Photoshop 7.0. The observers assessed the percentage of epithelial cells 
representing each color of the scale (0-9) and an overall score was ca1culated from 
the sum of the products derived from percentage (0-100%) multiplied by the scale 
value (0-9) for each core. Hence, aIl staining intensity values are on a continuous 
sca1e of 0 to 9. Notab1y, intra-c1ass correlation coefficients (rCC) (a measure of 
reliability between the two observers) were found to be excellent using this 
method (lCC>O.75, (41)), in sharp contrast with initial estimates done using 
conventional microscopy methods (lCC<0.5). Overall intensity values from each 
observer, obtained using the digital pictures, were then averaged and used for 
further statistical analyses. 
Statistics 
Mean staining intensities of cores from cancer-free patients, of non-
neoplasic, PIN and cancer cores from hormone-sensitive PCa patients as weIl as 
of cancer TURP cores from hormone-refractory PCa patients were ca1culated. 
Kruskal-Wallis non-parametric tests were used to assess statistical significance of 
observed differences in mean staining intensity. AlI correlation coefficients were 
computed using Spearman's non-parametric test. Cut-off determination and 
survival tree construction was done using the RPART (Recursive PARTitioning) 
libraries (33), which extends the CART (Classification and Regression Trees) 
routine (34). Model accuracy was assessed using the integrated Brier score for 
censored data (lBS) (42). We used 200 bootstrap (43) samples to compute the 
95% confidence interval (CI) on the lBS. Survival tree growth was controlled 
using the minimum splitting (minsplit) criterion implemented in RPART. This 
parameter controls the minimum number of observations that must exist in a 
node, in order for a split to be attempted. For combination models inc1uding 
NOXA and/or PUMA as weIl as combinations of the four c1inical markers, all 
possible RP ART models were generated using three different values of minsplit 
(20, 25 and 30). This generated 180 combinations corresponding to 69 different 
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umque tree models, which were ranked according to lBS. Kruskal-Wallis, 
Spearman, and Kaplan-Meier analyses were performed using Statistical Package 
for the Social Sciences (SPSS) version Il (SPSS, lnc., Chicago, USA). Tree 
building and the calculation of lBS were carried out in the R (version 2.4.0; (44)) 
system for statistical computing (www.cran.r-project.org).using rpart and ipred 
packages respectively. 
Results 
NOXA and PUMA Expression in Prostate Cancer Cell Lines 
We used western blotting on whole cell extracts in order to assess the 
expression ofNOXA and PUMA proteins in PCa celllines. As shown in figure 1, 
the antibodies targeting NOXA and PUMA detected the expected ~6 kD and 23 
kD bands (respectively) and revealed variable but apparent NOXA and PUMA 
expression in all PCa celllines. For PUMA, cellline expression levels were found 
to be highest in 22Rvl followed by LNCaP and PC3 cells, with DUl45 exhibiting 
the lowest PUMA expression. NOXA expression levels were highest in DU 145 
cells, followed by PC3 and 22Rvl cells, with lowest expression leve1s in LNCaP 
cells. 
NOXA Expression in Prostate Tissue Sub-types 
To determine whether NOXA expression could be linked to PCa progression, 
we stained prostate tissue micro-arrays using the antibody recognizing NOXA 
(same as used in Fig.1). In general, we found that this antibody stained the 
cytoplasm of epithelial cells (Fig.2 a, c, e). In many normal cores from cancer-
free patients and non-neoplastic cores found adjacent to cancer (hereby referred to 
as NA), we observed more intense staining in the basal cell layer of epithelial 
glands (Fig. 2a). To increase interobserver re1iability and facilitate retrospective 
interpretation of the results obtained, we used a standard color scale (Fig.2h) 
constructed from digital pictures of tissue cores as described in materials and 
methods. Overall, we found that cores taken from normal patients expressed 
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significantly less NOXA than all other tissue sub-types obtained from PCa 
patients, inc1uding NA cores (Fig 3a). We also observed a slight but statistically 
insignificant decrease in PIN as opposed to NA cores (p=0.09). Although 
hormone-sensitive (HS) cancer tissues exhibited higher mean NOXA expression 
than both NA and PIN cores, (p<O.OOl), hormone-refractory (HR) TURP 
specimens exhibited the highest mean NOXA staining (mean=5.09, p<O.OOl). 
Notably, in the subgroup of patients for which we had both NA and HS cores 
(n=51), 68% exhibited increased NOXA expression in HS cores. 
PUMA Expression in Prostate Tissue Sub-types 
Similarly to what was observed with the anti-NOXA antibody, we found 
that the antibody targeted against PUMA (same as l.lsed in Fig.l) generally stained 
the cytoplasm of epithelial cells (Fig 2b, d, t). Basal cell staining was also 
apparent in several normal prostate cores as well as in NA cores (Fig 2b). PUMA 
staining was subsequently evaluated using the same method employed for NOXA 
and mean core intensity was calculated for each core sub-type. As shown in figure 
3b, we observed a significant increase in PUMA expression in NA cores as 
compared to normal prostate cores (p<O.OO 1). While PUMA expression was 
similar in NA and PIN cores, HS cancer cores exhibited significantly higher 
PUMA expression than both NA/PIN (p<O.OO 1). It should be noted however that 
mean PUMA expression in HR cores was not found to be significantly different 
from that observed in NA cores (p=0.654). Similarly to what was observed for 
NOXA, in the subgroup of patients for which we had both NA and HS cancer 
cores (n=51), 70% exhibited increased PUMA expression in HS cancer. 
NOXA and PUMA Expression Can Predict the Onset of Biochemical 
Recurrence 
Pro-apoptotic proteins such as PUMA and NOXA play a role in the 
initiation of cell death to various cellular stresses. Hence, we wondered whether 
NOXA and/or PUMA expression could be predictive of PCa re-emergence 
following radical prostatectomy. To address this question, we used BCR as a 
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surrogate endpoint and determined whether NOXA and/or PUMA expressIOn 
could be predictive of BCR. We employed the rpart function in R to assess 
whether NOXA or PUMA status alone could stratify patients in function of BCR 
onset within the sub-cohort of 62 patients presenting HS cancer. Using optimal 
cut-offs obtained by rpart, corresponding to the primary splitter of the root node, 
we found that high NOXA expression (~5.5 on a scale of 0-9) was associated with 
an earlier and more frequent onset of BCR (Log Rank or LR=8.6 p=0.003; Fig. 
4a). On the other hand, PUMA expression alone was not significantly predictive 
of the onset of BCR (LR=2.5 p=O.l14; Fig. 4b). Interestingly, including both 
NOXA and PUMA in the RPART model revealed that low PUMA expression 
was associated to more rapid progression towards BCR but specificaHy wh en 
NOXA expression was also low (LR=15.6 p<5xl0-4, Fig 4c, Table 2). In this 
model, patients exhibiting high NOXA (~5.5) expression were most likely to 
quickly undergo BCR, with approximately 77% (10/13) of these patients having 
undergone relapse before 3 years. Within the group of patients expressing low 
levels of NOXA, 10w expression of PUMA «6.6) was associated to earlier and 
more frequent onset ofBCR with close to 46% (16/35) ofpatients having relapsed 
within 3 years. In contrast, patients exhibiting both low NOXA and high PUMA 
infrequently underwent BCR, with only 14% (2/14) having undergone relapse at 3 
years. Because ofpotential over-fitting due to the application of cut-offs obtained 
by RPART from the same test data set, Kaplan-Meier plots and associated LR p-
values should be considered as purely descriptive measures since the survival 
outcomes were used to define the prognostic groups. 
NOXA and PUMA Expression Predict the Onset of BCR in Combination 
with Clinical Markers 
We next wondered whether NOXA and PUMA expression could help to 
predict BCR in combination with other clinico-pathological parameters such as 
pre-operative PSA, Gleason score, pathological stage and resection margin status. 
We thus generated several RPART models by using as input variables aH possible 
combinations of the four clinical markers with NOXA and/or PUMA and ranked 
107 
them according to the lBS, where lower lBS means greater accuracy. The top-
ranking model stratified patients first on the basis of margin status 
(negative=good prognosis) then on the basis of NOXA within negative margins 
(NOXA<5.2=good prognosis) and on the basis of PUMA within the positive 
margms (PUMA <6.1 =good prognosis). Furthennore, PUMA also stratified 
negative margin patients expressing low levels of NOXA, with high PUMA 
expression (PUMA~6.1) being surprisingly associated with good prognosis (0/13 
patients relapsed, Fig 5a). This model had an lBS of 0.107 (95% CI=0.065-0.128, 
table 2). Interestingly, we found that nine of the top ten RPART mode1s exhibited 
an initial stratification according to resection margin status followed by that of 
NOXA expression in negative margins (Fig 5b). In contrast, only three of the top 
ten models included PUMA. In seven of the top ten models, positive margin 
patients as well as negative margin patients with low NOXA expression could be 
further stratified by pre-operative PSA and/or Gleason score where patients 
exhibiting low pre-operative PSA or low Gleason had a better prognosis. Notably, 
in all of these seven models the best prognostic group (negative margin, low 
NOXA expression and low pre-operative PSA or Gleason) did not relapse. In one 
ofthese models with an lBS of 0.114 (95% CI=0.069-0.l42, table 2), 0/9 patients 
exhibiting negative margins, low NOXA expression and low pre-operative PSA 
«6.5) relapsed in the best prognostic group (Fig 5c). In contrast, the top model 
that included only margin status and pre-operative PSA had an lBS of 0.135 (95% 
CI=0.093-0.157, table 2) where 3/20 patients relapsed in the best prognostic 
group. Of the RPART models composed exclusively of clinical markers, the top-
ranking model was one that included margin status and Gleason score and had an 
lBS of 0.132 (95% CI=0.090-0.160, table 2). 
Discussion 
To our knowledge this is the first study describing the expreSSIOn of 
NOXA or PUMA in a cohort of patients representing various histopathological 
sub-types of PCa. In our overall cohort of 135 patients we found that mean 
NOXA expression increased gradually going from nonnal prostate cores to NA 
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and PIN cores, followed by HS cancer cores and finally to HR cancer cores, the 
latter expressing the highest leve1s of NOXA (Fig 2a). These data suggest that 
increasing NOXA expression may be associated to PCa progression. In contrast 
with what has been previously observed in colorectal cancer (32), we found that 
increased NOXA expression is a frequent occurrence in PCa (16% in colorectal 
cancer vs. 68% of PCa patients). In addition, we found that NOXA expression is 
associated with clinical outcome, which was not observed in the colorectal cancer 
study. In contrast with NOXA, the association between PCa progression and 
PUMA appears to be more complex. Although we found that 70% of HS patients 
showed elevated PUMA (as opposed to 29% in melanoma (31)), our data suggest 
that PUMA expression does not further increase in HR PCa. 
These findings are somewhat reflected in what was observed in PCa cell 
lines using western blots probing for NOXA and PUMA expression. In Figure l, 
we can see that taken together, the two androgen-insensitive cell lines PC3 and 
DUl45 express relatively higher levels of NOXA as compared to androgen-
responsive LNCaP and 22Rvl cells. In contrast, LNCaP and 22Rvl cells appear 
to exhibit higher leve1s of PUMA. These findings are somewhat surpnsmg 
because NOXA and PUMA have been found to have more than one 
transcriptional regulator in common, including p53 and E2FI (45). However, we 
found that within cores there was a generally strong correlation between PUMA 
and NOXA expression (Spearman Coefficient = 0.586; p<IO.6 ; data not shown). 
Altogether, these data may be indicative of the involvement of molecular 
pathways that lead to "de-coupled" PUMAINOXA in HRPCa. Further 
investigation will be required to address this possibility. 
To date, investigators have typically used linear Cox proportional hazard 
models to stratify patients' risk with respect to the expression of molecular 
markers. However, Cox models neither handle complex interactions among 
prognostic factors efficiently, nor take into account nonlinear effects (46, 47). To 
overcome these limitations, tree-based methods offer an attractive alternative to 
Cox models (48). In this study, we used survival trees to assess the ability of 
NOXA and PUMA to predict BCR alone and in combination with clinical 
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markers. Although this method is increasingly used for immunohistochemical 
analyses in cancer, its specific application to PCa cohorts has been thus far limited 
and generally focused on existing clinical parameters (49-52). However, one PCa 
study has recently applied the survival tree method to assess the prognostic ability 
of a1pha-methylacyl CoA racemase detected by immunohistochemistry as was 
done here for PUMA and NOXA (53). 
Assessing the predictive performance measure and mode1 selection criteria 
for prognostic models remains a matter of debate. For survival tree-based 
methods, the lBS is currently thought to be the most appropriate index (42, 54). 
Using IBS, we determined that the most accurate mode1 for predicting BCR in our 
cohort was one that included surgi cal margin status, NOXA, and PUMA 
expression (IBS=O.l 07). A1though this mode1 was particularly good at predicting 
which patients wou1d not undergo BCR (0/13 in the best prognostic group, fig 5a-
b), it presented a comp1ex behavior of PUMA wherein its effect on BCR onset in 
negative margins was opposite to that found in positive margins. Because PUMA 
expression al one could not significantly predict BCR as shown in Kaplan Meier 
analyses (Fig 4b), it is unclear whether PUMA expression tru1y holds va1uab1e 
clinica1 information. On the other hand, NOXA was a significant predictor of 
BCR when assessed alone (Fig 4a) and was incorporated into the top nine RPART 
models where low NOXA expression was consistently associated with good 
prognosis. For this reason as well as for practical considerations pertaining to 
sorne degree of subjectivity in the Gleason grading, we favor the mode1 presented 
in Fig 5d-e, including NOXA expression, surgical margin status and pre-operative 
PSA, for future evaluation. 
One limitation in the present study is the relatively small size of our 
prognostic cohort (n=62), which may affect the reliability of the RP ART 
algorithm. Nonetheless, we could observe recurrent and stable tree structures that 
were consistently present in the top ni ne models. Another relevant concern is that 
re-applying a RP ART model established from one data set onto the same data set 
can lead to over-fitting. To account for this, we used bootstrap re-sampling to 
calcu1ate 95% confidence intervals for the lBS as has been done elsewhere (55). 
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Nonetheless, the results obtained here remain of an exploratory nature and will 
require subsequent external validation in another cohort. In addition, it will be of 
significant interest to determine whether NOXA/PUMA expression can also be 
useful prognostic markers at the biopsy level. In either case, the color sc ale 
method for measuring staining intensity devised here wi1l likely be useful for the 
evaluation and classification of future samples. 
Overall, our findings are somewhat at odds with the roles of NOXA and 
PUMA as pro-apoptotic factors. While sorne have found that increasing apoptotic 
index is associated with disease recurrence (56) others have detected decreasing 
apoptosis in PCa progression (57). One possible reason for these discrepancies is 
that increased apoptosis may be counterbalanced by increased cell proliferation, 
leading to more rapid cellular turnover. Notably, others have found that increasing 
expression of the cell proliferation marker Ki67 correlates with Gleason grade and 
with decreased PCa patient survival (58, 59). Although we are currently 
investigating whether this is the case for our patient cohort (Gannon P.O. et al, 
manuscript in preparation), it is important to note that we did not find a significant 
correlation between Gleason score and either NOXA or PUMA in the present 
study (data not shown). As such, another possibility is that increased 
NOXA/PUMA expression is an indirect result of de-regulated activation of 
factors mediating NOXA/PUMA transcription or prote in stabilization. Potential 
candidates for this are varied and include p53, E2F as weIl as forkhead family 
transcription factors (45, 60, 61). 
Conclusion 
We conclude that NOXA and PUMA expression may be linked to PCa 
progression. We also suggest that the assessment of NOXA expression may be 
particularly useful for PCa prognosis, as it may extend the ability of existing 
clinical markers to predict BCR. We believe that a survival tree model including 
NOXA, surgical margin status and pre-operative PSA status deserves external 
validation in a larger cohort. 
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Table 1. Patient cohort characteristics. Mean patient follow up was 72 
months. 
Overall patient cohort 
Age median (min-max) 
Cancer-free patients 
PCa patients 
AIPCa patients 
Primary Prostate Cancer Patient Cohort 
Stage 
Stage 2 
Stage 3 
Invasion 
Extraprotatic extension 
Lymph node imetastasis 
Seminal vesicle invasion 
Became Hormone-refractory 
Had Prostatitis 
Gleason Score 
Gleason 4 
Gleason 5 
Gleason 6 
Gleason 7 
Gleason 8-9 
Pre-operative PSA 
<10 ng 
>10 ng 
l'Jot available 
PSA relapse 
Relapse 
No relapse 
Surgical margins 
Negative 
Positive 
Deaths within follow-up period 
35 (15-45) 
62 (49-70) 
79 (65-95) 
34 
28 
20 
9 
9 
5 
1 
8 
14 
13 
17 
10 
32 
28 
2 
35 
27 
31 
31 
9 
119 
120 
Table 2. Brier scores and associated 95% CI for selected RP ART models. 
95% CI were calculated from 200 bootstrapped samples. 
Parameters included Rank # lBS 9S 0/0 CI in the RPART model 
NOXA + PUIIIIA + margin 1 0.107 0.065-0.128 
NOXA + margin + PSA 6 0.114 0.069-0.142 
Margin + Gleason 23 0.132 0.09-0.16 
Margin + PSA 31 0.135 0.093-0.157 
NOXA + PUMA 59 0.155 0.123-0.207 
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Figure 1. NOXA and PUMA expression in PCa ceIllines. The Western blot 
was probed for NOXA, PUMA and actin in whole ceIl extracts obtained from 
androgen-responsive (LNCaP, 22Rvl) and androgen-independent PCa cell 
Hnes. Because the anti-NOXA and anti-PUMA antibodies used here 
recognized their respective targets with little background, they were 
subsequently deemed adequate for immunohistochemistry. 
NOXA 
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Figure 2. NOXA and PUMA expression in prostate tissues 
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Figure 2. lmmunohistochemical staining of paraffin-embedded prostate 
tissues using anti-NOXA and anti-PUMA antibodies. A-B) Normal prostate 
tissue probed for NOXA and PUMA respectively. Note enhanced staining in 
the basal celllayer. C-D) Hormone-sensitive prostate carcinomas probed for 
NOXA and PUMA respectively. F-G) Hormone-refractory TURP specimens 
stained using anti-NOXA and anti-PUMA antibodies respectively. H) Color 
scale standard used for assessment of pictures obtained from tissue 
microarrays probed for NOXA and PUMA. Scale was constructed from 
several digital pictures evaluated in the study as described in materials and 
methods. Numeric values correspond to the associated intensity score. 
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Figure 3. Average NOXA and PUMA expression in prostate tissue 
subtypes. 
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Figure 3. Average NOXA (A) and PUMA (B) expression in prostate tissue 
subtypes. Average was calculated over aH the available cores in each subtype 
category. Normal = normal prostate tissue from autopsied patients (NOXA 
n=94; PUMA n=96 cores), NA= normal tissue found adjacent to cancer in 
radical prostatectomy specimens (n=9l cores), PIN = PIN tissue obtained 
from radical prostatectomy (n=43), HS cancer = hormone-sensitive cancer 
tissues obtained by radical prostatectomy (NOXA n=225; PUMA n=227), HR 
cancer = hormone-refractory cancer tissue obtained from TURP specimens 
(n=159). Two independent pathologists verified aH core classifications. Error 
bars represent the standard error. Associated p-values were calculated using 
the Kruskal-WaHis non-parametric test. P-values under 0.05 were considered 
significant. 
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Figure 4. NOXA and PUMA expression in relation to the onset of 
biochemical recurrence following radical prostatectomy 
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Figure 4. Kaplan Meier plots for NOXA and PUMA categorized usmg 
optimal cutpoints obtained by RPART. A) NOXA expression in PCa is 
associated to BCR. Low (thin line) indicates average patient NOXA staining 
intensity was below 5.5 whereas High (thick line) indicates NOXA staining 
intensity over or equal to 5.5. B) PUMA expression al one does not 
significantly predict the onset of BCR. Low (thin line) indicates average 
patient PUMA staining intensity was below 6.6 whereas High (thick line) 
indicates PUMA staining intensity over or equal to 6.6. C) RPART model 
obtained for combined NOXA and PUMA. 1BS=0.155 (95% C1=0.123-
0.2073). Circ1ed numbers correspond to the groups depicted in the associated 
Kaplan Meier plot shown in the right panel. 1mmediate1y be10w circ1ed 
numbers, fractions (in bold font) represent number of patients that 
relapsedlnumber of patients in the group. LR=Log Rank; P= p-value. Note 
that p-value and Log Rank statistics should be considered as pure1y 
descriptive measures (see materials and methods). 
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Figure 5. Top-ranking multivariate survival tree models. 
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Figure 5. Kaplan Meier plots for RPART model including NOXA, PUMA 
and clinical markers. A) Top ranking RPART model obtained in the study 
(MGNXPU). IBS=0.107 (95% CI=0.065-0.128). The left panel shows the 
associated survival tree where the numbers within circles corresponds to the 
MGNXPU groups depicted in the Kaplan-Meier plots (right panel). B) 
General survival tree structure determined from the top 9 models ranked by 
lBS. Recurrent structures (bold line) were those present in all of the top 9 
ranking models. X and Y denote node-splitting variables (discontinuous line) 
within the top 9 models. In the top 9 ranking models, splitting parameter X 
was either PUMA, Gleason, pre-operative PSA. One model exhibited no 
variable for X (no split). Splitting variable Y was either PUMA, Gleason, pre-
operative PSA, or NOXA. C) Favored RPART model obtained from the top 
ni ne RPART models from this study (Rank#6). IBS=0.113 (95% CI=0.069-
0.142). Numbers within circles in the survival tree (left panel) correspond to 
the groups depicted in the Kaplan-Meier plots right panel. In A and C, the 
fractions below the colored circles represent the number of patients 
relapsedlnumber of patients in the group. 
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Abstract 
Background: The role of the androgen receptor (AR) in the development of 
androgen-independent (Al) prostate cancer (PCa) is well established. However, 
the contribution of nuclear AR in the early stages of PCa and its value as a marker 
for predicting biochemical recurrence (BCR) following radical prostatectomy 
(RP) remains controversiaL The goal of this study was to address this issue by co-
assessing cytoplasmic and nuclear AR expression in prostate tissues. 
Materials and Methods: ArchivaI prostate specimens from cancer-free patients 
(n=43), hormone-sensitive (HS) PCa patients (n=62), and AIPCa patients (n=30) 
were used to construct tissue microarrays (total 35). Prostatic intra-epithelial 
neoplasia (PIN) as weIl as non-neoplasic tissues found adjacent to HSPCa (NA) 
were also inc1uded. Nuc1ear and cytoplasmic AR expression was scored by two 
observers using a composite scale following immunohistochemical detection of 
the AR. The nuc1ear/cytoplasmic AR expression ratio was also computed. 
Univariate Kaplan-Meier plots, as weIl as multivariate Cox and survival tree 
analyses were subsequently used to assess the ability of the AR to predict BCR in 
the sub-cohort of HSPCa patients. 
Results: We found that the most striking increase in nuclear AR staining intensity 
when comparing normal prostate tissues from cancer-free patients to NA. 
Cytoplasmic AR expression was highest in AIPCa and increased considerably in 
relation to HSPCa. The nuc1ear/cytoplasmic AR expression ratio was highest in 
NA and PIN. In univariate analyses, we found that low nuclear AR, low 
cytoplasmic AR, and a high nuclear/cytoplasmic AR expression ratio were 
associated with BCR. Although cytoplasmic AR was an independent predictor of 
BCR in a Cox multivariate model (Hazard Ratio=2.736, 95% confidence interval 
1.228-6.091, p-value=0.014), survival tree analyses suggest a complex 
relationship between AR expression and c1inico-pathological features. 
Conclusion: We propose that increased nuclear AR expression may be a 
precursor to PCa and that cytoplasmic AR could contribute to the AIPCa 
phenotype. We also conclu de that the predictive ability of the AR may be closely 
linked to clinico-pathological features. 
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Introduction 
Prostate cancer (PCa) remains a leading cause of cancer-related death in 
North-American men (1). Though localized forms of the disease can often be 
successfully treated by surgery or radiotherapy, a significant proportion of 
patients having undergone such interventions are at risk of disease relapse. 
Particularly, patients exhibiting an early rise in serum prostate specific antigen 
(PSA) levels (termed biochemical recurrence or BCR) following surgery are more 
likely to die from the disease (2). As such, it is likely that this specifie group of 
patients would benefit from more aggressive treatment whereas in contrast, a less 
invasive approach may be more appropriate for patients at low risk of recurrence. 
Consequently, a growing number of studies have attempted to identify molecular 
markers that can accurate1y predict whether and how quickly patients will relapse 
following surgery. 
Since the pioneering works of Huggins and Hodges(3), the mainstay for 
treatment of advanced or recurrent PCa has been androgen deprivation therapy. 
Though this treatment modality can increase patient life by several years, it 
eventually fails, giving rise to androgen-independent PCa (or AIPCa) for which 
treatment is essentially palliative (4-7). The principle target of androgen 
deprivation (or blockade) is the androgen receptor (AR), a nuclear receptor family 
transcription factor involved in prostate development, which is essentiai for 
growth and survival of the normal prostate epithelium. Bound by androgens, this 
transcription factor is released from its sequestration by heat shock proteins and 
translocates to the nucleus where it drives the expression of various genes, many 
ofwhich are involved in cell proliferation and survival (reviewed in (8)). This has 
led to the suggestion that various AR-dependent mechanisms can drive the 
progression towards AIPCa. These include AR mutations within various domains 
involved in transactivation and ligand binding, AR gene amplification and/or up-
regulation, as weIl as increased expression of AR co-activators or hyper-
activation of pathways Ieading to increased AR transactivation (reviewed in (9)). 
Aithough much evidence supports a role for the AR, either direct or 
indirect, in the development of AIPCa following androgen depletion therapy, the 
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link between the AR and PCa aggressiveness prior to treatment by androgen 
deprivation is far from clear. Indeed, the literature is divided as to whether 
expression of the AR is associated to more or less aggressive disease. Sorne 
studies have reported decreased expression of the AR in cancerous prostate tissue 
as opposed to benign prostate tissue (10, 11). However, this is not consistently 
found (9). Similarly, there is no consensus as to how the AR relates to disease 
relapse following surgery (10, 12-15). It is 1ike1y that these conflicting findings 
are largely responsible for the absence of the AR from the relatively short list of 
clinically used prognostic markers for PCa. 
Likely due to the well established role of the AR as a transcription factor, 
most of the immunohistochemical studies that have looked at the AR in prostate 
tissues obtained from patients have either not discriminated between nuclear and 
cytoplasmic staining (10, 12-14) or have focused exclusively on AR nuclear 
localization (15, 16). N onetheless, several AR binding partners have been 
identified and while sorne are nuclear proteins (e.g CBP/p300 and SRC-1 (17)), 
others reside in the plasma membrane or cytoplasm (e.g EGFR (18), Caveolin-1 
(19)) or can shuttle between nuclear and cytoplasmic compartments (e.g cyclin 
Dl (20), Rb (21), Akt (22), NF-KB (23)). The AR has ev en been reported to 
interact with mitochondrial proteins (COXVb (24)). Altogether, this suggests that 
the expression of the AR in the cytoplasm may also have an impact on PCa 
progression. 
In light of this, we set out to study cytoplasmic AR expression in parallel 
with nuclear AR expression in prostate tissues of various sources. We looked at 
the intensity of both cytoplasmic and nuclear AR staining using tissue micro-
arrays containing normal prostate tissue, primary PCa and its adjacent non-
neoplasic tissue, as well as androgen-independent specimens, representing a total 
of 135 patients. We then evaluated the ability of nuclear and cytoplasmic AR to 
pre di ct BCR within patients that had undergone radical prostatectomy, but that 
were not subjected to androgen deprivation therapy prior to relapse. To evaluate 
the prognostic ability of the AR in combination with established clinical markers, 
we used Cox proportional hazard models as well as survival trees, a method based 
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on recursive partitioning of the covariate space whose graphical output facilitates 
the visualization ofprognostic groups reflecting multi-marker interactions. 
Materials and Methods 
Patient cohort 
A total of 51 normal prostate specimens were obtained from cancer-free 
patients. An additional 64 paraffin-embedded hum an primary PCa specimens 
from patients who had undergone radical prostatectomy between 1993 and 2000 
were also used. Futhermore, trans-urethral resections of the prostate (TURP) 
specimens from 30 AIPCa patients were obtained. Regions of non-neoplasic and 
cancerous epithe1ial tissue were identified by two pathologists and subsequently 
spotted on tissue micro-arrays. In the sub-cohort of 64 primary PCa tumors, which 
was used for retrospective prognostic studies, no patient received preoperative 
hormone therapy and a11 cases had a clinical fo11ow-up of at least 5 years or until 
death (average follow up of 72 months). No age difference was observed between 
the group of patients who re1apsed and the group that did not. Postoperative PSA 
was available for a11 patients. The time to biochemical recurrence (BCR) was 
defined as the time elapsed between the date of surgery and the date where PSA 
first increased from undetectable leve1s to above 0.3 ng/ml and rising, consistent 
with previous publications (25-27). Non-relapsed patients had a PSA remaining 
below 0.3 ng/ml after radical prostatectomy. For PCa specimens, the final 
pathological staging, grading and histo-pathological diagnosis was based on the 
pathology report in agreement with the review from an independent pathologist. 
Specimens were obtained from consenting patients and the institutional ethics 
review committee approved the study. 
Tissue array construction and verification 
Tissue arrays containing a total of 613 one millimeter-wide cores of 
prostate tissues were built and used for IHC studies. For the sub-cohort containing 
normal tissue cores obtained from 51 autopsied patients, two cores per patient 
were spotted on a tissue micro-array. For the prognostic sub-cohort of primary 
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tumors, two non-neop1asic and four cancerous cores per patient were spotted on 
tissue arrays. For the hormone-refractory TURP sub-cohort, four cores from each 
patient were included on a tissue-microarray. Following tissue-array construction, 
4 !lm thick cross-sections were put on glass slides and stained with 
hematoxylin/eosin as well as for cytokeratin 34~E12 and reviewed by two 
pathologists. AlI cores were subsequently re-categorized as containing no 
epithelia1 cells, non-neop1asic epithe1ium, focal atrophy, PIN or adenocarcinoma. 
Cores containing no epithelial cells or focal atrophy were not considered in the 
analysis. Following reclassification, the final specimen cohort consisted of 601 
cores representing 43 patients with normal prostate tissues, 62 patients presenting 
primary PCa tissues and 30 patients with hormone-refractory-PCa for a total of 
135 patients. Patient characteristics are summarized in Table 1. 
Immunohistochemistry 
Samples were immunostained with an anti-AR antibody (NeoMarkers, 
Clone AR-441, MS-443-P) diluted 1:250 in PBS. Primary antibody detection was 
done using the LSAB 2 peroxidase system from Dako Diagnostics Inc (CA, 
USA). Staining was performed as described previously (25, 28-30). Briefly, tissue 
samples were deparaffinized, rehydrated, and treated with 0.3% H202 to eliminate 
endogenous peroxidase activity. An antigen retrieval step was performed using 10 
mM citrate buffer (pH 6.0) applied for 17.5 minutes at 95°C. AlI following steps 
were performed at room temperature. The sections were blocked with a protein-
blocking serum-free reagent (Dako) and incubated with primary antibody for 60 
minutes, followed by a 20 minute treatment with the secondary biotinylated 
antibody (Dako), washed 5 minutes in PBS, and then incubated for 20 minutes 
with streptavidin-peroxidase (Dako). Following an additional5 minute PBS wash, 
reaction products were developed with diaminobenzidine (Dako) containing 0.3% 
H202 as a substrate for peroxidase. Nuclei were counterstained with Harris 
hematoxylin (Sigma-Aldrich, MO, USA). No non-specific secondary antibody 
staining was observed when PBS was used in ste ad of the primary antibody. 
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Scoring procedure 
Digital images were obtained of each tissue mlcro-array core usmg an 
Olympus BX5l microscope equipped with the Q capture imaging software 
(Olympus, London, UK). Two observers quantified average nuc1ear and 
cytoplasmic epithelial cell AR staining intensity using a color scale (0-9, Fig.ld) 
constructed from the various staining intensities observable in the digital images 
using the eyedropper tool in Adobe Photoshop 7.0 as described previously (31). 
Statistics 
Mean cytoplasmic and nuc1ear staining intensities of epithelial ceHs 
associated with either normal tissue, non-neoplasic tissue adjacent to cancer (NA), 
PIN, HSPCa and AIPCa tissues were ca1culated. The nuc1ear/cytoplasmic AR 
ratio was also ca1culated for each core and averaged per tissue sub-type. Notably, 
aH cores exhibited cytoplasmic staining over zero and aH nuc1ear/cytoplasmic 
intensity ratios were computable. Kruskal-Wallis non-parametric tests were used 
to assess statistical significance of observed differences in mean staining intensity 
between tissue sub-types. AH correlation coefficients were computed using 
Spearman's non-parametric test. Cutoff determination and survival tree 
construction was done using the RPART (Recursive PARTitioning) libraries (32), 
which extends the CART (Classification and Regression Trees) routine (33). 
Model accuracy was assessed using the integrated Brier score for censored data 
(lBS) (34. We used 200 bootstrap {Effron, 1993 #35) samples to compute the 
95% confidence interval (CI) on the lBS. Survival tree growth was controHed 
using the minimum splitting (minsplit) criterion implemented in RP ART. This 
parameter controls the minimum number of observations that must exist in a 
node, in order for a split to be attempted. For combination models inc1uding 
cytoplasmic AR intensity and/or nuc1ear AR intensity or the ratio ofboth with the 
four clinical parameters (stage, surgical margin status, pre-operative PSA and 
Gleason score), RPART models were generated using three different values of 
minsplit (20, 25 and 30). AH the generated combination models were ranked 
according to lBS. Optimal cutoffs for cytoplasmic AR, nuc1ear AR, and nuc1ear / 
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cytoplasmic AR ratio were defined as values associated to the root node of the 
survival trees generated from the variables taken individually (minsplit=25). 
Kruskal-Wallis, Spearman, and Kaplan-Meier analyses were performed using 
Statistical Package for the Social Sciences (SPSS) version Il (SPSS, Inc., 
Chicago, USA). Tree building and the calculation ofIBS were carried out in the R 
statistical package (version 2.4.0; (35)), using rpart and ipred packages 
respectively (www.cran.r-project.org). 
ResuUs 
Cytoplasmic and Nuclear Androgen Receptor Expression in Prostate tissues 
To assess AR expression and subcellular localization at various steps of 
PCa progression, we used tissue microarrays containing prostate tissues 
originating from autopsied patients presenting no signs of PCa (n=43), from 
radical prostatectomies (RP) of patients not subjected to prior hormone therapy 
(n=62), and from TURP specimens of AIPCa patients (n=30). In addition, regions 
of normal tissue, PIN, and cancer were identified within RP specimens and 
included in the tissue microarrays. An antibody previously shown to be specific 
for the AR was used to stain the tissue microarrays (36, 37). This antibody stained 
both the cytoplasm and the nucleus of prostate epithelial cells to various extents 
as expected (Fig.la-c). Average cytoplasmic and nuclear AR staining intensity in 
cores from each tissue type was assessed from digital images using a color scale 
(Fig. Id) as described (see materials and methods). 
Looking at average cytoplasmic AR staining intensity (Fig. 2a), we found 
a minimal but significant increase in non-neoplasic tissues adjacent to cancer 
(NA) as opposed to normal tissues obtained from cancer-free patients (p<O.OOOI). 
A slight decrease in cytoplasmic AR was observed in PIN tissues as compared to 
NA tissues (p=0.0145), although cytoplasmic AR in PIN was not significantly 
different compared to normal tissues obtained from autopsied patients. In contrast, 
there was a significant increase in cytoplasmic AR within hormone-sensitive 
cancer tissues (obtained by RP) as compared to both normal and NA tissues 
(p<O.OOOl). Notably, the highest expression of cytoplasmic AR was observed in 
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AIPCa reaching substantially higher levels than those observed III hormone-
sensitive (HS) PCa (4.9 vs 2.8 respectively, p<O.OOOI). 
In contrast with what was observed for cytoplasmic AR, we detected the 
most striking increase in nuclear AR staining intensity when comparing NA 
tissues to normal tissues obtained from cancer-free patients (Fig 2b). Although 
there was a slight increase in nuclear AR in HSPCa as compared to NA tissues 
(p=O.002), we observed a mode st but significant decrease in nuclear AR in AIPCa 
as compared to HSPCa (p=O.015). We then explored how the ratio of nuclear / 
cytoplasmic AR staining intensity varied in PCa progression (Fig. 2c). We found 
that this ratio increased substantially from normal to NA tissues (p<O.OOOl). From 
a maximum value in PIN tissues, nuc1ear/ cytoplasmic ratio decreased slightly but 
significantly in HSPCa. From HSPCa to AIPCa, there was a substantial drop in 
the nuclear / cytoplasmic AR ratio (p<O.OOOl), which retumed to values close to 
those observed in normal tissues obtained from cancer-free patients. 
Cytoplasmic and nuclear AR staining intensities are associated to 
biochemical recurrence. 
To de termine wh ether cytoplasmic and/or nuclear AR staining intensity 
could predict BCR following surgery, we focused on the sub-cohort of 62 HSPCa 
patients that did not undergo androgen ablation prior to RP or prior to BCR. We 
re-categorized cytoplasmic, nuclear and nuclear/cytoplasmic AR values according 
to an optimal cutoff (see material and methods). Survival curves were 
subsequently plotted using the categorized data. For cytoplasmic AR, we found 
that low staining intensity «2.1) was associated with an increased risk of BCR 
(Fig. 3a, Log rank or LR=1O.82, p=O.OOI). Similar results were obtained for 
nuclear AR staining intensity (Fig. 3b, low < 7.3, LR=9.018, p=O.008). In 
contrast, a high nuclear/cytoplasmic ratio (~ 3.5) was associated with an increased 
risk ofBCR (Fig. 3c, LR=9.25, p=O.0023). As optimal cutoffs were obtained from 
the same cohort, p-values associated to the Log Rank statistic from Kaplan Meier 
plots are subject to over-fitting and are best interpreted qualitatively. 
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Cytoplasmic and nuclear AR staining intensity: relationship with clinical 
markers and patient outcome. 
We next detennined whether the association between cytoplasmic and 
nuclear AR expression with BCR was due their potential correlation with clinico-
pathological parameters. We found that cancer-positive surgi cal margins were 
associated with decreasing cytoplasmic AR, decreasing nuclear AR, as weIl as 
increasing nuclear/cytoplasmic AR ratio, when these were assessed as continuous 
variables (Table 2). When categorized according to optimal cutoffs, we found that 
low cytoplasmic AR expression as weIl as high nuclear/cytoplasmic AR ratio also 
correlated with increasing pathological stage, extracapsular invasion and lymph 
node invasion (Table 2). In light of this, we assessed whether AR expression in 
the cytoplasm, nucleus, or both (ratio), could be useful to predict BCR in 
combination with tumor stage, Gleason score, surgical margin status and pre-
operative PSA. Using Cox multivariate proportional hazard models on the sub-
cohort of 62 patients, we found that un-categorized AR staining intensity was not 
an independent predictor of BCR, irrespectively of the sub-cellular compartment 
assessed (data not shown). However, when categorized according to the optimal 
cutoff, cytoplasmic AR expression was retained in a multivariate model that also 
contained tumor stage and Gleason score (Hazard Ratio=2.736, 95% confidence 
interval 1.228-6.091, p-value=0.014), where patients exhibiting low cytoplasmic 
AR expression were at higher risk of BCR. 
To gain a more visual perspective on the relationship between AR 
expression, clinico-pathological parameters, and BCR, we proceeded to generate 
RP ART survival trees using cytoplasmic and nuclear AR as weIl as the 
nuclear/cytoplasmic AR ratio, in combination with pathological stage, surgi cal 
margin status, Gleason score and pre-operative PSA (see materials and methods, 
(31 )). These models were then classified according to the lBS, a measure of the 
predictive accuracy where a 10wer value indicates better outcome prediction. The 
top ranking survival tree (IBS=O.l18, 95% confidence interval=0.081-0.144) 
included surgi cal margin statu s, cytoplasmic AR expression, and Gleason score 
(Fig. 4). Notably, the top 20 trees contained cytoplasmic and/or nuclear AR or the 
141 
nuclear/cytoplasmic AR ratio. However, there was no consistently re-occurring 
tree structure in the top ranking models (data not shown). As a reference, the top-
ranking model composed exclusively of clinical markers (rank # 21 of 82 overall) 
was one that contained surgical margin status and Gleason score (IBS=0.132, 
95% confidence interval = 0.096 - 0.165, not shown) as was found in a previous 
study (31). 
Surprisingly, in the top ranking survival tree model, low cytoplasmic AR 
«3.4) was associated with better prognosis (Fig. 4a), specifically within the 
subset of patients with negative surgi cal margins. We thus looked at whether 
cytoplasmic, nuclear or nuclear/cytoplasmic AR ratio predicted different 
outcomes depending on the subgroup of patients delineated by clinical parameters 
within the survival trees. For cytoplasmic AR, we found that while a low 
expreSSIOn was commonly associated with better prognosis in patients with 
cancer-negative surgical margins, this was instead associated with worse 
prognosis in patients exhibiting high stage tumors. In contrast, high nuclear AR 
was generally associated with good prognosis within patients exhibiting low stage 
tumors or negative surgi cal margins. In concordance with both of these findings, 
low stage tumors with a high nuclear/cytoplasmic AR ratio indicated a better 
prognosis as exemplified in the survival tree that ranked second overall 
(IBS=1.22, 95% CI=0.08-0.l4, Fig 4b). 
Discussion 
In this study we found clear differences between the expression of the AR 
in cytoplasmic and nuclear compartments within histo-pathological subtypes of 
prostate tissues (Fig la-c, 2a-c). Notably, we found that while cytoplasmic AR 
expression only slightly increased in NA tissues as opposed to normal tissues 
obtained from cancer-free patients (Fig. 2a), nuclear AR staining intensity was in 
comparison substantially higher in NA and PIN tissues (Fig. 2b). One possible 
explanation why AR nuclear localization is more prevalent in NA and PIN tissues 
as compared to normal tissues from cancer-free patients is the difference in 
average patient age (35 in cancer-free patients vs. 62 in HSPCa patients, Table 1). 
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Notably, AR expression has been observed to increase with age in a rat model, an 
event that was linked to spontaneous prostate hyperplasia (38). On the other hand, 
we did not find any correlation between patient age and AR expression within 
HSPCa patients (Table 2). Hence, another possibility is that AR expression is up 
regulated in response to one or more genetic events. Interestingly, increased levels 
of AR prote in are observed in NKX3.1 knockout mice, where NKX3.1 is thought 
to act as a negative regulator of AR expression (39). Notably, the loss ofNKX3.1 
has been suggested to be an early event in the deve10pment of localized PCa (40). 
Although further studies will be necessary to address the cause, our data 
suggest that increasing AR nuc1ear localization could be a precursor to PCa 
development and that additional genetic events may be important for PCa 
progression. Consistent with this notion, it has been previously shown that 
prostate-specific AR over-expression in transgenic mice leads to enhanced cell 
proliferation and PIN but does not lead to adenocarcinoma (41). In this context, it 
is tempting to speculate that increased AR expression could act as a "primer" for 
further transformation of prostate cells. This idea is particularly appealing in light 
of the recent discovery of chromosomic fusions between oncogenic ETS family 
transcription factors and the AR-regulated TMPRSS2 gene, which are detectable 
in over 80% ofprimary PCa tumors (42, 43). 
On the other hand, we found that although AR staining intensity in both 
nuc1ear and cytoplasmic compartments was significantly increased in HSPCa as 
compared to NA tissue, this difference was much less impressive than when 
comparing normal tissues to NA tissues, particularly at the nuc1ear level (Fig 2a-
b). Furthermore, we observed a slightly lower nuc1ear AR staining in AIPCa 
tissues as opposed to HSPCa (Fig. 2b). Although these findings support an early 
rather than late contribution of the AR in PCa progression, they do not necessarily 
absolve the AR as a major contributor in the later stages of PCa. Of note, several 
co-activators can enhance AR transcriptional activity. Hence, it is possible that 
AR co-activators can be up regulated in parallel, as has been observed for 
CDC25B when comparing PCa tumors to their adjacent normal tissues (44). 
Similarly, we cannot exc1ude the possibility that at least in sorne cases, the AR 
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may harbor mutations that lead to constitutive transcriptional activation of the AR 
(45). In this scenario, one could expect that AR transcriptional activity may be 
heightened not only in HSPCa, but also in AIPCa, ev en though nuclear levels are 
only modestly increased or similar to those observed in NA tissues. 
ln addition to looking at AR staining in the cytoplasm and nucleus of 
prostate epithelial cells, we deemed it relevant to also compute the 
nuclear/cytoplasmic AR staining intensity ratio. This was done for two main 
reasons. First, we rationalized that an increasing nuclear / cytoplasmic ratio 
should theoretically correlate with increasing AR transcriptional activity. Second, 
in the likelihood that certain tissues may exhibit differential staining solely on the 
basis of differences in tissue processing (as opposed to truly biologically 
significant differences), the nuclear / cytoplasmic ratio should remain the same 
and consequently act as an internaI normalization control. Interestingly, the 
nuclear / cytoplasmic ratio revealed a clear propensity towards nuclear 
accumulation in NA and PIN tissues as compared to normal tissue from cancer-
free patients. However, this ratio decreased in HSPCa and even further in AIPCa, 
reaching levels comparable to those observed in normal tissues (Fig. 2c). 
Although we would expect that androgen ablation should lead to increased 
cytoplasmic AR and decreased nuclear AR, which is what we observe here (Fig 
2a-c), it is clear that cytoplasmic AR fluctuates much more than nuclear AR in 
response to androgen deprivation (compare Fig 2a to 2b). However, overall AR 
expression in both compartments combined was far greater in AIPCa supporting 
results obtained in other studies looking at AR gene amplification and over-
expression in AIPCa (reviewed in (8, 9, 46)). Importantly, although cytoplasmic 
localization of the AR may be an effect of androgen deprivation, it is a likely 
possibility that the striking increase in cytoplasmic AR could have repercussions 
on the AIPCa phenotype. Indeed, numerous potential AR binding partners that 
either mainly reside in the cytoplasmic compartment or that shuttle between the 
nucleus and cytoplasm have also been implicated in PCa progression including 
EGF receptors (14,26,29), Akt (27) and NF-KB (25,47). 
ln the sub-cohort of patients having undergone RP that did not receive 
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honnone therapy prior to disease recurrence, we found that low AR expression in 
both cytoplasmic and nuclear compartments was associated to an increased risk of 
BCR (Fig. 3a-b). Interestingly, a high nuclear/cytoplasmic ratio was associated to 
a worse prognosis (Fig. 3c). This finding is particularly interesting because it may 
partly explain why the literature is so divided on the relationship between AR 
expression and both BCR and PCa progression. Notably, while our observation 
that low nuclear AR is associated to BCR is in line with one study (14), the 
nuclear/cytoplasmic AR ratio is rather in agreement with another study (10). 
Interestingly, the latter study also reported deereased nuclear AR expression in 
PCa as opposed to non-neoplasie tissues, similarly to what was observed here for 
the nuc1ear / eytoplasmie ratio (Fig. 2e). At the same time, other studies have also 
found increased nuclear AR in PCa (9), whieh is in line with our results looking 
exelusively at nuclear AR (Fig. 2b). In the framework where nuclear/cytoplasmic 
AR ratio is an internally nonnalized value, this suggests that certain conflicting 
results presented in the literature may be partly due to differences in tissue 
fixation between samples within each given study. Hence, it is likely that these 
discrepancies eould be reetified by sorne means of data nonnalization using an 
internaI control. As sueh, it would be interesting to look at the nuclear / 
cytoplasmic AR ratio in future immunohistochemistry, particularly those aiming 
to evaluate the AR as a prognostic markeT. 
Within the HSPCa patient cohort, we found that nuc1ear, cytoplasmie, and 
nuc1ear/eytoplasmie AR expression eorrelated with pathologieal stage and 
surgieal margin status (Table 2). In addition, cytoplasmic and nuc1ear/eytoplasmie 
ratios also correlated with lymph node invasion and extracapsular invasion. 
Interestingly, we found that only eytoplasmic AR was an independent predietor of 
BCR in a multivariate Cox model. Using RPART to generate survival trees, we 
found that the top ranking survival tree model (lowest lBS) stratified BCR risk 
according to surgical margin statu s, cytoplasmic AR, and Gleason score. In this 
model, low cytoplasmic AR was associated with better outcome within patients 
with negative surgi cal margins (Fig 4a). Similarly, in the second highest ranked 
survival tree model, high nuclear/cytoplasmie ratio was associated with better 
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outcome in patients with low stage tumors (Fig. 4b). 
When we further explored the interactions between cytoplasmic, nuc1ear, 
nuc1ear / cytoplasmic ratio and clinical parameters using an the generated survival 
trees, we found that the predictive value of AR expression was highly dependent 
on what clinical parameters were included in the model. Interestingly the 
prognosis associated to AR status was often counter to what was observed in the 
overall cohort (Fig. 3a-c) in patients with cancer-negative surgi cal margins (see 
Fig.4a). Perhaps this finding can be linked to an inherent difference between 
recurrent margin-negative and margin positive tumors, in relation to the type of 
PCa cells that remain following RP. For example, in order to be detected in 
histopathological cross sections, PCa cells remaining at and beyond the surgical 
margins may require a certain c1ustering density. In addition to the observation 
that positive surgi cal margin status correlates with both extra-prostatic (Spearman 
coefficient or SC 0.621, p<O.OOI, data not shown) and seminal vesicle invasion 
(SC 0.289, p<0.05; data not shown), this might suggest that in general, 
recurring tumors from positive margins initiate from denser, pre-established 
groups of cells than those remaining from tumors with "negative" surgical 
margins. In contrast, undetected PCa cells remaining from an excised tumor 
deemed to have cancer-free surgical margins are likely to be more scattered and 
detached. In this context, low cytoplasmic AR and/or high nuclear AR expression 
may more severely impact the survival or proliferation of these "scattered" cells, 
leading to a better outcome from the perspective of the patient. Notably, several 
groups have reported that exogenous expression of the AR in AR-negative PC3 
cells reduces proliferation and induces apoptosis in the presence of androgens (48, 
49). Although the biological significance of these findings will certainly require 
further investigation, our results suggest at the very least that AR expression may 
be intimately linked to clinico-pathological characteristics further implying that 
the composition of patient cohorts can have a strong influence on the conclusions 
drawn regarding the association between AR expression and the onset of BCR. 
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Conclusion 
We propose that increased nuclear AR expression may be a precursor to 
PCa development and that other genetic events are likely required to initiate PCa 
transformation. We also conclude that the most significant change in AR 
expression in AIPCa occurs at the cytoplasmic level and propose that this may 
contribute to the AIPCa phenotype. We find that although low nuclear and low 
cytoplasmic expression is associated with PCa relapse following surgery, a high 
nuclear/cytoplasmic AR ratio is associated with an increased risk of early BCR. 
Overall, we conclude that although cytoplasmic AR is an independent predictor of 
BCR in a Cox model, extensive survival tree analyses suggest a complex 
interaction between AR expression and pathological features, which will require 
further evaluation in a larger cohort. 
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Table 1. Patient cohort characteristics 
Overall patient cohort 
Age median (min-max) 
Cancer-free patients 
PCa patients 
AIPCa patients 
Primary Prostate Cancer Patient Cohort 
Pathological Stage 
Stage 2 
Stage 3 
Invasion 
Extraprotatic extension 
Lymph node imetastasis 
Seminal vesicle invasion 
Became Hormone-refractory 
Gleason Score 
Gleason 4 
Gleason 5 
Gleason 6 
Gleason 7 
Gleason 8-9 
Pre-operative PSA 
<10 ng 
>10 ng 
Not available 
PSA relapse 
Relapse 
No relapse 
Surgical margins 
Negative 
Positive 
Deaths within follow-up period 
35 (15-45) 
62 (49-70) 
79 (65-95) 
34 
28 
20 
9 
9 
5 
8 
14 
13 
17 
10 
32 
28 
2 
35 
27 
31 
31 
9 
153 
154 
Table 2. AR expression in correlation with clinico-pathological features 
Cytoplasmic Nuclear / Nuclear AR Nuclear / Cytoplasmic Cytoplasmic AR Nuclear AR categorized Cytoplasmic AR ratio AR categorized 
** AR ratio categorized 
* 
*** 
0.002 -0.103 -0.009 -0.002 -0.007 0.117 
age p=0.989 p=0.424 p=0.943 p=0.998 p=0.959 p=0.367 
pre-operative 0.210 0.07 -0.030 -0.100 -0.223 -0.106 
PSA p=0.108 p=0.597 p=0.819 p=0.448 p=0.086 p=0.421 
Margin -0.431 -0.590 -0.297 -0.315 0.356 0.49 p<O.OOOI p<O.OOOI p=0.019 p=0.013 p=0.005 p<O.OOOI 
Stage -2.11 -0.354 -0.100 -0.170 0.172 0.294 p=0.100 p=0.005 p=0.440 p=0.186 p=0.181 p=0.02 
Gleason 0.058 -0.001 0.011 -0.112 -0.085 -0.110 p=0.656 p=0.994 p=0.935 p=0.386 p=0.509 p=0.396 
Lymph node -0.217 -0.280 -0.114 -0.123 0.219 0.262 
invasion p=0.091 p=0.027 p=0.377 p=0.340 p=0.088 p=0.04 
Extra-capsular -0.174 -0.303 -0.044 -0.140 0.187 0.361 
invasion p=0.176 p=0.017 p=0.732 p=0.278 p=0.145 p=0.004 
Seminal vesicle -0.07 -0.103 -0.086 -0.057 -0.005 -0.067 
invasion p=0.588 p=0.426 p=0.505 p=0.659 p=0.967 p=0.606 
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Table 2. Correlation between cytoplasmic, nuc1ear, nuc1ear/cytoplasmic AR 
expression, and clinico-pathological parameters. Non-parametric Spearman rank 
tests were used to assess correlation coefficients (top numbers). Cytoplasmic, 
nuclear and nuclear/cytoplasmic AR expression were used either as continuous 
variables or as binary variables (*low=cytoplasmic AR <2.1 , **low=nuclear AR 
< 7.3, ***low=nuclear/cytoplasmic AR <3.5, see materials and methods). A 
negative number indicates that increasing AR expression was associated with 
decreasing status (e.g. low age, low PSA, negative margins, low stage, low 
Gleason, no lymph node, extracapsular, or seminal vesic1e invasion). Significant 
correlations are highlighted in bold (p<O.05). AU cutoffs were obtained using 
RPART. 
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a) 
b) 
c) 
Figure 1. AR expression and sub-cellular localization in prostate tissues 
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Figure 1. lmmunohistochemical staining of paraffin-embedded prostate tissues 
using AR-specific antibody. An antibody recognizing the AR was used to stain A) 
Normal prostate tissue from cancer-free patients. B) Hormone-sensitive prostate 
carcinomas. C) Hormone-refractory TURP specimens. Note the increased 
intensity of cytoplasmic staining in hormone-refractory samples. D) Color scale 
standard used for the evaluation of images obtained from tissue microarrays. 
Scale was constructed from several digital pictures evaluated in the study as 
described in materials and methods. Numeric values correspond to the associated 
intensity score. 
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Normal NA PIN HSPCa AIPCa 
Figure 2. Average cytoplasmic, nuclear and nuclear / cytoplasmic AR 
staining intensity ratio in prostate specimen subtypes 
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Figure 2. Average cytoplasmic, nuclear and nuclear / cytoplasmic AR staining 
intensity ratio in prostate specimen subtypes. A) Cytoplasmic AR expression. B) 
Nuclear AR expression. C) Nuclear / cytoplasmic AR ratio. Normal = normal 
prostate tissues obtained from cancer-free patients (n=96 cores). NA=non-
neoplasic tissue found adjacent to HSPCa (n=92 cores). PIN = Prostatic 
intraepithelial neoplasia (n=44 cores), HSPCa= hormone-sensitive prostate cancer 
(n=227 cores), AIPCa= androgen-independent prostate cancer specimens obtained 
by TURP (n=157). Kruskal-Wallis non-parametric test was used to assess 
significance of observed differences. 
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Figure 3. AR expression and sub-cellular localization in relation to 
biochemical recurrence following radical prostatectomy. 
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Figure 3. Prediction of biochemical recurrence using cytoplasmic, nuc1ear and 
nuc1ear/cytoplasmic AR staining intensity ratio. A) Low cytoplasmic AR is 
associated to an early onset of BeR. Low (dashed) indicates cytoplasmic AR 
expression below 2.1 and high (full) indicates cytoplasmic AR expression over or 
equal to 2.1. B) Low nuc1ear AR is associated to an early onset of BeR. Low 
(dashed) indicates nuc1ear AR expression below 7.3 and high (full) indicates 
nuc1ear AR expression over or equal to 7.3. B) High nuc1ear / cytoplasmic AR 
ratio is associated to an early onset of BeR. Low (dashed) indicates nuc1ear / 
cytoplasmic AR expression ratio below 3.5 and high (full) indicates nuc1ear AR 
expression over or equal to 3.5. 
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Figure 4. Top-ranking RPART survival tree models for prediction of BCR and 
assoeiated Kaplan-Meir plots. A) Rank #1. IBS=0.118 (95% CI=0.081-0.144). 
Cyto AR=cytoplasmic AR expression B) Rank #2. IBS=0.122 (95%CI=0.08-
0.14). nie AR ratio= nuelear / eytoplasmie AR staining intensity ratio. Colored 
circles within the survival trees represent the different prognostie groups and are 
depieted in the assoeiated Kaplan-Meier plots represented by eurves of the same 
coler (and number). Below each colored circle, n indicates the number of patients 
in eaeh group. 
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Abstract 
Effective treatments for androgen-independent prostate cancer (AIPCa) 
are lacking. To address this, emerging therapeutics such as proteasome inhibitors 
are currently undergoing clinical trials. Inositol hexakisphosphate (IP6) is an 
orally non-toxic phytochemical that exhibits anti-tumor activity against several 
types of cancer including prostate cancer (PCa). We have previously shown that 
treatment of PC3 cells with IP6 induces the transcription of a subset of NF -KB-
responsive and pro-apoptotic BCL-2 family genes. In this study we report that 
although NF-KB subunits p50/p65 translocate to the nucleus of PC3 cells in 
response to IP6, inhibition ofNF-KB-m~diated transcription using non-degradable 
IKB-a does not modulate IP6 sensitivity. Treatment with IP6 also leads to 
increased protein levels of PUMA, BIKlNBK and NOXA between 4 and 8 hours 
of treatment and decreased levels of MCL-l and BCL-2 after 24-hours. Although 
blocking transcription using actinomycin D does not modulate PC3 cell sensitivity 
to IP6, inhibition of prote in translation using cycloheximide has a significant 
protective effect. In contrast, blocking proteasome-mediated prote in degradation 
using MG-132 significantly enhances the ability of IP6 to reduce cellular 
metabolic activity in both PC3 and DU145 AIPCa cell lines. This effect of 
combined treatment on mitochondrial depolarization is particularly striking and is 
also reproduced by another proteasome inhibitor (ALLN). The enhanced effect of 
combined MG 1 32/IP6 treatment is almost completely inhibited by cycloheximide, 
and correlates with changes in BCL2-family prote in levels. Altogether these 
results suggest a role for BCL-2 family proteins in mediating the combined effect 
of IP6 and proteasome inhibitors and warrant further pre-clinical studies for 
treatment of AIPCa. 
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Introduction 
Prostate cancer (PCa) remains a leading cause of cancer-related death in 
North-American men (1). Though localized forms of the disease can often be 
successfully treated by surgery or radiotherapy, a significant proportion of 
patients having undergone such interventions are at risk of disease recurrence. 
Androgen deprivation therapy can prolong the life expectancy of these patients; 
however, androgen-independent (AI) PCa eventually arises. As currently 
available treatment options for AIPCa are lacking, there is a growing need for 
novel therapeutics that can be effective against this advanced stage of the disease. 
Inhibitors of the proteasome are showing promise as anti-cancer agents 
against several cancers. Although the proteasome harbors active sites for several 
types of proteolytic activity, these inhibitors generally consist of small synthetic 
peptides targeting the chymotryptic activity of the proteasome, which is thought 
to be a rate-limiting catalytic step in proteasome-mediated protein degradation 
(2). Notably, one proteasome inhibitor (bortezomib) has been recently approved 
by both the Food and Drug Administration (FDA, USA) and the European 
Agency for Evaluation of Medicinal products (EMEA) for treatment of recurrent 
multiple myeloma and is currently undergoing clinical trials for AIPCa (3-6). 
Sorne studies have suggested that a major downstream target of 
proteasome inhibition is nuclear factor KB (NF-KB), a transcription factor 
involved in the transcriptional regulation of hundreds of genes implicated in cell 
proliferation, differentiation and cell survival (7). NF-KB is a dimeric protein 
composed of hom or hetero-dimers of p50, p65 (RelA), p52, RelB and c-Rel 
subunits. NF-KB activity is directly regulated by the action of inhibitor of KB 
(lKB) proteins (e.g. IKB-a, p, E, P 100) and IKB kinases (8-10). IKBs retain NF -KB 
in the cell cytoplasm and diminish its transactivation potential whereas IKB 
kinases phosphorylate both IKBs as weIl as NF-KB itself. Importantly, 
phosphorylation of IKBs by IKKs leads to their proteasome-mediated degradation 
and to the release and nuclear translocation of NF-KB subunits (classically 
p50/p65). Altemately, in what is referred to as the non-canonical pathway, the 
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proteasome catalyses the processing of p100 into the NF-KB p52 subunit, which 
may also translocate to the nuc1ear compartment (7, 10, Il). 
More recently, proteasome inhibitors have also been found to up-regulate 
the expression of BCL-2 family proteins. Notably, pro-apoptotic BH3-only 
proteins such as NOXA, BIKlNBK, BIM, and PUMA see their leve1s increased 
following treatment with proteasome inhibitors such as MG-132, ALLN, 
Lactacystin, and Bortezomib (12-16). In paraUe1, anti-apoptotic proteins su ch as 
MCL-1 can also be up regulated following proteasome inhibition, leading 
investigators to combine proteasome inhibitors with strategies aimed at thwarting 
the anti-apoptotic response with sorne success (13). 
BCL-2 family proteins play a major role in the control of mitochondrial 
permeability. Importantly, mitochondrial outer-membrane permeation (MOMP) is 
a key event in cell death whether by means of apoptosis or necrosis (17). 
Although the role of pro-apoptotic proteins BAX and BAK in this process is c1ear, 
the nature of how these are activated to initiate MOMP is currently under debate. 
In particular, how BH3-only BCL-2 family proteins initiate BAX/BAK-assisted 
mitochondrial permeability pore formation remains unc1ear. It has been suggested 
that a subset of BH3-only proteins act as sensitizers to the action of other BH3-
only proteins thought to play the role of BAXlBAK activators (18). Other recent 
evidence suggests that BH3-only proteins such as NOXA, BAD, and BIKlNBK, 
may act as inactivators ofanti-apoptotic BCL-2/BCL-XL and MCL-1, preventing 
their inhibitory interaction with activator BH3-only proteins such as PUMA, BID 
and BIM (19). In either event, it is c1ear that the increased activity of pro-
apoptotic BH3-only proteins is important for the initiation of cell death by various 
stimuli. 
Inositol hexakisphosphate (IP6) is a naturally occurring phytochemical 
abundant in soy and legumes that exhibits anti-cancer activity in a wide range of 
cancers (20). Although definite mechanisms have yet to be established, IP6 
activity has been reported to involve several processes (21). In DU145 AIPCa 
cells, IP6 has been suggested to inhibit phosphatidyl inositol-3-kinase (PI3K), 
prevent epidermal growth factor receptor (EGFR) signaling through the mitogen 
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activated protein kinase (MAPK) signaling cascade (22), and diminish 
constitutive NF-KB activity (23). Still in the context of DU145 cells, IP6 was 
found to modulate cdk-cyclin and pRblE2F complexes leading to p21 and p27 up-
regulation and cell cycle arrest in G 1 (24). 
Treatment of AIPCa cells with IP6 can also induce classic hallmarks of 
apoptotic death such as caspase-3 activation, cleavage of poly ADP-ribose 
polymerase (PARP), increased cell-surface phosphatidyl-serine and DNA 
fragmentation (24, 25). In LNCaP cells, treatment with IP6 was found to increase 
the expression of pro-apoptotic BAX while decreasing levels of anti-apoptotic 
BCL-2(26). In addition, we have recently shown that in PC3 cells, IP6 induces the 
mRNA expression of PUMA, NOXA and BAX as weIl as a subset of NF-KB-
responsive genes including ItdJ-a and IRF-2 (25). As such, we hypothesized that 
the up-regulation ofNF-KB-responsive genes as well as of genes coding for pro-
apoptotic proteins could play a role in mediating the pro-apoptotic effects of IP6 
in PC3 cells. In this study, we investigated the role of NF-KB and BCL-2 family 
members in IP6-induced cell death. We also evaluated whether IP6 could be 
useful in combination with proteasome inhibitors. 
MateriaIs and methods 
Cell culture 
22Rvl, PC3, LNCaP and DU145 were obtained from ATCC (Manas sas, VA). 
Cells were maintained in RPMI 1640 complemented with 10% fetal calf serum, 
gentamicin (50 Ilg/ml) and amphotericin B (250 ng/ml) (Gibco-BRL, MD, USA). 
Cell cultures were incubated at 37°C in a humidified 5% CO2 atmosphere and 
sub-cultured at 1:3 (LNCaP), or 1:5 (PC3, 22Rvl, DU145) by trypsinization with 
0.25% trypsin for 5-10 minutes at 37°C (Gibco-BRL, MD, USA). 
Drugs and inhibitors 
IP6 (Myo-Inositol hexakisphosphate dodecasodium salt, Sigma-Aldrich, USA) 
was kept as a 100 mM stock solution diluted in water. Actinomycin D (Sigma-
Aldrich, USA) was dissolved in DMSO and kept as a 1 mg/ml stock solution. 
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Cycloheximide (Supelco, PA, USA) stock solution (50 mg/ml) was dissolved in 
ethanol. MG-132 (Calbiochem, USA) was also diluted in ethanol as a 20 mM 
stock solution. ALLN (Calbiochem, USA) was reconstituted in DMSO and kept 
at a stock concentration of 10 mM. 
Cell seeding and treatments 
For WST -1 assays, whole cell extracts, nuclear/cytoplasmic extracts, RNA 
extractions and JC-l assays, a similar cell seeding procedure was used. Briefly, 
cells were trypsinized and counted on a hemocytometer, then diluted in the 
appropriate media at 200 000 cells/ml and distributed in 96-well plates (100 
,.d/well for WST-l and Luciferase reporter assays) or 6-well plates (2 ml/weIl for 
JC-l assay and RNA extractions). For whole cell and nuclear/cytoplasmic 
extracts, cens (at a density of 200 000 cells/ml) were seeded in 60 mm petris (3 
ml/Petri), 100 mm petris (5ml/petri), or 150 mm petris (10 ml/petri) petris. Cells 
were allowed to adhere ovemight prior to treatment. For the experiments 
assessing the effects of dominant-negative (DN) IKB-a on IP6 efficacy, cells were 
transfected with DN-IKB-a (pCMV-IKB-aM, Clontech, CA, USA) or control 
plasmid pCMV -Neo (Clontech, CA, USA) 24-hours prior to seeding. Efficacy of 
DN-IKB-a transfection was verified in parallel by luciferase assay (see below). 
Cells were then treated with the indicated concentrations of IP6. In the 
experiments where the effect of actinomycin D, cycloheximide, MG-132, 
cycloheximide + MG-132, and ALLN on the activity of IP6 was assessed, cells 
were pre-treated 4 hours prior to addition of IP6. 
WST-l metabolic assay 
After a 24-hour treatment with IP6 (in addition to treatment with the appropriate 
inhibitors where indicated), 10 !-lI of WST -1 reagent (Roche, USA) was added to 
wells and plates were incubated at 37°C in a humidified 5% CO2 atmosphere. 
Incubation times were optimized for each cell line as recommended by 
manufacturer. WST -1 signal was measured on a Bio-Rad Model 3550 microplate 
reader at 450 nm with reference at a wavelength of .655 nm. Fol1owing data 
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acquisition, cell metabolic activity was calculated by first subtracting the readout 
of the WST-l background (media + WST-1) from all values. For each 
independent experiment, the median of the replicates was calculated for each 
treatment. Subsequently, relative metabolic activity was calculated as being the 
median WST -1 readout of the drug treated weIl / median WST -1 readout of 
vehiele-treated weIl. In the cases where cells were pre-treated with an inhibitor 
(actinomycin D, cyc1oheximide, or MG-132), values were norma1ized relative to 
the inhibitor-treated weIl that was not challenged with IP6. Cellular metabolic 
activity was plotted as a function of IP6 concentration. 
Protein extracts 
Cells were scraped in their media, collected by centrifugation and washed twice 
with cold PBS. Pellets were frozen at -80°C. Subsequently, whole cell extractions 
were performed by applying cold lysis buffer (10 mM Tris-Hel, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1 mM DTT, 1 mM NaF, 0.5% NP-40, 10 J.lg/mL aprotinin, 2 
J.lg/mL leupeptin, 2 J.lg/mL pepstatin, 10 J.lmol/L phenylmethylsulfonyl fluoride, 
200 J.lmol/L orthovanadate) on ice for 30 min. Whole cell extracts were collected 
after centrifugation in a Heraeus Biofuge (13,000 rpm for 10 min at 4°C) and 
were immediately stored at -80°C. Protein concentration was measured by 
Bradford assays (Bio-Rad Laboratories, Inc., Hercules, CA) according to the 
manufacturer' s instructions. 
Nuclear and cytoplasmic protein extracts 
After cell treatments, media was aspirated, cells were scraped and washed twice 
with cold PBS, and pellets were frozen at -80°C. Ice-cold buffer l (10 mmol/L 
HEPES, 50 mmol/L NaCl, 10 mmol/L EDTA, 5 mmol/L MgC12) with freshly 
added protease and phosphatase inhibitors (10 J.lg/mL aprotinin, 2 J.lg/mL 
leupeptin, 2 J.lg/mL pepstatin, 10 J.lmol/L phenylmethylsulfonyl fluoride, 200 
J.lmol/L orthovanadate) was added and cells were incubated on ice for 30 min. 
Cell membranes were lysed by incubating with 1 % NP40 for 10 min. Cytosolic 
fractions were collected after centrifugation (3,000 x g for 5 min at 4°C). Ice-cold 
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buffer II (10 mmollL HEPES, 400 mmollL NaCl, 0.1 mmol/L EDTA, 0.5 mmollL 
DTT) with freshly added protease and phosphatase inhibitors was then added to 
the nuclear aggregates and incubated on ice for 1 h. Nuclear protein fractions 
were collected after centrifugation (14,000 x g for 15 min at 4°C). Each fraction 
was immediately stored at -80°C. 
Antibodies 
Antibodies recognizing NOXA (OP180) and PUMA (PC686) were obtained from 
Calbiochem (USA). Antibodies detecting BAX (N-20, sc-493), BCL-2 (C-2, sc-
7382), BIKlNBK (N-19, sc-171O), MCL-l (H-260, sc-20679), RAN (C-20, sc-
1156), IKB-a (C-21, sc-371), NF-KB p65 (F-6, sc-8008), a-TUBULIN (TU-02, 
sc-8035), as weIl as horseradish peroxidase-conjugated secondary antibodies were 
obtained from Santa Cruz Biotechnology (CA, USA). The anti-NF-KB p50 (06-
886) antibody was purchased from Upstate (NY, USA). Antibodies recognizing 
~-ACTIN (AC-15, ab6276) and GAPDH (ab-9485) were obtained from Abcam 
(MA, USA). 
Western blot analysis 
For Western b10t analyses, 20-75 /lg of whole cell prote in or nuclear/cytoplasmic 
prote in extracts were resolved on 10-17% polyacrylamide gels and then 
transferred onto nitrocellulose or PVDF membranes at 60V for 1 to 2 hours. Blots 
were blocked using 5% non-fat dry milk in PBS-Tween 0.1 % buffer for 2 hours at 
room temperature. Membranes were then probed using antibodies recogrnzing 
PUMA (1:1000), NOXA (1:200), BAX (1:1000), MCL-l (1:100), BIKlNBK 
(1 :200), BCL-2 (1 :200), RAN (1 :3000), IKB-a (1: 1000), NF-KB p65 (1 :750), NF-
KB p50 (1:750), a-TUBULIN (1:1000), ~-ACTIN (1:10000) and GAPDH 
(1 :5000). Membranes were then incubated with appropriate secondary antibody 
conjugated to horseradish peroxidase (Amersham Life Sciences Inc., Arlington 
Heights, IL) in blocking buffer for 45 minutes at room temperature and developed 
with enhanced chemiluminescence (ECL) substrate (Amersham Life Sciences 
Inc., Arlington Heights, IL). When necessary, membranes were stripped using the 
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protocol described in the ECL kit (Amersham Life Sciences Inc., Arlington 
Heights, IL) and re-probed. Densometric analysis was done using the BioRad 
Quantity One® software (CA, USA). 
Quantitative Real time PCR 
After the indicated times of treatment with IP6 and/or actinomycin D, media was 
removed and RNA was extracted with Trizol reagent according to manufacturers' 
instructions (Invitrogen, ON, Canada). Concentration of RNA samples was 
determined using a Beckman DU-600 spectrophotometer. 2 !lg of RNA was used 
to synthesize a cDNA using the SuperScript first-strand synthesis system (random 
hexamer method) according to manufacturers' instructions (Invitrogen, ON, 
Canada). The QuantiTect SYBR Green PCR kit was used as recommended 
(Qiagen, ON, Canada). Real time PCR reactions were performed on a Rotor-gene 
RG-300 (Corbett Research, Australia). Optimal threshold and reaction efficiency 
were determined using the Rotor-gene software. Melt curves for each primer 
exhibited a single peak, indicating specific amplification, which was also 
confirmed by agarose gel. Ct values were determined using the Rotor-gene 
software at the optimal threshold previously determined for each primer. Relative 
IKB-a/actinB ratios were calculated using the Pfaffl method (27). Fold induction 
was calculated relative to the vehicle treated control. Experiments were done 
twice and real time measurements were done in duplicate. Primer sequences used 
were described previously (25). 
JC-l mitochondrial depolarization assay 
PC3 cells were incubated with 10 !lg/ml of JC-l (5,5',6,6'-tetrachloro-l,I',3,3'-
tetraethyl-benzimidazolcarbocyanide iodide, Molecular Probes, OR, USA) at 
37°C in a humidified 5% CO2 atmosphere for 15 minutes. Cells were washed 
twice with PBS and trypsinized with 500 !lI 0.25% trypsin for 10 minutes. Cells 
were then collected and put in fluorescence activated cell sorting (F ACS) 
counting tubes containing 500 !lI RPMI 1640 complemented with 10% FCS. JC-l 
emission was measured in individual cells using a Coulter Epics® XL-MCL. The 
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fold change in cells presenting de-polarized mitochondria (green-shift in JC-I 
fluorescence) was ca1culated relative to vehic1e-treated control for each time 
point. 
Luciferase Reporter Assays. 
PC3 cells were seeded at 400000 cells/ml in 60 mm petris (3 ml). The following 
moming, lipofectamine PLUS reagent (lnvitrogen, ON, Canada) was used to 
transfect 1 Ilg pCMV-IxB-aM (or pCMV-Neo control), 0.8 Ilg of a 3enh-xB-
ConA-Iuc green luciferase reporter (or control ptkGL3 luciferase gene driven by a 
minimal thymidine kinase promoter), and 0.2 Ilg of a pCMV -RL Renilla 
luciferase reporter (Promega, WI, USA). The following day, transfected cells 
were re-seeded at a density of 20 000 cells per well in 96-well plates. To assess 
the effects MG-132 on xB-Iuc activity, transfected cells were then treated with 
MG-132 for 24 hours after which time green and renilla luciferase activity was 
assayed using the dualluciferase reporter assay system (Promega, WI, USA) on a 
Victor3 luminometer/fluorimeter (Perkin Elmer, ON, Canada). To ca1culate the 
relative xB reporter activity, green luciferase activity was first normalized 
according to renilla luciferase output (transfection efficacy control) then corrected 
for background effects by subtracting the basal activity detected from the ptkGL3 
plasmid. The 3enh-xB-ConA-Iuc (hereby refered to as xB-Iuc), carrying a firefly 
luciferase gene under the control of a trimer of KB consensus was a kind gift from 
Dr. Juana Wietzerbin (Institut Curie, Paris, France). To construct the ptkGL3 
control plasmid, the SV40 promoter (BglII/HindII fragment) was removed from 
the pGL3 basic plasmid (Promega, WI, USA) and a minimal thymidine kinase 
promoter (BglII/HindIII fragment) from the pNF-xB-d2EGFP plasmid (Clontech, 
USA) was inserted in its place. 
Statistics 
Averages, standard errors ofthe mean, and p-values (calculated using T-test) were 
ca1culated from individual experiments. The numbers of replicates as well as the 
number of independent experiments are indicated in the figure legends. All 
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statistical tests were performed in Excel (Microsoft®, WA, USA). For WST-l 
assays, an effect was deemed significant when a p-value <0.05 was reached for at 
least one concentration of IP6. 
Results 
IP6 indu ces NF -KB nuclear translocation in PC3 cells 
We have previously observed that a subset ofNF-KB responsive genes is 
up regulated in response to IP6 in PC3 cells. Notably, we have found that !JcB-a 
mRNA levels can increase up to 20 fold following a 24-hour treatment with 2 mM 
IP6 (25), beginning as early as 4 hours post-treatment (data not shown). As 1 KB-a 
is thought to be regulated by p50/p65 NF-KB subunits (28), we set out to 
determine the effects of IP6 of NF-KB subunit nuclear translocation. Fig. la 
shows that although only minimal changes in the status of p52 and its precursor 
plOO could be observed, nuclear p50 and p65 increased substantially following a 
24 hour treatment with IP6 (Fig. la), an event that was visible as early as 4 hours 
following challenge with IP6 (data not shown). Notably, the increase in nuclear 
p50/p65 was not due to contamination from cytoplasmic proteins as evidenced by 
the absence of u-TUBULIN in the nuclear extracts (Fig .. la). In contrast to 
observations at the mRNA level (25), a slight decrease in IKB-u protein (which 
was primarily located in the cytoplasm), was detected in parallel (Fig .. la and 3). 
Overall, these data indicated that canonical NF-KB subunits translocate to the 
nucleus in response to treatment with IP6. 
Reduced NF-KB transcriptional activity by expression of a non-degradable 
IKB-a does not modulate the response to IP6. 
Others have reported that in DUl45 ce 11 s, NF-KB nuclear translocation 
decreases in response to IP6, resulting in reduced NF-KB DNA-binding activity 
(23). Consequently, the observation that NF-KB p50 and p65 translocate to the 
nucleus in response to IP6 in PC3 cells lead us to ask whether the modulation of 
NF-KB-mediated transcription was implicated in the activity ofIP6 in PC3 cells. 
To address this, we transfected PC3 cells with a non-degradable dominant-
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negative mutant of IKB-a (29) (DN-IKB-a) or a control vector (pCMVNeo) and 
determined whether this could modulate the effects of IP6. As shown in Fig. lb, 
transient transfection of DN-IKB-a effectively reduced NF-KB transcriptional 
activity relative to the pCMVNeo control as assessed using the KB-Iuc reporter. 
However, WST-I assays indicate that DN-IKB-a and pCMVNeo-transfected PC3 
cells respond similarly to a challenge with IP6 (Fig .. lc), suggesting that NF-KB 
transcriptional activity does not correlate with IP6 cytotoxicity. 
IP6 modulates BCL-2 family protein expression 
In parallel with NF-KB-responsive genes, we have previously reported that 
the mRNA levels of BCL-2 family pro-apoptotic genes such as NOXA, PUMA 
and BAX increase in response to IP6 [25].Hence, we next set out to determine 
how the prote in levels of these pro-apoptotic BCL-2 family proteins changed in 
time following treatment with IP6. To address this, PC3 cells were challenged 
with 2 mM IP6 and whole cell extracts were prepared after 4, 8 and 24 hours of 
continuous treatment. The extracts were then probed by western blot. As shown in 
Fig. 2, the expression of PUMA increased as early as 4 hours following treatment 
with IP6 until at least 8 hours post-treatment. Similarly, increased NOXA 
expression was also observed although later (8 hours) and to a lesser extent. Both 
PUMA and NOXA expression subsequently returned to normal after 24 hours of 
treatment with IP6. In contrast, no clear changes in BAX prote in expression were 
observed. We also looked at whether prote in expression of other pro and anti-
apoptotic BCL-2 family members could be modulated in response to IP6. As can 
be seen in Fig. 2, BIKlNBK expression is also up regulated by IP6 similarly to 
PUMA though to a lesser extent, particularly at 4 hours. In contrast, we could 
observe decreased expression of anti-apoptotic proteins MCL-I and BCL-2, 
though only after 24 hours of treatment with IP6. These data suggested that IP6 
induces temporal changes in the ratio of pro and anti-apoptotic BCL-2 family 
proteins. 
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Protein synthesis is important for IP6-induced cytotoxicity. 
In light of the results presented in Fig. 2 in addition to our observation of 
increased mRNA expression of pro-apoptotic BCL-2 family members in previous 
study (25), we next set out to determine whether transcriptional up regulation of 
pro-apoptotic genes such as PUMA, NOXA and potentially BIKlNBK could be 
important for mediating the effects of IP6. To gain an overall appreciation of this, 
we compared the efficacy of IP6 in PC3 cells pre-treated (4 hours) with an 
inhibitor of mRNA transcription (actinomycin D(30)) or vehicle (DMSO). Fig. 3a 
shows that continuous treatment with actinomycin D starting 4 hours prior to 
addition of IP6 (for 24 hours) did not modulate PC3 cell sensitivity to IP6. To 
verify that actinomycin D effectively blocked mRNA synthesis in our conditions, 
we looked at the rnRNA levels of I!d3-a in response to IP6. Fig. 3b shows that 
IP6-induced IKB-a up-regulation after 24 hours of treatment was effectively 
blocked by actinomycin D but not by DMSO. Because IP6 treatment could lead to 
prote in up-regulation independently of transcription, we next assessed the efficacy 
of IP6 in PC3 cells where prote in production was blocked using cycloheximide 
(50 Jlg/ml, 4h pre-treatment). Fig. 3c shows that a continuous treatment with the 
translation inhibitor cycloheximide (30) starting 4 hours prior to treatment with 
IP6 significantly protected from IP6-induced toxicity (p<0.05 at 1.5mM IP6). 
These data suggested a role for protein synthesis in mediating the effects of IP6 
and that one possible effect of blocking protein translation would be to hinder on 
the temporal shift of the ratio between pro-apoptotic to anti-apoptotic protein 
induced by IP6. 
A proteasome inhibitor sensitizes androgen-independent prostate cancer cells 
to the effects of IP6 
Because blocking protein translation reduced the efficacy of IP6, 
potentially by preventing increases in pro-apoptotic protein levels, we rationalized 
that blocking proteasome-mediated prote in degradation could have the opposite 
effect and instead enhance the effect of IP6. To test this hypothesis, we treated 
177 
PC3 AIPCa ceUs with the commonly used proteasome inhibitor MG-132 (20 J.lM) 
(31), beginning 4 hours prior to the addition of IP6, and assessed the efficacy of 
IP6 using WST -1 assays. Fig. 4a shows that over 24 hours, ceUs co-treated with 
MG-132 were significantly more sensitive to IP6 treatment than control ceUs 
(p<0.005, IP6 1 mM). As inhibitors of the proteasome have been reported to 
inhibit NF-KB transcriptional activity, we also assessed the effect of MG-132 on 
KB-luc reporter activity in PC3 cells. We found that, at least in the PC3 cellline, 
MG-132 did not inhibit NF -KB-mediated-transcription of the KB-Iuc reporter. In 
fact, a slight increase in KB-Iuc reporter activity was detected with increasing 
doses of MG-132 (Fig. 4b). We then looked at whether MG-132 couid increase 
the sensitivity of IP6 in other PCa cell Hnes. Fig. 4c shows that MG-132 co-
treatment aiso significantly sensitized DUl45 AIPCa ceUs to the effects of IP6 
(p<O.OI, IP6 ImM). In contrast, MG-132 did not sensitize androgen-responsive 
LNCaP or 22Rvl cells to the effects ofIP6 (Fig. 4e). 
IP6 and proteasome inhibitors elicit enhanced mitochondrial depolarization 
in a protein translation-dependent fashion. 
The potentiai involvement of one or more members of the BCL-2 family 
proteins in the observed effect of IP6 next prompted us to look at whether a 
treatment with IP6 and/or proteasome inhibitors initiated mitochondrial outer 
membrane permeation (MOMP). To address this, we stained both treated and 
control PC3 ceUs with JC-I dye, and used F ACS to measure the percentage of 
ceUs exhibiting a green shift in JC-I fluorescence in treated cells relative to the 
control at various times foUowing treatment. Notably, a JC-I fluorescence shift 
from red to green is indicative of cells having undergone MOMP (32). We found 
that IP6 (2 mM) used aione caused a modest but time dependent increase in 
MOMP (Fig. 5a-c). As we had observed that cyc10heximide protected from the 
effects of IP6 using WST-I assays, we looked at whether cyc10heximide (50 
J.lg/ml) could protect from IP6-induced MOMP. We found that cyc10heximide on 
its own couid induce MOMP to an extent similar to what was observed for IP6 
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(Fig. 5a, c). However, co-treatment with IP6 and cycloheximide did not further 
increase the amount of ceUs exhibiting a green shift in JC-I fluorescence (Fig. 5a, 
c). Similarly, we found that MG-132 used alone also caused a time-dependent 
increase in green-shifted JC-I stained ceUs. Although likely due to the extra 4 
hours of pre-treatment with MG-132, at 8 hours (plus 4 hours "pre-treatment"), 
MG-132 appeared to induce roughly twice the relative amount of MOMP as 
compared to IP6 (Fig., 5a-e). Importantly, eo-treatment with MG-132 and IP6 
caused a drastic increase in cells presenting MOMP. After 8 hours, ceUs eo-
treated with IP6 and MG-132 had nearly 3-fold the quantity of ceUs exhibiting 
MOMP as eompared to MG-132 alone and 6-fold the quantity of eeUs exhibiting 
MOMP as compared to IP6-treated ceUs (Fig. 5a-c). We next questioned whether 
the observed enhaneed effeet of combined IP6 and MG-132 at the level of MOMP 
was specifie to MG-132 or whether it could aiso be observed with other 
proteasome inhibitors. Fig. 5b shows that ALLN (l0 J.l.M) (33) also enhances the 
induction of MOMP when eombined with IP6 in PC3 ceUs. In order to assess 
whether the enhaneement of MOMP elicited by combined treatment with IP6 and 
proteasome inhibitors required de nove protein synthesis, we eo-treated eells with 
eycloheximide (50 J.l.g/ml), MG-132 (20 J.l.M) and IP6 (2 mM). We found that 
although addition of cycloheximide did not reduce MG-I32 induced MOMP (Fig. 
5a, c), addition of cycloheximide almost completely blocked the enhanced 
MOMP observed in response to combined treatment with MG-132 and IP6 (Fig. 
5c). 
MG-132 and Cycloheximide modulate the expression of BCL-2 family 
proteins in PC3 ce lis 
As blocking protein translation prevented MOMP in response to combined 
IP6 and MG-132 treatment, we deemed it relevant to look at how BCL-2 family 
member expression was modulated in response to MG-132 and eycloheximide 
with and without IP6 (added 4 hours later). Western blotting ofwhole eeU extraets 
was used to deteet the expression of BCL-2 family members as weIl as IKB-u. 
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The results presented in Fig. 6 suggest that treatment of PC3 cells with MG-132 
substantially increased the levels of NOXA and to a lesser extent of BIKlNBK, 
PUMA and MCL-1. The addition of IP6 led to a slight further increase in the 
levels of NOXA, BIKlNBK and MCL-I. In contrast, the treatment of PC3 ceUs 
with cycloheximide on its own caused almost complete loss ofNOXA expression 
and substantially decreased BIKlNBK and MCL-1 protein levels. Interestingly, 
subsequent addition of IP6 curtailed the decrease in the levels of MCL-I but not 
that of NOXA or BIKlNBK. Cyc10heximide did not modulate the expression of 
PUMA or BAX when used alone although notably, it did not completely block 
IP6-induced up-regulation of PUMA. Similar to MG-132, cycloheximide used 
alone slightly decreased the expression of IKB-a. However, addition of IP6 to 
cycloheximide treated ce Us caused a further decrease in IKB-a. Although co-
treating PC3 ceUs with MG-132 and cycloheximide nullified their respective 
effects on MCL-I and BIKlNBK expression levels, reduced NOXA and BCL-2 
expression remained observable. Interestingly, combined treatment with MG-132 
and cycloheximide reduced IKB-a levels more than either treatment used alone 
independently of IP6. 
Discussion 
In contrast with studies done using other celI lines (23, 34), the data 
presented here suggests that, at least in PC3 ceUs, classical NF -KB subunits p50 
and p65 translocate to the nucleus up to 24 hours following treatment with IP6 
(Fig. la). In parallel, we found that the non-canonical pathway (pIOO/p52) is 
largely unaffected by a similar treatment. In parallel, IKB-a protein levels slightly 
decrease in response to IP6 (Fig. la, 2), even though b(B-a mRNA increases 
substantially over 24 hours (Fig. 3b and (25)), beginning as early as 4 hours post-
treatment (data not shown). Interestingly, blocking protein production using 
cycloheximide further decreased the expression of IKB-a protein in response to 
IP6 (Fig. 6), suggesting that the increase in IKB-a rnRNA induced by IP6 may act 
in an auto-feedback loop to re-establish the levels of IKB-a protein. Although 
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these results altogether suggest that the NF-KB c1assical pathway may be 
triggered in response to treatment of PC3 cells with IP6, inhibiting NF-KB 
transcriptional activity (assessed by KB-luc assay, Fig. lb) by transfecting PC3 
cells with a non-degradable dominant negative form of IKB-a (29) does not 
modulate PC3 cell sensitivity to IP6 (Fig. lc). Rence, our results are at odds with 
the suggestion that IP6-induced cell death is mediated by inhibition of constitutive 
NF-KB activity. 
Based on our results, a more likely possibility is that IP6 modulates BCL-
2 family prote in expression in a manner that leads to an increased pro-
apoptotic/anti-apoptotic BCL-2 family prote in ratio. Indeed, Fig. 2 shows that IP6 
induced a graduaI shi ft in the levels of BCL-2 family members at the prote in 
level, wherein pro-apoptotic proteins such as PUMA, NOXA and BIK were up-
regulated early on (4 and 8 hours) and where the levels of anti-apoptotic proteins 
such as MCL-l and BCL-2 decreased somewhere between 8 and 24 hours 
following treatment with IP6. Because we had previously observed the up-
regulation of PUMA, NOXA and BAX rnRNA, we initially hypothesized that this 
could be mediated by the up regulation of pro-apoptotic genes at the mRNA level. 
Rowever, we were surprised to find that a transcription inhibitor (actinomycin D, 
(30)), although effectively blocking IP6-induced up regulation of gene expression 
(Fig. 3b), did not prote ct cells from the effects of IP6 (Fig. 3a). As prote in 
expression can be modulated by post-transcriptional events inc1uding rnRNA 
export, mRNA translation and proteasome-mediated protein degradation, it 
remained possible that the ratio of pro-apoptotic to anti-apoptotic proteins could 
shift in response to IP6 independently of mRNA transcription and of actinomycin 
D. Indeed, PC3 cells in which prote in translation was blocked using 
cyc10heximide were significantly protected from the effects of IP6 (Fig. 3c). At 
the very least, these data suggest that prote in translation is more relevant than 
mRNA transcription in communicating the observed effects of IP6. With respect 
to this, it is a likely possibility that the effect of IP6 at least partially involves 
increased ratios of pro-apoptotic to anti-apoptotic BCL-2 family proteins. 
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One potential mechanism that could lead to increased protein production 
independently of transcription is that IP6 stabilizes pro-apoptotic proteins. For 
example, this could result from the inhibition of specific ubiquitin ligases such as 
MULE/ARF-BPI (that targets MCL-I for degradation) (35) or from direct 
inhibition of the proteasome. On the other hand, the observed decrease in MCL-I, 
BCL-2 and IKB-a after longer exposure times of PC3 cells with IP6 argues 
against both of these possibilities (Fig. 2). Another potential mechanism is that 
IP6 stimulates ribosomal protein production of pro-apoptotic pro teins. Potential 
candidate targets that could mediate such an effect of IP6 include mTOR and 
RaIA, that has been recently found to regulate the translation of the anti-apoptotic 
protein FLIPs (36). Notably, mTOR is well know to be regulated by Akt (37), 
which in tum is also an upstream activator ofNF-KB (7, 10, Il), who se classical 
p50/p65 subunits translocate to the nucleus in response to IP6 (Fig. 1 a). However, 
activation of mTOR is generally associated to increased expression of cyclin Dl 
and cell proliferation, not cell death (37). Finally, reports showing that 
endogenous IP6 plays a role in mRNA export (38, 39) suggest the intriguing 
possibility is that IP6 increases the cytoplasmic export of existing pools of 
accumulated pro-apoptotic nuclear mRNA. However, it is unclear whether the 
nuclear mRNA export machinery is so specific as to allow for the export of pro-
apoptotic but not anti-apoptotic BCL-2 family members. 
Although the observed effect of cycloheximide on the efficacy of IP6 and 
IP6/MG-132 co-treatrnent may involve de novo protein synthesis, we cannot 
exclude the possibility that these observations are linked with reductions in basal 
pro-apoptotic protein levels resulting from pre-treatment with cycloheximide. 
Indeed we can observe decreased levels of NOXA and BIK/NBK in response to 
treatrnent with cycloheximide alone (Fig. 6, lane 3). On the other hand, treatrnent 
with cycloheximide led to a similar decrease in anti-apoptotic MCL-I (Fig. 6). 
Surprisingly, we found that MCL-I levels decreased less in response to treatment 
with cycloheximide when cells were subsequently treated wÎth IP6 (Fig. 6, 
compare lane 3 to lane 7). Analogously, IP6-induced expression of PUMA was 
not fully inhibited in the presence of cycloheximide (Fig. 6 compare lane 4 to lane 
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7). This observation is interesting in light of reports suggesting that 
cycloheximide inhibits cytoplasmic ribosomes but not mitochondrial ribosomes, 
which are of notably different composition (40). Although re1ative1y little is 
known about nuclear mRNA sorting to the mitochondria (41), mitochondrial 
import of nuclear tRNAs is better described and is required for mitochondrial 
protein translation (42, 43). It is tempting to speculate that certain BCL-2 family 
proteins can be synthesized by mitochondrial ribosomes from imported 
cytoplasmic mRNAs. 
FolIowing from our observations in Fig. 2 and 3, we rationalized that if 
blocking the production of pro-apoptotic BCL-2 family proteins by treatment with 
cycloheximide reduced IP6 efficacy, then increasing their levels using proteasome 
inhibitors may lead to an enhanced effect. Indeed, we found that co-treatment 
with MG-132 significantly increased the effect of IP6 in at least two AIPCa celI 
lines (Fig. 4a-b). Our results suggest that this effect is not due to the inhibition of 
NF-KB transcriptional activity as treatment of PC3 celIs with MG-132 increased 
NF-KB transcription from a KB-luc reporter (Fig. 4b). This is in line with other 
studies that have reported that in sorne ce Ils at least, proteasome inhibitors do not 
inhibit NF-KB (14). In addition, MG-132 did not appear to stabilize the expression 
of IKB-a, as evidenced by the strong reduction in IKB-a protein observed in celIs 
treated with both cycloheximide and MG-132 with or without IP6 (Fig. 6, lanes 4 
and 8). It seems rather unlike1y that this is due to a lack of activity on behalf of 
MG-132, as evidenced by the clear increase in NOXA, BIKlNBK and MCL-l 
leve1s in response to treatment with the proteasome inhibitor. Notably, treatment 
of PC3 celIs with cycloheximide led to decreased leve1s of these same proteins, 
suggesting that the se may be quickly synthesized and degraded equalIy rapidly by 
the proteasome. As MG-132 has been reported to mainly inhibit chymotryptic 
proteasome activity, this may also suggest that the degradation of IKB-a in 
prostate celIs could be mediated by peptidylglutamyl peptide hydrolyzing, 
trypsin-like, or even caspase-like proteasome-associated activities (2, 44). In 
contrast, NOXA, BIKlNBK and MCL-l may be preferred clients of the 
chymotryptic active site. 
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The observation that blocking prote in translation using cycloheximide 
almost completely inhibits MOMP induced by combined IP6 and proteasome-
inhibitor treatment strongly points to the involvement of pro-apoptotic BCL-2 
family members. In particular, proteins with potentially rapid degradation kinetics 
such as NOXA and BIKlNBK that are further increased by treatment with IP6 
(albeit only slightly) may act in concert to elicit this enhanced effect on 
mitochondrial depolarization. At the same time, it must be noted that anti-
apoptotic MCL-l also seems to respond, particularly to combined MG-132 and 
IP6 treatment. With respect to this, it will be interesting to determine whether a 
MCL-l-targeting siRNA can further enhance the efficacy of combined 
IP6/proteasome inhibitor treatment. Notably, others were able to increase the 
potency of Bortezomib using this MCL-l-knockdown approach in melanoma 
cells (13). 
In light of the multitude of pro-apoptotic BCL-2 family members, it is 
likely that other BCL-2 family members are also up regulated by both IP6 and 
MG-132, further perturbing the pro-apoptotic/anti-apoptotic ratio. It is equally 
possible that a subset of pro-apoptotic proteins is specifically up regulated by IP6, 
while another complementary subset is up regulated by MG-132. This could lead 
to enhanced cytotoxicity according to a recently proposed hierarchical BCL-2 
family model of BAX/BAK activation. In this model, sorne BH3-only proteins 
such as NOXA, BAD, BMF and BIKlNBK may act up-stream of "activator-only" 
pro-apoptotic proteins su ch as BID, BIM, and PUMA, by releasing them from the 
inhibitory clutches of anti-apoptotic BCL-2/BCL-XL and MCL-l (19). In this 
context, the combined up regulation of NOXA and BIKlNBK by MG-132 may 
complement the up-regulation of activator-only proteins following challenge with 
IP6. Although PUMA was a potential candidate, its expression also appears to be 
up regulated by MG-132 (Fig. 6 lane 2). In addition, our attempts to prevent the 
enhanced cytotoxic effect of combined IP6 and MG-132 treatment by shRNA-
mediated down-regulation of PUMA have proved unsuccessful so far (data not 
shown). Hence, we suspect that other pro-apoptotic "activator-only" proteins may 
be up regulated by IP6 but not by MG-132, or that altemately IP6 induces post-
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translational modifications that activate pro-apoptotic proteins up regulated by 
MG-132. We are currently investigating these possibilities. 
Nonetheless, the enhanced effect of IP6 was seen when combined with at 
least two proteasome inhibitors. This was most clearly visible when MOMP was 
assessed in individual PC3 cells using JC-l dye (Fig. 5a-c). In addition to the 
observation that combining IP6 with MG-132 leads to an enhanced effect in at 
least two AIPCa cell lines, these results suggest that IP6 may be useful in 
combination with proteasome inhibitor drugs for treatment of AIPCa. This 
possibility is particularly exciting since proteasome inhibitors are already 
undergoing pre-clinical trials for AIPCa (3-5) and since previous studies have also 
shown that IP6 can exhibit anti-cancer activity in mice when administered as a 
dietary supplement in drinking water (45). 
Conclusion 
In conclusion, we find that IP6 triggers an NF-lCB response in PC3 cells 
but that this response does not likely play a major role in either preventing or 
promoting the cytotoxic effects of IP6. We propose that the up-regulation of pro-
apoptotic BCL-2 family members at the protein level is likely involved in 
skewing the pro-apoptotic/anti-apoptotic protein ratio and in mediating the 
cytotoxic effects of IP6. Finally, we conclude that proteasome inhibitors enhance 
the effect of IP6 on mitochondrial depolarization, potentially involving multiple 
pro-apoptotic BCL-2 family members. Altogether, our results suggest that the pre-
clinical evaluation of proteasome inhibitors in combination with IP6 is warranted 
and could provide an alternative for the treatment of AIPCa. 
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Figure 1. A) IP6 induces canonical NF-KB subunit nuc1ear translocation. Nuc1ear 
(N) and cytoplasmic (C) extracts of PC3 cells treated with vehic1e (0 mM) or IP6 
(2 mM) for 24 hours, were probed by Western blot to assess the expression and 
subcellular localization of plOO, p52, IKB-a, p50, and p65. a-TUBULIN was 
used as a control for nuc1ear extract purity. ~-ACTIN was used as a loading 
control. B) A non-degradable dominant-negative of IKB-a inhibits NF-KB 
transcriptional activity. DN-IKB-a or pCMVNeo control plasmids were co-
transfected with KB-luc/Renilla luciferase in PC3 cells. KB-luc activity was 
measured after 72 hours and normalized according to renilla and basal tkGL3 
activity (see Materials and Methods). Data represents average of 2 independent 
experiments done in 4-8 replicates each. *p-value <0.05. C) Inhibition of NF -KB 
transcriptional activity does not modulate the efficacy of IP6. PC3 cells 
transiently transfected (48h) with pCMVNeo and DN-IKB-a cells were plated at a 
density of 20 000 cells per well and treated with increasing doses of IP6. 
Metabolic activity was measured using WST -1 reagent and relative metabolic 
activity was normalized according to vehic1e-treated pCMVNeo or DN-IKB-a 
transfected cells (see Materials and Methods). Data represents average of 2 
independent experiments done in 3-6 replicates each. Error bars represent the 
standard error. 
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Figure 2. IP6 induces temporal changes in the levels of BCL-2 family 
pro teins 
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Figure 2. IP6 modulates the expression of BCL-2 family proteins. PC3 cells were 
treated with 2mM IP6 or vehicle and whole cell extracts were prepared from cells 
harvested upon treatment (tO) and after 4 (t4) and 8 (t8) hours of additional 
treatment with IP6 (+) or vehicle (-). Western blotting was used to probe extracts 
for MCL-l, BCL-2, IKB-a, BIK/NBK, PUMA, NOXA, and BAX expression. 
RAN expression was used as a loading control. Solid boxes signal increased 
prote in levels in treated cells as compared to time-matched control cells whereas 
dashed boxes indicate decreased prote in levels relative to time-matched controls. 
Blot was representative of 2 independent experiments each done in duplicate. 
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Figure 3. The effect of IP6 requires protein translation but not rnRNA 
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Figure 3. A) A transcription inhibitor does not prote ct PC3 cens from the effects 
ofIP6. Actinomycin D (1 )lg/ml) and DMSO pre-treated PC3 cens (density of 20 
000 cells per wen) were treated with increasing doses of IP6 for 24 hours. 
Metabolic activity was measured after 24 hours (plus 4-hour pre-treatment) using 
WST -1 and the data was normalized according to DMSO or actinomycin D pre-
treated cens not treated with IP6. Data represents average of 5 independent 
experiments each done in 3-6 replicates. No significant difference was observed 
between actinomycin D and DMSO treated cens. B) Actinomycin D inhibits IP6-
induced up regulation of IKB-a mRNA. PC3 cells were pre-treated for 4 hours 
with 1 )lg/ml actinomycin D or DMSO (CTRL) then treated with 2mM IP6 or 
vehic1e (OmM). cDNA were synthesized from RNA extracted 24 hours later and 
real-time PCR was used to measure the fold change in IKB-a rnRNA expression. 
Data represents an average of 2 independent experiments done in duplicate. C) An 
inhibitor of prote in translation protects PC3 cens from the effects of IP6. As in B, 
cyc10heximide (50 )lg/ml) and ethanol pre-treated PC3 cens were treated with 
increasing doses of IP6 for 24 hours and metabolic activity was measured using 
WST -1. Data represents an average of 3 independent experiments done in 3-6 
replicates. Error bars represent the standard error. *p-value <0.05, #p-value=0.06. 
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Figure 4. The proteasome inhibitor MG-132 sensitizes AIPCa cells to the effects 
of IP6. In A) (PC3), C) (DU145), D) (LNCaP) and E) (22Rvl), cells were plated 
at 20 000 cells per well and pre-treated for 4 hours with MG-132 (or ethanol 
control) prior to addition of IP6 at increasing concentrations. Metabolic activity 
was measured 24 hours later using WST -1. For each cell line, relative metabolic 
activity was ca1culated according to the WST -1 output MG-132-treated or control 
cells treated with vehicle (0 mM IP6). Data represent average of 3 independent 
experiments done in 3-6 replicates each. ***p-value<0.005, **p-value<O.Ol, #p-
value=0.08, ##p=0.09 B) As described in Fig. lc, KB-Iuc reporter and control-
transfected cells were treated with 2 or 20 )lM MG-132 or vehic1e (CTRL) and 
assayed for relative luciferase activity. Data represents average of 2 independent 
experiments done in 4-8 replicates each. Error bars represent the standard error. 
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Figure 5. IP6 and proteasome inhibitors present an enhanced effect on 
mitochondrial depolarization that requires protein translation. 
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Figure 5. IP6 and proteasome inhibitors present an enhanced effect on 
mitochondrial depolarization. A) PC3 cens pre-treated with 50 )lg/ml 
cyc10heximide (CHX), 20 )lM MG-l32 (MG) or control ethanol and were stained 
with JC-l dye 0, 2, 4, and 8 hours fonowing treatment with 2mM IP6 (or vehic1e). 
cens were trypsinized and sorted by F ACS and the percentage of green-shifted 
JC-l cens was assessed. Data was then normalized to vehic1e-treated control for 
each time point. Data represents an average of 3 independent experiments. B) PC3 
cens were pre-treated with 20 )lM MG-l32, 10 !-lM ALLN, or DMSO prior to 
addition of 2mM IP6 (or control). Eight hours later, green-shifted JC-l stained 
cens were counted by F ACS and data was normalized according to vehic1e treated 
controls. Data represents average of 2-3 experiments. An error bars represent the 
standard error. C) PC3 cens were pre-treated with 20 )lM MG-l32, 50 !-lg/ml 
cyc1oheximide, or a combination of MG-132 and cyc10heximide or control 
ethanol prior to addition of 2mM IP6 (or vehic1e). 8 hours later, green-shifted JC-
1 stained cells were counted by F ACS _and data was normalized according to 
vehic1e treated controls. Data represents average of 2-3 experiments. 
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Figure 6. Modulation of BCL-2 family protein expreSSIOn III PC3 cells in 
response to IP6. MG-132 (MG), and cyc10heximide (CHX). PC3 cells were pre-
treated with 20 JlM MG-132, 50 Jlg/ml cyc10heximide or both. Four hours later, 
cells were treated with 2mM IP6 (or control) for an additional 4 hours. Whole cell 
extracts were prepared and probed for MCL-l, BCL-2, IKB-a, PUMA, NOXA, 
BIK/NBK and BAX by Western blot. GAPDH was used as a loading control. The 
presented blots were representative of 3 independent experiments each done in 
duplicate. 
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CHAPTERVI 
.6. Discussion 
6.1. AR expression and the sensitivity to IP6 
In chapter 2, we explored the effect of IP6 on four commonly used PCa 
cen lines and observed that the efficacy of IP6 correlated with AR expression. In 
this study we found that AR-negative DU145 and PC3 cens were more sensitive 
to IP6 than AR-positive LNCaP and 22Rvl cens. In light of these observations, 
we went on to determine whether the sensitivity of IP6 could be modulated by 
supplementation with androgens or steroid depletion. Although our results 
suggested that the efficacy of IP6 was not modulated by androgens, we observed 
that PC3 cens stably transfected with the AR were more resistant to the effects of 
IP6 than wild-type PC3 cens. Furthermore, an siRNA targeted against the AR 
could sensitize PC3(AR) cens to the effects of IP6 although this was insufficient 
to sensitize LNCaP or 22Rvl cells. In addition, we found that in PC3 cens, 
treatment with IP6 led to an increase in caspase-3 like activity as wen as to an 
increase in DNA fragmentation. The mRNA expression of a subset of NF-KB-
responsive genes (bell-a, IRF-2) and of genes encoding for pro-apoptotic proteins 
(PUMA, NOXA and BAX) was also found to increase in response to treatment 
with IP6. An ofthese events were significantly reduced in PC3(AR) cens. At least 
in the context of PC3/PC3(AR) ce 11 s, this suggested the implication of an 
androgen-independent AR-associated function implicated in the resistance to IP6 
cytotoxicity . 
The nature of the androgen-independent AR-associated function that led to 
decreased IP6 efficacy in PC3(AR) ce11s according to WST -1 metabolic assays, 
fluorigenic caspase-3 substrate assays, DNA fragmentation (by filter elution) and 
gene expression profiling remains obscure. Based on the observation that IP6 led 
to substantial up regulation of the p50/p65-responsive gene bcB-a [590]) but only 
minima11y affected the expression ofp52-responsive CyclinDJ and BCL-2, [143, 
591]), we initia11y proposed that IP6 could preferentia11y activate the c1assical NF-
KB p50/p65 pathway in PC3 ce11s (Chapter II, Fig. 5). We also hypothesized that 
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through a putative interaction with p65/RELA [370] stable expression of the AR 
could potentially inhibit classical NF-KB activity and protect from the effects of 
IP6 in light of the observation that NF-KB can be pro-apoptotic in sorne 
circumstances [592, 593]. Although the results obtained in chapter V (Chapter V, 
Fig la) suggest that our initial hypothesis on the activation of the classical versus 
non-cl as sic al NF-KB pathway may have been correct, the observation that 
reducing NF-KB transcriptional activity does not modulate sensitivity to IP6 in 
PC3 cells (Chapter V Fig Ib-c) argues against our second proposition. 
ln light of a similar effect of stable AR expression on the up regulation of 
pro-apoptotic genes in response to treatment with IP6, particularly of PUMA, 
NOXA and BAX, we considered the possibility that the up-regulation of pro-
apoptotic mRNA could play a role in the observed effect of IP6. We also 
proposed that given that PC3 cells harbor a p53 mutation leading to a premature 
stop codon and a p53-null phenotype, potential alternative mediators of PUMA 
and NOXA up-regulation (initially described as p53-responsive genes) could be 
E2Fs. As the transcriptional activity of E2Fs is regulated by pRb-family proteins, 
and since the AR has been reported to interact with pRb in an androgen-
independent fashion [357], such a role of E2Fs could have explained our 
observations. At least two of these hypotheses are likely refutable. First, it appears 
from preliminary experiments using a dominant-negative E2F construct that 
blocking E2F transcription does not modulate the efficacy of IP6 (unpublished 
results). Second, experiments using actinomycin D done in chapter V (Chapter V, 
Fig 3a-b) suggest that inhibiting the transcriptional response induced by IP6 does 
not modulate the efficacy of IP6. Although these results do not exclude a role of 
E2F transcription factors in mediating PUMA and NOXA expression and do not 
eliminate the possibility of an androgen-independent interaction of pRb with the 
AR, they certainly argue against a primary role of E2F transcription factors in 
mediating the response to IP6. 
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Although we were able to observe DNA fragmentation in response to 
treatment with IP6, it must be noted that this hallmark of apoptosis is not 
exclusive and can result from other modes of cell death, including necrosis (see 
section). In addition, IP6-induced cell death may not present aIl of the 
characteristic hallmarks of apoptosis. One study found that treatment of DU145 
ce Ils with 2mM IP6 induced an increase of only roughly 2% in cell surface 
exposed membrane phosphatidyl serine as measured by Annexin V combined 
with fluorescence activated cell sorting. In paraIlel, the cleavage of P ARP and 
caspase-3 were evident following a similar treatment [585]. Furthermore, we have 
found that· a pan-caspase inhibitor ZVAD-fmk, while effectively blocking 
caspase-3 activity, does not modulate the effects of IP6 on the metabolic activity 
ofPC3 cells (unpublished results). Similarly, ZVAD was found to have no impact 
on the efficacy of IP6 in mouse prostate cancer cells [594]. Hence, it remains 
possible that at least a proportion of cells die by necrosis or another form of 
caspase-independent death. 
With respect to this, sorne studies suggest that likely depending on the 
mode of death, the cellular response to drug treatments as measured by metabolic 
assays such as WST -1 may appear with slower or faster kinetics as compared to 
biochemical assays looking more specifically at hallmarks of apoptosis or 
necrosis respectively [595, 596]. By comparing the results obtained using 
metabolic activity (WST-l) and apoptosis markers (such as caspase-3 activation 
and DNA fragmentation) as endpoints for assessing IP6 efficacy, we noted that 
the effect of IP6 appeared greatest at the metabolic level. For example, whereas a 
24 hour treatment of PC3 cells with 2mM IP6 reduced metabolic activity by 
approximately 80-90% (Chapter II, Fig la, 2b, 3a-b) we only observed a 4-fold 
increase in caspase-3 activity in response to a similar treatment with IP6 (Chapter 
II, Fig. 3f). This increase is modest when we consider that for a similar effect of 
the DNA damaging agent camptothecin on metabolic activity in 22Rv 1 cells, a 
nearly 120-fold increase in caspase-3 activity is observed (unpublished 
preliminary data). Similarly, we detected an increase of roughly 15% in 
fragmented DNA 24-hours following treatment with 2mM IP6 (Chapter II, Fig. 
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3g). At 48 hours, 30% of the DNA was fragmented which is still far from the 80% 
reduction in metabolic activity typically observed after only 24 hours of treatment 
with IP6. Hence, these observations support the possibility that IP6 induces 
caspase-independent modes of cell death in a certain proportion of cells. 
Interestingly, cells having initiated the apoptotic program can undergo 
necrosis or caspase-independent death when cellular stores of ATP are rapidly 
depleted [197]. Importantly, WST-l measures the activity of NADH 
oxidoreductases, indicating proper electron transfer chain activity and ATP 
production [597]. As mentioned in section 1.2.3.1.1, the electron transfer chain 
requires the activity of several cytochrome complexes. Interestingly, cytochrome 
proteins contain he me prosthetic groups and are very c10sely related to 
hemoglobin, a prote in that cames oxygen in the blood [598, 599]. Notably, IP6 is 
weIl known to tightly bind hemoglobin and release heme-oxygen complexes 
[600]. As such it is not inconceivable that IP6 interferes with the electron transfer 
chain present within the mitochondrial inner membrane, thus reducing metabolic 
activity and consequently WST -1 output. In this context, it is tempting to 
speculate that the known interaction of the AR with mitochondrial electron chain 
transfer components such as COXVb [362] could explain the protective effect of 
the AR. 
One intriguing question is why siRNA-mediated depletion of the AR in 
ceIllines that endogenously express it, such as LNCaP and 22Rvl cells, does not 
sensitize these ce Ils to the effects of IP6. This observation argues against a direct 
role of the AR in mediating the resistance to IP6 at least in these cells. One 
possibility is that the effect of the AR is indirect and that it involves a secondary 
AR transcriptional target. As such this target would need to be extremely stable so 
as to not decrease in expression following a transient knockdown of the AR in 
these cells (chapter II figure 4a). At the same time, we would expect a similar 
result in PC3(AR) cells if this were the case. On the other hand, it may be that 
proteins that regulate the degradation of this hypothetical "IP6-resistance prote in" , 
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such as ubiquitin ligases for example, are absent in LNCaP and 22Rvl but are 
active in PC3 and DUl45 cells. 
Another possibility is that AIPCa cells that have evolved to survive in 
complete absence of AR expression (or that originate from AR-negative prostate 
cells such as neuro-endocrine or basal cells) are fundamentally different from PCa 
cells that express the AR. This notion has been evoked by others to explain why 
androgens reduce cellular proliferation and induce apoptosis in PC3 cells stably 
transfected with the AR while a similar treatment increases proliferation in AR 
positive cells [601]. As such, it is possible that the molecular signature shared by 
AR-negative DU145 and PC3 cells is linked to IP6 sensitivity and that the 
expression of the AR interferes with components specific to this "AR-negative 
signature" in PC3 cells, leading to IP6 resistance. 
Although the results are somewhat controversial, sorne studies suggest that 
a similar androgen-independent AR-linked phenomenon may be observed when 
looking at the response to DNA-damaging agents. One study suggests that 
cytoplasmic androgen-bound AR leads to the activation of MAPK and to the 
resistance to the DNA-damaging agent etoposide in the context of AR-negative 
HeLa and Osteoblast cens [396]. On the other hand, another study reported that 
androgens sensitizes to the effects of DNA-damaging agents in AR-positive 
prostate cens. Interestingly, this study showed that PC3(AR) cens were sensitized 
to DNA-damaging agents even in absence of androgens. This phenomenon was 
suggested to be mediated by the androgen-dependent up regulation of NOXA 
[602]. However, our observations are somewhat at odds with a role of NOXA 
since the data presented in chapter III (Chapter III, Fig 1) suggest that NOXA 
expression is in fact higher in AR-negative AIPCa cells. In addition, we did not 
observe increased NOXA expression in the PC3(AR) cenline used in chapter II 
(unpublished results). 
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FinaIly, one interesting possibility is brought to light by the recent finding 
that in PC3 ceIls, the AR inhibits EGFR signaling in an androgen-independent 
manner by interfering with receptor intemalization through the caveolin-lIclathrin 
pathway [397]. As mentioned in section 1.4.4.2.2, one study suggests that 
treatment of DU 145 cells with IP6 also leads to inhibition of EGFR signaling 
through receptor intemalization, among others through decreased binding of 
EGFR to the AP-2 clathrin prote in [537]. As such, the relative effect of IP6 may 
be decreased in a context where the AR already exerts an analogous function. On 
the other hand, we would once again expect that AR down-regulation wou Id have 
a similar effect in PC3(AR), LNCaP and 22Rv1 cells. This is of course 
notwithstanding the possibility that AR-negative and AR-positive exhibit 
differences in ErbB family member expression and sub-cellular localization, or in 
the rates of receptor endocytosis. In relation to this, we have recently shown that 
ErbB3 translocates to the nucleus of PCa cells [603]. In this study, we found that 
LNCaP and 22Rv1 cells exhibited more nuclear ErbB3 than PC3 or DU145 cells. 
In light of this, it will be interesting to determine whether sub-cellular localization 
ofErbB family members can influence the efficacy ofIP6. 
6.2. NOXA and PUMA as molecular targets and prognostic markers for 
prostate cancer 
Following our initial observations made in chapter II, we hypothesized 
that pro-apoptotic BCL-2 family proteins including NOXA, PUMA and BAX 
may play a role in the mediating the effects of IP6. Although the expression of 
BAX had been weIl studied in the context of the prostate, PUMA and NOXA 
expression had not yet been characterized in prostate tissues. As such, we set out 
to characterize the expression of NOXA and PUMA in prostate tissues and to 
assess their relationship to biochemical recurrence (BCR) in chapter III. Using 
immunohistochemical methods and a novel color scale method, we assessed 
NOXA and PUMA expression in tissue micro-arrays encompassing tissues from 
autopsied cancer-free patients, radical prostatectomy specimens from hormone-
sensitive PCa patients (including non-neoplasic, PIN, and cancerous regions), as 
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weIl as TURP specimens coIlected from AIPCa patients. We observed that 
NOXA and PUMA were expressed in aIl prostate tissues analyzed and that both 
were frequently up-regulated in PCa when comparing non-neoplasic to cancerous 
tissues obtained from the same radical prostatectomy specimens (68% for NOXA 
and 70% for PUMA). While on average PUMA expression appeared to attain 
peak levels in hormone-sensitive PCa samples, NOXA expression was at its 
highest in AIPCa tissues. In contrast with PUMA, we found that high NOXA 
expression was associated to increased risk of BCR. Several survival tree models 
were subsequently generated using NOXA and PUMA staining intensity, the 
Gleason Score, surgical margin status, pathological stage and pre-operative PSA, 
as input parameters. These were then ranked according to the predictive accuracy. 
From these analyses, we found a recurrent structure within the top ranking 
survival trees, where patient BCR risk was first stratified according to surgi cal 
margin status then according to NOXA expression within patients with negative 
surgical margins. On the basis as of this and other practical considerations, we 
proposed that a model inc1uding surgical margin status, NOXA expression, and 
pre-operative PSA may warrant further validation. 
From the data presented in chapter III, one can argue that NOXA and 
PUMA could be considered as potential targets for PCa treatment. Both proteins 
are expressed in aIl PCa specimens encountered and are frequently over-expressed 
in cancerous relative to adjacent non-neoplasic tissues. Average PUMA and 
NOXA staining intensities are at their lowest in normal tissues from cancer-free 
patients and at their highest in cancerous tissues (Chapter III, Fig 3a-b). In the 
case of NOXA, levels were at their highest in AIPCa patients. Whether PUMA 
and NOXA can be further activated beyond mere protein up-regulation remains 
somewhat of a hypothetical concept; however, if this were to occur, we can 
predict therapies that increase the activity of NOXA and PUMA may hold sorne 
therapeutic bene fit for PCa and AIPCa patients. Indirectly, this finding also 
argues for the development of siRNA strategies targeting anti-apoptotic BCL-2 
family members, such as Oblimersen that targets BCL-2, for use against PCa and 
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AIPCa [510]. As such, we would predict that antisense drugs such as Oblimersen 
would have a greater effect in cells where the expression levels of pro-apoptotic 
BCL-2 family members are already elevated. 
When looking at the ability of NOXA and PUMA to predict BCR in 
patients having undergone radical prostatectomy, we found that NOXA 
expression was adversely predictive of BCR, but that PUMA on its own was not 
predictive of BCR (Chapter III, Fig 4a-b). Although it is qui te possible that 
PUMA is not well suited as a prognostic marker, it must be noted that the 
antibody used in this study may not be specific for only one isoform of PUMA. 
Although we found that, to various extents, all of the PCa celllines expressed pro-
apoptotic PUMA-a (22 kDA band; Chapter III, Fig.l), the better known BH3-
containing pro-apoptotic isoform (generally referred to as PUMA), we cannot 
exclude the possibility that other isoforms are expressed in prostate tissues. 
Notably, the expression of isoforms that don't contain a BH3 domain and whose 
functions are poorly understood su ch as PUMA-ô and y, could confound the 
conclusions drawn with respect to the prognostic value of bone fide pro-apoptotic 
PUMA, which is primarily associated to both a and ~ isoforms [117]. It will be 
interesting to determine whether the different PUMA isoforms could hold 
different prognostic information. However, to this effect, the availability of 
antibodies that are truly specific for each isoform may pose the greatest challenge. 
As discussed in chapter III, the observation of increased NOXA and 
PUMA expression in PCa in addition to the finding that high expression of 
NOXA is associated to a worse prognostic is somewhat counter-intuitive. We 
emitted the hypothesis that, counter to increased expression of pro-apoptotic 
proteins, there may be a parallel increase in cell proliferation, leading to increased 
tissue turnover. Recently, by comparing our results with those of another mutli-
marker study done on the same tissue micro-arrays (Gannon PO et a1., Clin 
Cancer Res, submitted), we observed that within the sub-cohort of PCa patients 
having undergone radical prostatectomy, patients that exhibited high NOXA 
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expression also exhibited an increased frequency of nuclear Ki67, a well known 
indicator of cellular proliferation (unpublished results). Re1ating back to tissue 
homeostasis, these observations may indicate that increased cellular turnover, as 
opposed to either manifestations of apoptosis or cellular proliferation taken alone, 
may be of relevance to the aggressiveness of PCa and potentially other cancers. 
However, as we cannot directly correlate NOXA or PUMA expression with 
apoptosis per se, it will be interesting to address this possibility more directly. For 
example, this could be done by co-assessing activated caspase-3 expression in 
parallel with Ki67 in the same tissues using immunofluorescence. The ratio of 
these two markers in combination could then be confronted to the onset of BCR. 
The survival tree analyses used in this study allowed us to sketch the 
relationship between NOXA, PUMA, clinico-pathological parameters and BCR. 
Using this method, we generated models and ranked them according to their 
predictive accuracy as determined by the lBS. In terms of prognosis, the top-
ranking models were particularly apt at identifying patients at very high or very 
low risk of BCR. For example, in the top-ranking model, no patients relapsed 
following surgery within the follow up period (0/13) whereas 14/15 patients 
relapsed in the worst prognostic group (Chapter III, Fig. 5a). In other words, this 
mode1 allows us to say with very high certainty (over 95%) whether 28 of the 62 
patients present in the cohort will relapse or not. Hence, if this model were to be 
used in a clinical setting, it would be useful for patients in the extreme prognostic 
groups at very low or very high risk of relapse (45% of patients in this case), 
while not very informative for the rest (55%) of patients in the intermediate risk 
groups. As such, it may be argued that the best prognostic model in a clinical 
setting is not the one that can most accurately stratify patient risk but rather the 
one that can predict the most patients at very high and very low risk. Although 
survival trees as well as other modeling methods including multivariate Cox 
models and nomograms provide a step in the right direction, they do not account 
for this subtlety. However, until the emergence of such an ideal marker or 
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prognostic mode l, it remains important to further evaluate currently promising 
models as these are more likely to aid patients in the near future. 
6.3. The implications of androgen receptor expression and sub-cellular 
localization in the development of prostate cancer. 
As the observations made in chapter II suggested that AR expression 
could have an impact on the efficacy of IP6 we set out to explore the expression 
and sub-cellular localization of the AR in prostate tissues. In light of conflicting 
results presented in the literature regarding the link between AR expression and 
PCa progression prior to treatment by androgen deprivation, we also aimed to 
assess the association between AR expression and BCR following radical 
prostatectomy. In chapter IV, we used a similar strategy as in chapter III to assess 
the expression of both cytoplasmic and nuc1ear AR in prostate tissues, and to 
explore the relationship between AR expression, c1inico-pathological features and 
BCR. We found that the most striking change in nuc1ear AR (as well as 
nuc1ear/cytoplasmic AR ratio) was observed when comparing nonnal prostate 
tissues obtained from cancer-free patients to non-neoplasic tissues obtained from 
PCa patients having undergone radical prostatectomy. In contrast, cytoplasmic 
AR staining intensity was particularly elevated in AIPCa specimens. We also 
found that assessed alone, low cytoplasmic AR staining intensities, low nuc1ear 
AR staining intensities, and high nuc1ear/cytoplasmic AR staining intensity ratios 
were all associated to BCR. In a multivariate Cox model inc1uding Gleason score, 
preoperative PSA, surgical margin status and pathological stage, we found that 
low cytoplasmic AR remained an independent predictor of BCR. However, 
similar multivariate analyses using survival trees showed a complex re1ationship 
between AR expression, c1inico-pathological features and BCR. 
The results presented in Chapter IV bring forth the notion that increased 
nuc1ear activity of the AR may be an early event in the development of PCa 
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(Chapter IV, Fig. 2 a,c). Bowever, it remains unc1ear whether increased nuc1ear 
expression of the AR is a cause or a consequence of the progression of PCa in its 
early stages. To answer this question, transgenic mouse models wi11likely prove 
to be useful tools. As mentioned in section 1.3.4.3 and as discussed in chapter IV, 
transgenic mice that have lost the expression of NKX3.1 exhibit increased AR 
expression [343]. Bence, it would be interesting to see whether knockdown of the 
AR, for example using a shRNA under the control of an inducible promoter, 
could reduce the epithelial dysplasia and hyperplasia observed normally in the 
development of NKX3.1 knockout mice [342]. A more ambitious project would 
be to generate transgenic mi ce harboring androgen-responsive oncogenic 
TMRPSS2-ETS fusions. These mice could then be crossed with other transgenic 
models such as mice over-expressing the AR specifically in the prostate [345] or 
expressing an inducible shRNA targeted against the AR as described above. Such 
models may shed sorne light on the implication of the AR in what are potentially 
the early stages of prostate carcinogenesis [604]. 
Although the results presented in chapter IV highlight the potential 
involvement of nuc1ear AR during the initial stages of PCa, they provide a mixed 
view of whether the AR could be use fuI as a prognostic marker, particularly when 
confronted with relevant c1inico-pathological parameters. Although multivariate 
Cox analyses suggest that cytoplasmic AR in particular is an independent 
predictor of BCR, survival tree analyses paint a more complex picture. Whereas 
recurrent tree structures retaining surgical margin status and NOXA as prognostic 
c1assifiers were overwhelmingly present in the top-ranking models described in 
chapter III, no such trend was observed for the AR in chapter IV. Instead, we 
observed that the AR predicted different outcomes, particularly in relation to the 
surgi cal margin status and c1inico-pathological stage of the tumors. Altogether, 
these data suggest that the AR may hold only limited additional prognostic 
information. 
One important issue raised in chapter IV is the potential influence of 
artifacts on the interpretation of results obtained using immunohistochemistry. 
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Indeed, there is a pressmg need to develop ways to ensure that observed 
differences in tissue staining intensities (as assessed by immunohistochemtry) are 
truly due to differences in protein expression and not linked to differences in 
tissue collection and fixation methods or to the age of the archivaI specimens. To 
resolve this problem at the source will undoubtedly require a considerable 
coordination effort between c1inicians, pathologists, and researchers so as to 
establish a standardized protocol for collection and fixation of samples to be used. 
This problem applies both to prospective immunochemistry studies (such as those 
done in chapters III and IV) as weIl as to potential future diagnostic and 
prognostic applications. 
Normalization usmg an internaI control could be a valid alternative 
solution to this problem. In chapter IV, we used the ratio of nuc1ear to 
cytoplasmic AR staining as an additional parameter and found markedly different 
results as compared to nuc1ear or cytoplasmic AR expression taken alone. Of 
course, as nuc1ear and cytoplasmic AR are not independent of one another, the 
nuc1ear/cytoplasmic AR staining intensity ratio cannot be truly considered as an 
internaI control. Hence, developing novel methods of internaI normalization in 
immunohistochemistry is likely a worthwhile pursuit. However, like for any 
normalization procedure, one must be fairly certain that the internaI reference 
does not fluctuate in parallel with the gene/protein of interest. This poses a 
particular challenge in immunohistochemistry as ev en though the expression of a 
given protein may be similar across different cells, its sub-cellular distribution 
(and consequently visual densitometric properties) may change. Nonethe1ess, 
sorne indications suggest that our observations are not merely artifacts. For 
example, we can see that AIPCa tissues from patients that have undergone 
androgen deprivation therapy exhibit much higher leve1s of cytoplasmic AR than 
aIl other tissues not subjected to this treatment. This finding is in agreement with 
the effect of androgen deprivation on the sub-cellular localization of the AR 
observed using other methods [605]. In addition, other studies have observed 
increased overall AR expression in AIPCa tissues as we have reported in chapter 
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IV [363, 436, 606]. In relation to both chapter III and IV, the fact that NA tissues, 
PIN, and cancerous PCa tissues were taken from the same RP specimens strongly 
argue against the possibility that the observed differences in tissue staining 
between these tissue types is Iinked to variations in tissue fixation methods or to 
the age of the specimen. On the other hand, we cannot exc1ude the possibility that 
specimens obtained form autopsied cancer-free patients may exhibit differences 
solely based on differences in patient age or post mortum state of the patient. 
However, in the case of the AR, the nuc1ear/cytoplasmic staining intensity ratio 
should have theoretically been similar between the cancer-free tissues and NA 
tissues if it were not for actual biological differences (Chapter IV Fig 2c). 
In chapter IV, we found that essentially all prostate tissues expressed the 
AR although overall expression appeared to increase with the progression towards 
AIPCa. Considering that several AIPCa cell lines, inc1uding PC3 and DU145 
ceIls, do not express the AR, this finding is somewhat surprising. At the same 
time, it must be noted that both PC3 and DU145 cells were obtained from 
metastases to the bone and brain respectively (see sections 1.3.6.1 and 1.3.6.2). In 
contrast, aIl of the AIPCa specimens used in chapters III and IV were obtained 
from trans-urethral resections of the prostate (TURP). Hence, we cannot exc1ude 
the possibility that distant metastatic AIPCa tumors are more frequently negative 
for the AR. Supporting this may indeed be the case, one recent study has found 
that although strong expression of the AR was evident in 100% of localized PCa, 
this number deceased to 80% in lymph node metastases and to 40% in distant 
hormone-refractory metastases [607]. Although access to metastatic AIPCa 
samples is difficult, it will be interesting to confirm these findings by studying 
nuc1ear and cytoplasmic AR expression in function of the site of metastasis. 
In chapter II, we suggested that IP6 sensitivity may be Iinked to AR 
expression. Hence, in the eventuality where IP6 could be used for treatment of 
hum an PCa, we would expect from this suggestion that IP6 would likely have the 
most effect when AR expression is at its Iowest. Although a significant proportion 
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of distant metastases may also exhibit lowered AR expressIOn, the results 
presented in chapter IV suggest that AR expression is at its lowest during the 
initial stages of PCa progression. Hence, as mono-therapy, this argues in favor of 
using IP6 for chemoprevetion of PCa. To test this hypothesis, we have recently 
initiated a study using the transgenic adenocarcinoma of the mouse prostate 
(TRAMP) transgenic mouse mode!. TRAMP mice have been engineered to 
express oncogenic SV 40 antigens specifically in the prostate and are the best 
characterized and most widely used model for PCa chemoprevention studies. 
Heterozygous TRAMP mice develop localized tumors of both basal!luminal and 
neuroendocrine origin beginning at approximately 8-10 weeks of age and by 28 
weeks, 100% of mice exhibit signs of distant metastasis, mostly in the lymph 
nodes and lungs. TRAMP metastases notably express little to no AR and are 
generally of neuroendocrine origin [608-611]. These mice will be provided with 
2% IP6 in the drinking water and tumor progression will be compared to that of 
control mice. Using this model, we also aim to compare the effect of androgen-
depletion by surgi cal castration with and without IP6 provided in the drinking 
water. The underlying rationale to this aim is that whereas androgen-deprivation 
necessarily targets AR-positive cells, the action of IP6 could potentially 
complement androgen-deprivation by targeting AR-negative cells. 
As mentioned above, although TRAMP mice develop localized tumors of 
both basal/luminal and neuroendocrine origin, TRAMP metastases express little 
to no AR and are generally of neuroendocrine origin. In the human disease, 
neuroendocrine tumors are thought to be less frequent. Hence, it will be important 
to eventually use other transgenic mouse models if promising results are obtained 
using IP6 as a chemopreventive agent in the TRAMP mode!. To this effect, the 
prostate-specific conditional PTEN knockout model could be used. These mice 
exhibit a prostate-specific deletion in the phosphatase domain of the PTEN tumor 
suppressor. As mentioned in section 1.2.4.1.2, PTEN is a negative regulator of 
Akt, which phosphorylates key proteins involved in cell proliferation and survival 
such as IKKs, BAD and mTOR. Homozygous PTEN conditional knockout mice 
begin to develop invasive adenocarcinoma by 9-weeks of age and, similarly to 
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TRAMP mlce, begin to exhibit lymph node and pulmonary metastases at 
approximately 12 weeks. In contrast to TRAMP mice, metastases from PTEN 
conditional knockout mice express the AR and do not originate from 
neuroendocrine cells [335]. It may also be interesting to use NKX3.1 knockout 
and NKX3.1 / PTEN double knockout mice as well, since the loss of both 
NKX3.1 and PTEN are thought to be early events in the progression of localized 
PCa [604]. 
6.4. IP6 in combination with proteasome inhibitors: mechanistic and 
therapeutic implications 
While the data presented in chapter II warranted further studying the role 
of the AR in modulating the efficacy of IP6, it was clear from the multitude of 
AR-interacting proteins presented in section 1.3.5 that advancing our knowledge 
of the mechanisms of IP6 in PC3 cells would be necessary prior to this endeavor. 
Hence, with the underlying goal of innovating in the treatment of PCa, we 
continued our exploration of the molecular mechanisms of IP6 in PC3 cells based 
on the evidence obtained in chapter II. We found that although classical NF-KB 
subunits translocated to the nucleus in response to IP6, thwarting NF-KB-
mediated transcription had little effect on the efficacy of IP6. However, we found 
that treating cells with IP6 caused temporal fluctuations in the expression and 
ratios of pro and anti-apoptotic BCL-2 family proteins, wherein levels of pro-
apoptotic PUMA, BIKlNBK and NOXA rose early-on (between 4-8 hours post 
treatment) and levels of anti-apoptotic MCL-l and BCL-2 decreased after 24 
hours. Suggesting that the cytotoxic effects of IP6 may not depend on 
transcriptional events, we found that PC3 cells treated with a transcription 
inhibitor (actinomycin D) did not exhibit significant changes in PC3 cell 
sensitivity to IP6. However, suggesting the potential involvement ofpro-apoptotic 
BCL-2 family proteins, we found that inhibiting protein translation by pre-treating 
PC3 cells with cycloheximide had a significant protective effect. In light of this, 
we reasoned that blocking proteasome-mediated prote in degradation might 
219 
sensitize cells to the effects of IP6 by further increasing the pro to anti-apoptotic 
BCL-2 family protein ratio. We found that the proteasome inihibitor MG-132 
sensitized both AR-negative PC3 and DU145 AIPCa celllines to the effects of 
IP6. The enhanced effect of combining IP6 with proteasome inhibitors was found 
to implicate mitochondrial outer membrane permeation (MOMP) and required 
prote in translation. Suggesting a role of pro-apoptotic BCL-2 family members in 
this phenomenon, MG-132 led to increased protein levels of several pro-apoptotic 
BCL-2 family members. Albeit slightly, the levels of these proteins was further 
increased by addition of IP6 whereas co-treatment with cyc10heximide completely 
blocked this effect, with the notable exception of PUMA. 
The results obtained in chapter V suggest the involvement of BCL-2 
family members in the response to IP6 and in the response to the combination of 
IP6 with MG-132. However, it is unlike1y that the observed combined effect of 
IP6 and proteasome inhibitors can be explained solely on the observed 
modulations in NOXA, BIK/NBK, and PUMA pro-apoptotic prote in levels. As 
introduced in section~ 1.2.3.1.1 trough 1.2.3.2.3, there are over 20 known pro-
apoptotic and at least 10 known anti-apoptotic members of the BCL-2 family 
proteins. In addition, many of these proteins can be further modified by post-
translational modification. Hence, it will be necessary to probe for modulations in 
other BCL-2 family members, as well as for potential post-translational 
modifications to get a c1ear picture of which proteins may be particularly relevant 
to the results observed in chapter V. 
Given the large number of known and potentially unknown BCL-2 family 
members, probing for each ofthem individually by Western blotting is likely not 
the best strategy, particularly as potentially novel candidates cannot be found 
using this method. As such, a proteomics approach may be more promising. For 
example, PC3 cells could be treated with IP6, MG-132, MG-132 and IP6, as well 
as with a vehic1e control. Whole-cell prote in extracts could then be obtained and 
subjected to HPLC-based peptide separation methods such as MudPIT (multi-
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dimensional prote in identification technology) combined with sample tagging 
methods such as 1-TRAQ (isobaric tags for relative and absolute quantification) 
that also facilitate the identification of posttranslational modifications and the 
comparison of up to four samples simultaneously [612, 613]. By quantifying and 
comparing the peptide signatures of IP6/MG-132 co-treated cells to cells treated 
with either IP6 or MG-132 obtained by mass spectrometry, differentially 
expressed peptides (or post-translationally modified peptides) could then be 
identified. Since there is clear evidence that the enhanced effect observed when 
combining IP6 with MG-132 involves mitochondrial depolarization, it would be 
also interesting to do similar experiments using mitochondrial extracts instead of 
whole cell extracts. As such, in addition to providing more direct information on 
what proteins may be involved in the observed effects on MOMP, the potentially 
large number of candidates that can be expected to be obtained using a proteomics 
approach may be reduced. 
One possibility brought forth in chapter V is that IP6 may function by a 
transcription-independent mechanism. Although the observed down-regulation of 
MCL-l and BCL-2 after 24 hours of treatment with IP6 argues against this idea, 
one possibility is that IP6 stabilizes the expression of pro-apoptotic BCL-2 family 
members by inhibiting proteasome activity, at least during the first 4 to 8 hours of 
treatment. This hypothesis may be tested directly by measuring proteasome 
activity in whole cell extracts after treatment of PC3 cells with IP6. To this effect, 
fluorigenic substrates measuring chymotrypsin-like activity (Succ-LL VY -AMC), 
trypsin-like activity (Z-ARR-AMC), and peptidylglutamyl peptide hydrolyzing 
activity (Z-LLE-AMC) can be used [614]. Using these substrates, it would also be 
interesting to measure prote as orne activity upon treatment of PC3 cells with MG-
132 and with a combination of IP6 and MG-132 to assess whether co-treatment 
leads to further inhibition of proteasome activity as this could help to explain 
sorne of the results observed in chapter V. 
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Along the same line of thought as above, IP6 could potentially stabilize 
pro-apoptotic proteins by inhibiting their poly-ubiquitination and targeting for 
proteasome-mediated degradation. With respect to this idea, it is known that the 
anti-apoptotic prote in MCL-1 is targeted for degradation by the E3 ubiquitin 
conjugating prote in MULE/ARF-BP1 [38]. Interestingly, looking at the response 
ofMCL-1, NOXA, and BIKlNBK levels to treatment ofPC3 cells with MG-132 
and cyc10heximide reveals a similar pattern, suggesting that analogously to MCL-
1, NOXA and BIKlNBK may be active1y targeted for degradation by ubiquitin 
ligases (Chapter V, Fig 6). Beyond MULE/ARFBP1, it is quite possible that other 
su ch proteins exist that instead target NOXA and BIKlNBK for degradation by 
the proteasome. The activity of these hypothetical proteins could potentiallY be 
inhibited by IP6. Interestingly, such a mechanism may also explain why others 
have observed increased p21 CIPI and p27K1P1 expression as well as cell cycle arrest 
in DU145 cells treated by IP6 [585]. As mentioned in section 1.2.2.3 the 
degradation ofboth p21 CIPI and p27K1P1 is regulated by SCF ubiquitin ligases. 
Another possibility discussed in chapter V is that IP6 leads to increased 
protein translation by modulating the activity of pathways that control prote in 
translation. Such pathways inc1ude the well known AktimTOR pathway or the 
recently identified RalA pathway. RalA is an effector of Ras signaling that is 
involved in membrane trafficking, actin organization, and gene expression [615-
617]. Activation of RalA was found to lead to decreased expression of the anti-
apoptotic prote in FLIPs, which inhibits extrinsic apoptosis (such as that induced 
by TRAIL) by associating to the DISC (see section 1.2.3.3.1) [618]. The effect of 
RalA on FLIPs levels was found to be mediated by the inhibition of cdc42 that 
normally activa tes S6K1, a kinase that is involved in the control of ribosomal 
translation. Cdc42 and S6K1 are also downstream targets of mTOR signaling (see 
section 1.2.2.2). Hence, it will be interesting to de termine whether modulation 
mTOR, RalA or of Cdc42 and S6K1 that are common to both mTOR or RalA 
pathways can modulate the observed changes in PUMA, BIK/NBK and NOXA 
levels induced by treatment with IP6 and whether the efficacy of IP6 can be 
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modulated in consequence. This could be done, for example, by using siRNAs 
targeting mTOR, RaIA, S6KI or cdc42. Additionally, it may be interesting to 
evaluate the combined effect of mTOR inhibitors such as CCI-779 [518] with IP6, 
particularly considering that drugs such as CCI -779 are already undergoing 
clinical evaluation for renal cancer and are currently at the pre-clinical stage for 
treatment of prostate cancer. 
In light of the evidence presented in the literature suggesting that IP6 may 
play a role in rnRNA export through the TAPINFXI pathway (see sections 1.1.3 
and 1.4.4.1.3), a most intriguing possibility is that IP6 increases the export of 
accumulated nuclear transcripts towards the cytoplasm. Although we wou Id 
expect that such a mechanism should also lead to increased expression of various 
transcripts and not just pro-apoptotic BCL-2 family members, two observations 
prevent the rejection of this hypothesis. First, in absence of actinomycin D, we 
observe increased mRNA expression of PUMA, NOXA and BAX, detectable as 
early as 4 hours post-treatment (Chapter II, Fig 5, and unpublished data). Hence, 
if mRNA export were to be increased in these conditions, we wou Id expect that 
more of these pro-apoptotic rnRNAs would be translated once in the cytoplasmic 
compartment, which could effectively shift the balance of pro-apoptotic to anti-
apoptotic proteins. Second, a 24-hour treatment of PC3 cells with actinomycin D 
reduces the basal mRNA expression levels of BCL-2 and BCL-XL to less than 
5% the levels of the control, whereas the basallevels ofNOXA, PUMA and BAX 
remain significantly higher (65%, 15% and 14% respectively, unpublished data). 
Therefore, increased rnRNA export induced by IP6 could stilllead to a shift in the 
ratio of pro-apoptotic to anti-apoptotic BCL-2 family proteins in this context. As 
such, one possible way to test whether IP6 increases mRNA export is to use 
realtime PCR in combination with subcellular fractionation. Specifically, PC3 
cells could be treated with IP6 'or with control and both cytoplasmic and nuclear 
fractions could be prepared. RNA could then be extracted from both nuclear and 
cytoplasmic fractions and subsequently converted to cDNA. The relative 
nuclear/cytoplasmic expression of pro-apoptotic genes could then be evaluated 
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using realtime PCR, similarly to what was done in chapt ers II and V. Notably, 
such a procedure has been used successfully by others to demonstrate the ability 
ofVSV proteins to block nuc1ear mRNA export in infected cens [619]. 
Another intriguing point of discussion brought forth in chapter V is the 
possibility that certain BCL-2 family proteins such as PUMA may be translated in 
part by mitochondrial ribosomes. This idea stems mainly from the observation 
that cyc10heximide does not appear to completely prevent observed lP6-induced 
increases in prote in levels of PUMA (Chapter V, Fig. 6). As discussed in chapter 
V, cyc10heximide is known to be ineffective against mitochondrial ribosomes 
[620], which are of different composition than their cytoplasmic counterparts (see 
sections 1.1.3 and 1.2.3.1). However, other translation inhibitors such as 
chloramphenicol are selective for mitochondrial ribosomes [620]. Hence it will be 
interesting to compare the effects of cyc10heximide and chloramphenicol on the 
effects of lP6, both at the level of cytotoxicity and expression of BCL-2 family 
members. 
Analogously to what was observed in chapter II we found that the 
prote as orne inhibitor MG-132 sensitized AR-negative PC3 and DU145 AlPCa 
cens to the effects of IP6 but in contrast had little effect on the sensitivity of AR-
positive, androgen-responsive LNCaP and 22Rvl cens to IP6 (Chapter V, Fig 4a-
e). This further highlights what may be potentiany deep-rooted differences 
between AR-negative and AR-positive cells. It is tempting to speculate that this 
may have sorne link to the expression profiles of BCL-2 family members in AR-
negative and AR-positive cens, as hinted from the results obtained for NOXA and 
PUMA in chapter III (Chapter III, Fig.l). A first step could be to assess the effect 
of down-regulating NOXA or PUMA expression on the sensitivity to IP6 and 
combined IP6/MG-132 treatment. However, since it is likely that down-regulation 
of a single prote in may not be sufficient to elicit an effect because of the highly 
redundant nature of BCL-2 family proteins, it will also be interesting to 
characterize the expression of BCL-2 family members in DU145, LNCaP and 
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22Rvl cells as was done in chapter V for PC3 cells. As the differences observed 
between these celllines could potentially be due to their different cellular origins, 
it would be equally interesting to detennine whether there is any difference in 
vivo between basal cells, neuroendocrine cells, and epithelial cells, with respect to 
BCL-2 family member expression. This could be achieved using laser capture 
microscopy, where single basal, neuroendocrine, and epithe1ial cells could be 
isolated from frozen radical prostatectomy or even autopsy specimens, fOllowing 
immunohistochemical staining for differentiation markers such as those described 
in section. RNA could be subsequently extracted from these three cellular sub-
types and screened for the expression of BCL-2 family members either by RNA 
microarray and/or by realtime PCR. 
Following from our suggestion that pre-clinical evaluation of combined 
treatment with IP6 and proteasome inhibitors may be warranted, we have recently 
initiated an in vivo study using PC3 xenografts implanted subcutaneously in 
immunocompromised mice. In the context of the human disease, this model is 
most analogous to recurrent cancer, as tumors arise from a relative1y small 
number of "remaining" cells. U sing this model, we aim to assess whether IP6 can 
delay the progression of PC3 tumors when provided in the drinking water (2% 
w/v as done in [558] for DU145 cens). In addition, to test the combined effect of 
IP6 and MG-132, PC3 tumors will be allowed to grow to a pre-detennined size 
and will then be challenged with MG-132. Of the mi ce treated with MG-132, a 
subset will be provided with water containing a 2% solution of IP6. If these trials 
are successful, it will be interesting to see whether a similar effect can be obtained 
using DU145 cells and using other models, such as intra-cardiac injection, that 
lead to widespread metastasis [621]. Eventually, it will also be relevant to test 
whether the FDA and EMEA approved Bortezomib can be used in ste ad of MG-
132 or ALLN, which we believe to be a likely possibility. In the event that these 
pre-clinical trials are successful, it seems feasible that clinical trials could be 
initiated fairly rapidly as Bortezomib is already undergoing clinical trials for 
treatment of AIPCa in combination with Docetaxel. 
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6.5. Conclusion 
The over-arching goal of this doctoral project was to further our 
understanding of the factors involved in both therapeutic response and clinical 
outcome, and to innovate in the treatment of PCa. Our studies on IP6 have 
provided a backbone to this effect. With respect to understanding the factors 
involved in therapeutic response, we are among the first to have brought to light 
the concept that androgen-independent functions of the AR may be involved in 
conferring resistance to AIPCa against certain types of therapy, exemplified by 
the decreased sensitivity of AR-positive cells to the effects of IP6. In relation to 
our understanding of the factors involved in clinical outcome of prostate cancer, 
we have contributed both through the application of emerging methods in multi-
marker modeling and by discovering the prognostic potential of NOXA. In 
addition, we have brought forth evidence to suggest that nuclear AR activities 
may be involved in the early stages of PCa and have highlighted the relevance of 
studying cytoplasmic functions of the AR in PCa and AIPCa in vivo. Finally, in 
relation to innovation in the treatment of PC a, our studies on the mechanisms of 
IP6 have led to the discovery that combined treatment with IP6 and proteasome 
inhibitors can enhance cytotoxicity against AIPCa cells. Collectively with the 
future studies we hope to have inspired, we conclude that the innovative concepts 
and methods, the novel prognostic markers and models, as well as the new 
treatment strategies proposed during the course of this doctoral project could 
eventually lead to the better management of PCa. 
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